U.S. patent application number 09/761120 was filed with the patent office on 2002-03-28 for nucleic acids encoding kringle 1-5 region fragments of plasminogen.
Invention is credited to Folkman, M. Judah, O'Reilly, Michael S..
Application Number | 20020037847 09/761120 |
Document ID | / |
Family ID | 25348292 |
Filed Date | 2002-03-28 |
United States Patent
Application |
20020037847 |
Kind Code |
A1 |
O'Reilly, Michael S. ; et
al. |
March 28, 2002 |
Nucleic acids encoding kringle 1-5 region fragments of
plasminogen
Abstract
Fragments of an endothelial cell proliferation inhibitor and
method of use therefor are provided. The endothelial proliferation
inhibitor is a protein derived from plasminogen, or more
specifically is an angiostatin fragment. The angiostatin fragments
generally correspond to kringle structures occurring within the
endothelial cell proliferation inhibitor. The endothelial cell
inhibiting activity of these fragments provides a means for
inhibiting angiogenesis of tumors and for treating
angiogenic-mediated disease.
Inventors: |
O'Reilly, Michael S.;
(Winchester, MA) ; Folkman, M. Judah; (Brookline,
MA) |
Correspondence
Address: |
JOHN S. PRATT
KILPATRICK STOCKTON LLP
1100 PEACHTREE
SUITE 2800
ATLANTA
GA
30309
US
|
Family ID: |
25348292 |
Appl. No.: |
09/761120 |
Filed: |
January 16, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09761120 |
Jan 16, 2001 |
|
|
|
09309821 |
May 11, 1999 |
|
|
|
09309821 |
May 11, 1999 |
|
|
|
08866735 |
May 30, 1997 |
|
|
|
5945403 |
|
|
|
|
Current U.S.
Class: |
435/196 ;
424/94.63; 514/13.3; 514/15.3; 514/19.3 |
Current CPC
Class: |
C12Y 304/21007 20130101;
Y10S 530/828 20130101; A61P 43/00 20180101; C12N 9/6435 20130101;
G01N 33/574 20130101; A61K 38/00 20130101; A61K 48/00 20130101;
A61P 35/00 20180101 |
Class at
Publication: |
514/12 ;
424/94.63 |
International
Class: |
A61K 038/48 |
Claims
We claim:
1. A method of inhibiting endothelial cell proliferation comprising
administering to an endothelial cell a proliferation inhibiting
amount of a plasminogen fragment having an amino acid sequence
substantially similar to the kringle 1-5 region of a plasminogen
molecule.
2. The method of claim 1, wherein the plasminogen fragment is
derived from murine plasminogen, human plasminogen, Rhesus
plasminogen, porcine plasminogen or bovine plasminogen.
3. The method of claim 1, wherein the plasminogen fragment
corresponds to approximately amino acids 98 to 560 of a plasminogen
molecule.
4. A method of treating a mammal with an angiogenic-mediated
disease comprising administering to the mammal a treatment
effective amount of a plasminogen fragment having an amino acid
sequence substantially similar to the kringle 1-5 region of a
plasminogen molecule.
5. The method of claim 4, wherein the plasminogen fragment is
derived from murine plasminogen, human plasminogen, Rhesus
plasminogen, porcine plasminogen or bovine plasminogen.
6. The method of claim 4, wherein the plasminogen fragment
corresponds to approximately amino acids 98 to 560 of a plasminogen
molecule.
7. A therapeutic composition for inhibiting endothelial cell
proliferation comprising a pharmaceutically acceptable excipient
and a plasminogen fragment having an amino acid sequence
substantially similar to the kringle 1-5 region of a plasminogen
molecule.
8. The composition of claim 7, wherein the plasminogen fragment is
derived from murine plasminogen, human plasminogen, Rhesus
plasminogen, porcine plasminogen or bovine plasminogen.
9. The composition of claim 7, wherein the plasminogen fragment
corresponds to approximately amino acids 98 to 560 of a plasminogen
molecule.
10. A composition comprising an isolated nucleotide sequence that
codes for a plasminogen fragment having an amino acid sequence
substantially similar to the kringle 1-5 region of a plasminogen
molecule.
11. The composition of claim 10, wherein the plasminogen fragment
is derived from murine plasminogen, human plasminogen, Rhesus
plasminogen, porcine plasminogen or bovine plasminogen.
12. The composition of claim 10, wherein the plasminogen fragment
corresponds to approximately amino acids 98 to 560 of a plasminogen
molecule.
13. The composition of claim 12, further comprising a vector
associated with the DNA sequence encoding the plasminogen fragment,
wherein the vector is capable of expressing the plasminogen
fragment when present in a cell.
14. The composition of claim 13, further comprising a cell
containing said vector.
15. A method of expressing an plasminogen fragment having an
endothelial cell proliferation inhibiting activity and having an
amino acid sequence substantially similar to the kringle 1-5 region
of a plasminogen molecule, comprising transfecting in a mammalian
cell a vector, wherein the vector contains a DNA sequence encoding
said plasminogen fragment, and wherein the vector is capable of
expressing angiostatin fragment when present in the cell.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to endothelial inhibitors,
called angiostatin, which reversibly inhibit proliferation of
endothelial cells. More particularly, the present invention relates
to angiostatin proteins that can be isolated from body fluids such
as blood or urine, or can be synthesized by recombinant, enzymatic
or chemical methods. The angiostatin is capable of inhibiting
angiogenesis related diseases and modulating angiogenic processes.
In addition, the present invention relates to diagnostic assays and
kits for angiostatin measurement, to histochemical kits for
localization of angiostatin, to DNA sequences coding for
angiostatin and molecular probes to monitor angiostatin
biosynthesis, to antibodies that are specific for the angiostatin,
to the development of protein agonists and antagonists to the
angiostatin receptor, to anti-angiostatin receptor-specific
antibody agonists and antagonists, and to cytotoxic agents linked
to angiostatin proteins.
BACKGROUND OF THE INVENTION
[0002] As used herein, the term "angiogenesis" means the generation
of new blood vessels into a tissue or organ. Under normal
physiological conditions, humans or animals undergo angiogenesis
only in very specific restricted situations. For example,
angiogenesis is normally observed in wound healing, fetal and
embryonal development and formation of the corpus luteum,
endometrium and placenta. The term "endothelium" means a thin layer
of flat epithelial cells that lines serous cavities, lymph vessels,
and blood vessels.
[0003] Both controlled and uncontrolled angiogenesis are thought to
proceed in a similar manner. Endothelial cells and pericytes,
surrounded by a basement membrane, form capillary blood vessels.
Angiogenesis begins with the erosion of the basement membrane by
enzymes released by endothelial cells and leukocytes. The
endothelial cells, which line the lumen of blood vessels, then
protrude through the basement membrane. Angiogenic stimulants
induce the endothelial cells to migrate through the eroded basement
membrane. The migrating cells form a "sprout" off the parent blood
vessel, where the endothelial cells undergo mitosis and
proliferate. The endothelial sprouts merge with each other to form
capillary loops, creating the new blood vessel.
[0004] Persistent, unregulated angiogenesis occurs in a
multiplicity of disease states, tumor metastasis and abnormal
growth by endothelial cells and supports the pathological damage
seen in these conditions. The diverse pathological disease states
in which unregulated angiogenesis is present have been grouped
together as angiogenic dependent or angiogenic associated
diseases.
[0005] The hypothesis that tumor growth is angiogenesis-dependent
was first proposed in 1971. (Folkman J., Tumor angiogenesis:
Therapeutic implications., N. Engl. Jour. Med. 285:1182 1186, 1971)
In its simplest terms it states: "Once tumor `take` has occurred,
every increase in tumor cell population must be preceded by an
increase in new capillaries converging on the tumor." Tumor `take`
is currently understood to indicate a prevascular phase of tumor
growth in which a population of tumor cells occupying a few cubic
millimeters volume and not exceeding a few million cells, can
survive on existing host microvessels. Expansion of tumor volume
beyond this phase requires the induction of new capillary blood
vessels. For example, pulmonary micrometastases in the early
prevascular phase in mice would be undetectable except by high
power microscopy on histological sections.
[0006] Examples of the indirect evidence which support this concept
include:
[0007] (1) The growth rate of tumors implanted in subcutaneous
transparent chambers in mice is slow and linear before
neovascularization, and rapid and nearly exponential after
neovascularization. (Algire G H, et al. Vascular reactions of
normal and malignant tumors in vivo. I. Vascular reactions of mice
to wounds and to normal and neoplastic transplants. J. Natl. Cancer
Inst. 6:73-85, 1945)
[0008] (2) Tumors grown in isolated perfused organs where blood
vessels do not proliferate are limited to 1-2 mm.sup.3 but expand
rapidly to >1000 times this volume when they are transplanted to
mice and become neovascularized. (Folkman J, et al., Tumor behavior
in isolated perfused organs: In vitro growth and metastasis of
biopsy material in rabbit thyroid and canine intestinal segments.
Annals of Surgery 164:491-502, 1966)
[0009] (3) Tumor growth in the avascular cornea proceeds slowly and
at a linear rate, but switches to exponential growth after
neovascularization. (Gimbrone, M. A., Jr. et al., Tumor growth and
neovascularization: An experimental model using the rabbit cornea.
J. Natl. Cancer Institute 52:41-427, 1974)
[0010] (4) Tumors suspended in the aqueous fluid of the anterior
chamber of the rabbit eye, remain viable, avascular and limited in
size to <1 mm.sup.3. Once they are implanted on the iris
vascular bed, they become neovascularized and grow rapidly,
reaching 16,000 times their original volume within 2 weeks.
(Gimbrone M A Jr., et al., Tumor dormancy in vivo by prevention of
neovascularization. J. Exp. Med. 136:261-276) (
[0011] 5) When tumors are implanted on the chick embryo
chorioallantoic membrane, they grow slowly during an avascular
phase of >72 hours, but do not exceed a mean diameter of
0.93+0.29 mm. Rapid tumor expansion occurs within 24 hours after
the onset of neovascularization, and by day 7 these vascularized
tumors reach a mean diameter of 8.0+2.5 mm. (Knighton D., Avascular
and vascular phases of tumor growth in the chick embryo. British J.
Cancer, 35:347-356, 1977) (
[0012] 6) Vascular casts of metastases in the rabbit liver reveal
heterogeneity in size of the metastases, but show a relatively
uniform cut-off point for the size at which vascularization is
present. Tumors are generally avascular up to 1 mm in diameter, but
are neovascularized beyond that diameter. (Lien W., et al., The
blood supply of experimental liver metastases. II. A
microcirculatory study of normal and tumor vessels of the liver
with the use of perfused silicone rubber. Surgery 68:334-340,
1970)
[0013] (7) In transgenic mice which develop carcinomas in the beta
cells of the pancreatic islets, pre-vascular hyperplastic islets
are limited in size to <1 mm. At 6-7 weeks of age, 4-10% of the
islets become neovascularized, and from these islets arise large
vascularized tumors of more than 1000 times the volume of the
pre-vascular islets. (Folkman J, et al., Induction of angiogenesis
during the transition from hyperplasia to neoplasia. Nature
339:58-61, 1989)
[0014] (8) A specific antibody against VEGF (vascular endothelial
growth factor) reduces microvessel density and causes "significant
or dramatic" inhibition of growth of three human tumors which rely
on VEGF as their sole mediator of angiogenesis (in nude mice). The
antibody does not inhibit growth of the tumor cells in vitro. (Kim
K J, et al., Inhibition of vascular endothelial growth
factor-induced angiogenesis suppresses tumor growth in vivo. Nature
362:841-844, 1993)
[0015] (9) Anti-bFGF monoclonal antibody causes 70% inhibition of
growth of a mouse tumor which is dependent upon secretion of bFGF
as its only mediator of angiogenesis. The antibody does not inhibit
growth of the tumor cells in vitro. (Hori A, et al., Suppression of
solid tumor growth by immunoneutralizing monoclonal antibody
against human basic fibroblast growth factor. Cancer Research,
51:6180-6184, 1991)
[0016] (10) Intraperitoneal injection of bFGF enhances growth of a
primary tumor and its metastases by stimulating growth of capillary
endothelial cells in the tumor. The tumor cells themselves lack
receptors for bFGF, and bFGF is not a mitogen for the tumors cells
in vitro. (Gross J L, et al. Modulation of solid tumor growth in
vivo by bFGF. Proc. Amer. Assoc. Canc. Res. 31:79, 1990)
[0017] (11) A specific angiogenesis inhibitor (AGM-1470) inhibits
tumor growth and metastases in vivo, but is much less active in
inhibiting tumor cell proliferation in vitro. It inhibits vascular
endothelial cell proliferation half-maximally at 4 logs lower
concentration than it inhibits tumor cell proliferation. (Ingber D,
et al., Angioinhibins: Synthetic analogues of fumagillin which
inhibit angiogenesis and suppress tumor growth. Nature, 48:555-557,
1990). There is also indirect clinical evidence that tumor growth
is angiogenesis dependent.
[0018] (12) Human retinoblastomas that are metastatic to the
vitreous develop into avascular spheroids which are restricted to
less than 1 mm.sup.3 despite the fact that they are viable and
incorporate .sup.3H-thymidine (when removed from an enucleated eye
and analyzed in vitro).
[0019] (13) Carcinoma of the ovary metastasizes to the peritoneal
membrane as tiny avascular white seeds (1-3 mm.sup.3). These
implants rarely grow larger until one or more of them becomes
neovascularized.
[0020] (14) Intensity of neovascularization in breast cancer
(Weidner N, et al., Tumor angiogenesis correlates with metastasis
in invasive breast carcinoma. N. Engl. J. Med. 324:1-8, 1991, and
Weidner N, et al., Tumor angiogenesis: A new significant and
independent prognostic indicator in early-stage breast carcinoma, J
Natl. Cancer Inst. 84:1875-1887, 1992) and in prostate cancer
(Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor
angiogenesis correlates with metastasis in invasive prostate
carcinoma. American Journal of Pathology, 143(2):401-409, 1993)
correlates highly with risk of future metastasis.
[0021] (15) Metastasis from human cutaneous melanoma is rare prior
to neovascularization. The onset of neovascularization leads to
increased thickness of the lesion and an increasing risk of
metastasis. (Srivastava A, et al., The prognostic significance of
tumor vascularity in intermediate thickness (0.76-4.0 mm thick)
skin melanoma. Amer. J. Pathol. 133:419-423, 1988)
[0022] (16) In bladder cancer, the urinary level of an angiogenic
protein, bFGF, is a more sensitive indicator of status and extent
of disease than is cytology. (Nguyen M, et al., Elevated levels of
an angiogenic protein, basic fibroblast growth factor, in urine of
bladder cancer patients. J. Natl. Cancer Inst. 85:241-242,
1993)
[0023] Thus, it is clear that angiogenesis plays a major role in
the metastasis of a cancer. If this angiogenic activity could be
repressed or eliminated, then the tumor, although present, would
not grow. In the disease state, prevention of angiogenesis could
avert the damage caused by the invasion of the new microvascular
system. Therapies directed at control of the angiogenic processes
could lead to the abrogation or mitigation of these diseases.
[0024] What is needed therefore is a composition and method which
can inhibit the unwanted growth of blood vessels, especially into
tumors. Also needed is a method for detecting, measuring, and
localizing the composition. The composition should be able to
overcome the activity of endogenous growth factors in premetastatic
tumors and prevent the formation of the capillaries in the tumors
thereby inhibiting the growth of the tumors. The composition,
fragments of the composition, and antibodies specific to the
composition, should also be able to modulate the formation of
capillaries in other angiogenic processes, such as wound healing
and reproduction. The composition and method for inhibiting
angiogenesis should preferably be non-toxic and produce few side
effects. Also needed is a method for detecting, measuring, and
localizing the binding sites for the composition as well as sites
of biosynthesis of the composition. The composition and fragments
of the composition should be capable of being conjugated to other
molecules for both radioactive and non-radioactive labeling
purposes
SUMMARY OF THE INVENTION
[0025] In accordance with the present invention, compositions and
methods are provided that are effective for modulating
angiogenesis, and inhibiting unwanted angiogenesis, especially
angiogenesis related to tumor growth. The present invention
includes a protein, which has been named "angiostatin", defined by
its ability to overcome the angiogenic activity of endogenous
growth factors such as bFGF, in vitro, and by it amino acid
sequence homology and structural similarity to an internal portion
of plasminogen beginning at approximately plasminogen amino acid
98. Angiostatin comprises a protein having a molecular weight of
between approximately 38 kilodaltons and 45 kilodaltons as
determined by reducing polyacrylamide gel electrophoresis and
having an amino acid sequence substantially similar to that of a
fragment of murine plasminogen beginning at amino acid number 98 of
an intact murine plasminogen molecule (SEQ ID NO:2).
[0026] The amino acid sequence of angiostatin varies slightly
between species. For example, in human angiostatin the amino acid
sequence is substantially similar to the sequence of the above
described murine plasminogen fragment, although an active human
angiostatin sequence may start at either amino acid number 97 or 99
of an intact human plasminogen amino acid sequence. Further,
fragments of human plasminogen has similar anti-angiogenic activity
as shown in a mouse tumor model. It is to be understood that the
number of amino acids in the active angiostatin molecule may vary
and all amino acid sequences that have endothelial inhibiting
activity are contemplated as being included in the present
invention.
[0027] The present invention provides methods and compositions for
treating diseases and processes mediated by undesired and
uncontrolled angiogenesis by administering to a human or animal a
composition comprising a substantially purified angiostatin or
angiostatin derivative in a dosage sufficient to inhibit
angiogenesis. The present invention is particularly useful for
treating, or for repressing the growth of, tumors. Administration
of angiostatin to a human or animal with prevascularized
metastasized tumors will prevent the growth or expansion of those
tumors.
[0028] The present invention also encompasses DNA sequences
encoding angiostatin, expression vectors containing DNA sequences
encoding angiostatin, and cells containing one or more expression
vectors containing DNA sequences encoding angiostatin. The present
invention further encompasses gene therapy methods whereby DNA
sequences encoding angiostatin are introduced into a patient to
modify in vivo angiostatin levels.
[0029] The present invention also includes diagnostic methods and
kits for detection and measurement of angiostatin in biological
fluids and tissues, and for localization of angiostatin in tissues
and cells. The diagnostic method and kit can be in any
configuration well known to those of ordinary skill in the art. The
present invention also includes antibodies specific for the
angiostatin molecule and portions thereof, and antibodies that
inhibit the binding of antibodies specific for the angiostatin.
These antibodies can be polyclonal antibodies or monoclonal
antibodies. The antibodies specific for the angiostatin can be used
in diagnostic kits to detect the presence and quantity of
angiostatin which is diagnostic or prognostic for the occurrence or
recurrence of cancer or other disease mediated by angiogenesis.
Antibodies specific for angiostatin may also be administered to a
human or animal to passively immunize the human or animal against
angiostatin, thereby reducing angiogenic inhibition.
[0030] The present invention also includes diagnostic methods and
kits for detecting the presence and quantity of antibodies that
bind angiostatin in body fluids. The diagnostic method and kit can
be in any configuration well known to those of ordinary skill in
the art.
[0031] The present invention also includes anti-angiostatin
receptor-specific antibodies that bind to the angiostatin receptor
and transmit the appropriate signal to the cell and act as agonists
or antagonists.
[0032] The present invention also includes angiostatin protein
fragments and analogs that can be labeled isotopically or with
other molecules or proteins for use in the detection and
visualization of angiostatin binding sites with techniques,
including, but not limited to, positron emission tomography,
autoradiography, flow cytometry, radioreceptor binding assays, and
immunohistochemistry.
[0033] These angiostatin proteins and analogs also act as agonists
and antagonists at the angiostatin receptor, thereby enhancing or
blocking the biological activity of angiostatin. Such proteins are
used in the isolation of the angiostatin receptor.
[0034] The present invention also includes angiostatin, angiostatin
fragments, angiostatin antisera, or angiostatin receptor agonists
and angiostatin receptor antagonists linked to cytotoxic agents for
therapeutic and research applications. Still further, angiostatin,
angiostatin fragments, angiostatin antisera, angiostatin receptor
agonists and angiostatin receptor antagonists are combined with
pharmaceutically acceptable excipients, and optionally
sustained-release compounds or compositions, such as biodegradable
polymers, to form therapeutic compositions.
[0035] The present invention includes molecular probes for the
ribonucleic acid and deoxyribonucleic acid involved in
transcription and translation of angiostatin. These molecular
probes provide means to detect and measure angiostatin biosynthesis
in tissues and cells.
[0036] Accordingly, it is an object of the present invention to
provide a composition comprising an angiostatin.
[0037] It is another object of the present invention to provide a
method of treating diseases and processes that are mediated by
angiogenesis.
[0038] It is yet another object of the present invention to provide
a diagnostic or prognostic method and kit for detecting the
presence and amount of angiostatin in a body fluid or tissue.
[0039] It is yet another object of the present invention to provide
a method and composition for treating diseases and processes that
are mediated by angiogenesis including, but not limited to,
hemangioma, solid tumors, blood borne tumors, leukemia, metastasis,
telangiectasia, psoriasis, scleroderma, pyogenic granuloma,
myocardial angiogenesis, Crohn's disease, plaque
neovascularization, coronary collaterals, cerebral collaterals,
arteriovenous malformations, ischemic limb angiogenesis, corneal
diseases, rubeosis, neovascular glaucoma, diabetic retinopathy,
retrolental fibroplasia, arthritis, diabetic neovascularization,
macular degeneration, wound healing, peptic ulcer, Helicobacter
related diseases, fractures, keloids, vasculogenesis,
hematopoiesis, ovulation, menstruation, placentation, and cat
scratch fever.
[0040] It is another object of the present invention to provide a
composition for treating or repressing the growth of a cancer.
[0041] It is an object of the present invention to provide
compounds that modulate or mimic the production or activity of
enzymes that produce angiostatin in vivo or in vitro.
[0042] It is a further object of the present invention to provide
angiostatin or anti-angiostatin antibodies by direct injection of
angiostatin DNA into a human or animal needing such angiostatin or
anti-angiostatin antibodies.
[0043] It is an object of present invention to provide a method for
detecting and quantifying the presence of an antibody specific for
an angiostatin in a body fluid.
[0044] Still another object of the present invention is to provide
a composition consisting of antibodies to angiostatin that are
selective for specific regions of the angiostatin molecule that do
not recognize plasminogen.
[0045] It is another object of the present invention to provide a
method for the detection or prognosis of cancer.
[0046] It is another object of the present invention to provide a
composition for use in visualizing and quantitating sites of
angiostatin binding in vivo and in vitro.
[0047] It is yet another object of the present invention to provide
a composition for use in detection and quantification of
angiostatin biosynthesis.
[0048] It is yet another object of the present invention to provide
a therapy for cancer that has minimal side effects.
[0049] Still another object of the present invention is to provide
a composition comprising angiostatin or an angiostatin protein
linked to a cytotoxic agent for treating or repressing the growth
of a cancer.
[0050] Another object of the present invention is to provide a
method for targeted delivery of angiostatin-related compositions to
specific locations.
[0051] Yet another object of the invention is to provide
compositions and methods useful for gene therapy for the modulation
of angiogenic processes.
[0052] These and other objects, features and advantages of the
present invention will become apparent after a review of the
following detailed description of the disclosed embodiments and the
appended claims.
BRIEF DESCRIPTION OF THE FIGURES
[0053] FIG. 1 shows SEQ ID NO:1, the amino acid sequence of the
whole murine plasminogen.
[0054] FIG. 2 shows the beginning sequence of the angiostatin for
murine (SEQ ID NO:2) and compares the murine sequence with
corresponding human (SEQ ID NO:3), Rhesus monkey (SEQ ID NO:4),
porcine (SEQ ID NO:5) and bovine (SEQ ID NO:6) plasminogen protein
fragments. The mouse sequence is listed first, followed by human,
Rhesus, porcine and bovine.
[0055] FIG. 3 shows BrdU labeling index of tumor cells in the lung
in the presence or absence of a primary tumor.
[0056] FIG. 4 shows Matrigel analysis of the influence of a Lewis
lung primary tumor on bFGF driven angiogenesis in vivo.
[0057] FIG. 5 shows dose response curve for serum derived from mice
bearing Lewis lung carcinoma (LLC-Low) versus serum from normal
mice. Bovine capillary endothelial cells were assayed in a
bFGF-driven 72-hour proliferation assay.
[0058] FIG. 6 shows that both low and high metastatic tumors
contain endothelial mitogenic activity in their ascites, but only
the low metastatic tumor line has endothelial inhibitory activity
in the serum.
[0059] FIG. 7 shows a C4 Reverse Phase Chromatographic profile of
partially purified serum or urine from tumor-bearing animals.
[0060] FIG. 8 shows surface lung metastases after the 13 day
treatment of mice with intact plasminogen molecule, active fraction
from a lysine binding site I preparation of human plasminogen,
concentrated urine from tumor bearing mice and concentrated urine
from normal mice.
[0061] FIG. 9 shows lung weight after the 13 day treatment of mice
with intact plasminogen molecule of human plasminogen, active
fraction from lysine binding site I preparation, concentrated urine
from tumor bearing mice and concentrated urine from normal
mice.
[0062] FIG. 10 is a schematic representation of the pTrcHis
vector.
[0063] FIG. 11 depicts an immunoblot of E.coli expressed human
angiostatin from a 10 L scaled-up fermentation, probed with
monoclonal antibody against human plasminogen kringle region 1-3.
Arrow shows recombinant human angiostatin. A) shows recombinant
angiostatin eluted with 0.2 M amino caproic acid; B) shows the last
wash with 1.times.PBS of the lysine column; and C) shows clarified
lysate from cracked cells.
[0064] FIG. 12. Is a graph depicting percent inhibition of growing
bovine capillary endothelial cells as a function of dilution of
stock; A1, A2, B1, B2, and E are recombinant clones that express
human angiostatin anit-angiogenesis activity; C1 C2, D1 and D2
controls are negative controls clones containing vector only
without the human DNA sequence coding for angiostatin.
[0065] FIG. 13 shows the inhibitory effect on proliferation of
recombinant human angiostatin on bovine capillary endothelial cells
in vitro.
[0066] FIG. 14 shows the growth proliferation index and apoptotic
index after removal of the primary tumor and treatment with saline
or a fumagillin analogue with anti-angiogenic activity FIG. 15
shows the inhibition of growth of a T241 primary tumor in mice by
treatment with human angiostatin in vivo with a single injection of
40 mg/kg/day.
[0067] FIG. 16 shows the inhibition of growth of a LLC-LM primary
tumor in mice by treatment with human angiostatin in vivo at two
doses of 40 mg/kg per dose (80 mg/kg/day).
[0068] FIG. 17 shows the effect of the removal of a Lewis lung
carcinoma primary tumor on the growth of its lung metastases.
[0069] FIG. 18 shows the growth proliferation and apoptotic index
after tumor resection
[0070] FIG. 19 shows the effect of administration of angiostatin
protein to mice having implated T241 fibrosarcoma cells on total
tumor volume as a function of time.
[0071] FIG. 20 shows the effect of administration of angiostatin
protein to mice having implated Lewis lung carcinoma (LM) cells on
total tumor volume as a function of time.
[0072] FIG. 21 shows the effect of administration of angiostatin
protein to mice having implated reticulum cell sarcoma cells on
total tumor volume as a function of time.
[0073] FIG. 22 shows the effect of administration of angiostatin
protein to immunodeficient SCID mice having implated human prostate
carcinoma PC-3 cells on total tumor volume as a function of time
over a 24 day period.
[0074] FIG. 23 shows the effect of administration of angiostatin
protein to immunodeficient SCID mice having implated human breast
carcinoma MDA-MB cells on total tumor volume as a function of time
over a 24 day period.
[0075] FIG. 24 is a schematic representation of cloning of the
mouse DNA sequence coding for mouse angiostatin protein derived
from mouse plasminogen cDNA. The mouse angiostatin encompasses
mouse plasminogen kringle regions 1-4. PCR means polymerase chain
reaction; P1 is the 5'-end oligonucleotide primre for PCR; P2 is
the 3'-end oligonucleotide primre for PCR; SS designates the signal
sequence; ATG is the translation initiation codon; TAA is the
translation stop codon; HA represents the hemagglutinin epitope tag
(YPYDVPDYASL); K1, K2, K3 and K4 represent mouse plasminogen
kringle regions 1, 2, 3 and 4 respectively. CMV is the
cytomegalovirus promoter; T7 is the bacteria phage promoter; PA
represents pre-activation proteins; and SP6 is the Sp6
promoter.
[0076] FIG. 25 depicts the number of cells as a function of days
for non-transfected cells (mock); cells transfected with the vector
alone, without the DNA sequence coding for angiostatin (Vector 5),
and two angiostatin expressing clones (AST 31 and AST 37). Panel
(a) represents the results of transfection of T241 cells. Panel (b)
represents the results of LL2 cells.
[0077] FIG. 26 shows the results of culture medium derived from E.
coli cells containing the angiostatin clone on cell number.
Non-transfected cells (mock); cells transfected with the vector
alone, without the DNA sequence coding for angiostatin (Vector 5),
and three angiostatin expressing clones (AST 25, AST 31 and AST
37). Panel (a) represents the results of incubation of culture
medium from control (mock) and all angiostatin clones (expressing
and non-expressing) on cell number. Panel (b) represents the
results of incubation of culture medium from control (mock), vector
alone (vector 6) and angiostatin clones expressing mouse
angiostatin on cell number. Panel (c) represents the results of
incubation of purified culture medium from control (mock) and
angiostatin clones expressing mouse angiostatin on cell number,
wherein the culture medium was purified over a lysine-sepharose
colume to yield lysine binding components.
[0078] FIG. 27 shows the effect on total tumor volume as a function
of time of implanting T241 fibrosarcoma cells in mice, where the
fibrosarcoma cells have been transfected with a vector containing a
DNA sequence coding for angiostatin protein, and where the vector
is capable of expressing angiostatin protein. "Non-transfected"
represents unaltered T241 fibrosarcoma cells implanted in mice.
"Vector 6" represents T241 fibrosarcoma cells transfected with the
vector only, which does not contain the DNA sequence coding for
angiostatin protein, implanted in mice. "Clone 25, Clone 31 and
Clone 37" represent three angiostatin-producing clones of T241
fibrosarcoma cells transfected with a vector containg the DNA
sequence coding for angiostation protein implanted in mice.
[0079] FIG. 28 shows a schematic representation of the structure of
human plasminogen and its kringle fragments. Human plaminogen is a
single chain protein containing 791 amino acids with one side of
N-linked glycosylation at Asn.sup.289. The non-protease region of
human plasminogen consisting of the N-terminal 561 amino acids
existing in five separate domains, termed kringles as shown in
circles (K1, K2, K3, K4 and K5), along with proteins that separate
these structures. Each triple disulfide bonded kringle contains 80
amino acids. Angiostatin covers the first 4 of these kringle
domains (K1-4), kringle 3 (K1-3) and kringle 4 (K4) are obtained by
digestion of human plasminogen with elastase. The rest of the
kringle fragments are recombinant proteins expressed in E. coli.
SS=signal sequence. PA=preactivation protein.
[0080] FIG. 29 shows a SDS-PAGE analysis of purified recombinant
and native kringle fragments of plasminogen under reducing
conditions. (A) Individual recombinant kringle fragments purified
from E. coli bacterial lysates were loaded onto a 15% SDS gel
followed by staining with Coomassie blue. Approximately 5 .mu.g of
each protein was loaded per lane. (lane 2=kringle 1 (K1); lane
3=kringle 2 (K2); lane 4=kringle 3 (K3); lane 5=kringle 4 (K4);
lane 1=molecular weight markers). (B) Purified large kringle
fragments were stained with Coomassie blue. Kringles 1-4 (lane 2)
and kringles 1-3 (lane 3) were obtained by digestion of human
plasminogen with elastase and purified by lysine-Sepharose
chromatography. Recombinant fragment of kringles 2-3 (lane 4) was
expressed in E. coli and re-folded in vitro. Molecular weight
markers are indicated on the left (lane 1).
[0081] FIG. 30 shows an inhibition of endothelial cell
proliferation by recombinant individual kringle fragments of
angiostatin. Kringle fragments were assayed on bovine capillary
endothelial cells in the presence of 1 ng/ml bFGF for 72 hours. (A)
Anti-endothelial cell proliferative effects of two lysine-binding
kringles, rK1 and rK4. The high-affinity lysine binding kringle, K1
(-o-), inhibited BCE cell proliferation in a dose-dependent manner.
The intermediate-affinity lysine binding kringle, K4
(-.circle-solid.-), showed only little inhibitory effect at high
concentrations. (B) Inhibition of BCE cell proliferation by
non-lysine binding K2 and K3. Both K2 (-.box-solid.-) and K3
(-.quadrature.-) inhibited BCE cell proliferation in a
dose-dependent manner. Data represents the mean +/-SEM of
triplicates.
[0082] FIG. 31 shows an anti-endothelial proliferation activity of
large kringle fragments of angiostatin. Proteolytic fragments, K1-4
(angiostatin) (-o-) and K1-3 (-.box-solid.-), inhibited BCE cell
proliferation in a dose-dependent manner. Recombinant K2-3
(-.circle-solid.-) fragments exhibited a less potent inhibition
than those of K1-3 and K1-4. Data represents the mean of three
determinations (+/-SEM) as percentages of inhibition.
[0083] FIG. 32 shows an additive inhibitory activity of recombinant
kringle 2 and kringle 3. (A) The intact fragment of rK2-3 (also see
FIG. 31) displayed a weak inhibitory effect only at the
concentration of 320 nM. At the same concentration, an additive
inhibition was seen when mutant fragments of rK2 cysteine replaced
by serine at the position of 169) and K3 (cysteine replaced by
serine at the position of 297) were assayed together on BCE cells.
Each value represents the mean +/-SEM of triplicates. (B) Schematic
structure and amino acid sequence of K2 and K3. An inter-chain
kringle disulfide bond was previously reported to be present
between cysteinel.sup.69 of K2 and cysteine.sup.297 of K3 (Sohndel,
S., Hu, C. -K., Marti, D., Affolter, M., Schaller, J., Llinas, M.,
and Rickli, E. E. (1996) Biochem. in press).
[0084] FIG. 33 shows an inhibition of endothelial proliferation by
combinatorial kringle fragments. The assay was performed with a
concentration of 320 nM for each kringle fragment. Values represent
the mean of three determinations (+/-SEM) as percentages of
inhibition. (A) Inhibitory effects of fragments by combination of
various individual kringles. (B) Combinatorial inhibitory activity
of combined kringle fragments.
[0085] FIG. 34 shows an inhibitory activity of angiostatin on
endothelial cells after reduction and alkylation. (A) SDS-PAGE
analysis of the reduced (lane 2) and non-reduced (lane 1) forms of
human angiostatin. Purified human angiostatin was reduced with DTT
followed by alkylation of the protein with an excess amount of
iodoacetamide. The treated samples were dialyzed and assayed on BCE
cells. (B) Inhibition of BCE cell proliferation by reduced and
non-reduced forms of angiostatin at a concentration of 320 nM. Data
represents the mean of inhibition +/-SEM of triplicates.
[0086] FIG. 35 shows an amino acid sequence alignment of putative
kringle domains of human angiostatin. The sequences of four kringle
domains were aligned according to their conserved cysteines.
Identical and conserved amino acids are shaded. The boxed amino
acids in kringle 4 show the positively charged double lysines
adjacent to conserved cysteine residues of 22 and 80.
[0087] FIG. 36 shows lysine-binding characteristics and reactivity
of expressed angiostatin.
[0088] FIG. 36A shows a Coomassie stained gel (40 .mu.l load).
[0089] FIG. 36B shows an immunoblot (20 .mu.l load) of similar gel.
Lane:1 shows broth from shake flasks of induced cultures showing
angiostatin protein at about 50 kD and a few other proteins. Broth
from induced cultures is diluted 1:1 with buffer and directly
loaded onto lysine-sepharose. Lane:2 shows the unbound fraction
that passed through the lysine column. All angiostatin protein
expressed by P. pastoris binds to the lysine column. Lane:3 shows
specific elution with 0.2 M amino caproic acid showing that P.
pastoris expressed angiostatin protein binds lysine and can be
purified in a single step to homogeneity over a lysine-sepharose.
Also, the P. pastoris expressed angiostatin protein is recognized
by a conformationally dependent monoclonal antibody (VAP) raised
against kringles 1 to 3.
[0090] FIG. 37 shows P. pastoris expressed angiostatin protein is
seen as a doublet that migrates at 49 kD and 51.5 kD on denatured
unreduced SDS-PAGE Coomassie stained gels. Removing the single
N-linked complex chain from the expressed angiostatin protein with
N-glycanase specific for high mannose structures results in a
single band of 49.5 kD. Panel A and panel B show a Coomassie
stained gel and an immunoblot of a similar gel respectively. Lane:l
shows a purified P. pastoris expressed angiostatin protein. Lane:2
shows a purified P. pastoris expressed angiostatin protein
incubated in digestion conditions without N-glycanase. Lane:3 shows
purified P. pastoris expressed angiostatin protein digested with
N-glycanase.
[0091] FIG. 38A shows 4 .mu.g of purified P. pastoris expressed
angiostatin protein as a doublet on a Coomassie gel.
[0092] FIG. 38B shows that the purified recombinant inhibits BCE
proliferation. The BCE assay cell counts obtained after 72 hours is
shown, in the presence (.circle-solid.) or absence (o) of bFGF, and
in the presence of bFGF with PBS as control (.DELTA.), and in the
presence of bFGF with P. pastoris expressed angiostatin protein
(.DELTA.).
[0093] FIG. 3 8C shows that the inhibition is dose dependent.
[0094] FIG. 39 shows P. pastoris expressed purified angiostatin was
given systemically (subcutaneous) to mice with primary tumors.
[0095] FIGS. 39A and B show the number of metastases and the lung
weights respectively of mice treated daily with saline or P.
pastoris expressed angiostatin or plasminogen derived angiostatin
protein. In contrast to the lungs of mice treated with saline,
lungs of mice treated with P. pastoris expressed angiostatin
protein or with plasminogen derived angiostatin protein were
non-vascularized and metastases were potently suppressed.
[0096] FIG. 40 shows that the lungs of mice treated with P.
pastoris expressed angiostatin were pink with micrometastases while
the lungs of the saline control group were completely covered with
vascularized metastases.
DETAILED DESCRIPTION
[0097] The present invention includes compositions and methods for
the detection and treatment of diseases and processes that are
mediated by or associated with angiogenesis. The composition is
angiostatin, which can be isolated from body fluids including, but
not limited to, serum, urine and ascites, or synthesized by
chemical or biological methods (e.g. cell culture, recombinant gene
expression, protein synthesis, and in vitro enzymatic catalysis of
plasminogen or plasmin to yield active angiostatin). Recombinant
techniques include gene amplification from DNA sources using the
polymerase chain reaction (PCR), and gene amplification from RNA
sources using reverse transcriptase/PCR. Angiostatin inhibits the
growth of blood vessels into tissues such as unvascularized or
vascularized tumors.
[0098] The present invention also encompasses a composition
comprising, a vector containing a DNA sequence encoding
angiostatin, wherein the vector is capable of expressing
angiostatin when present in a cell, a composition comprising a cell
containing a vector, wherein the vector contains a DNA sequence
encoding angiostatin or fragments or analogs thereof, and wherein
the vector is capable of expressing angiostatin when present in the
cell, and a method comprising, implanting into a human or non-human
animal a cell containing a vector, wherein the vector contains a
DNA sequence encoding angiostatin, and wherein the vector is
capable of expressing angiostatin when present in the cell.
[0099] Still further, the present invention encompasses
angiostatin, angiostatin fragments, angiostatin antisera,
angiostatin receptor agonists or angiostatin receptor antagonists
that are combined with pharmaceutically acceptable excipients, and
optionally sustained-release compounds or compositions, such as
biodegradable polymers, to form therapeutic compositions. In
particular, the invention includes a composition comprising an
antibody that specifically binds to angiostatin, wherein the
antibody does not bind to plasminogen.
[0100] More particularly, the present invention includes a protein
designated angiostatin that has a molecular weight of approximately
38 to 45 kilodaltons (kD) that is capable of overcoming the
angiogenic activity of endogenous growth factors such as bFGF, in
vitro. Angiostatin is a protein having a molecular weight of
between approximately 38 kilodaltons and 45 kilodaltons as
determined by reducing polyacrylamide gel electrophoresis and
having an amino acid sequence substantially similar to that of a
murine plasminogen fragment beginning at amino acid number 98 of an
intact murine plasminogen molecule. Numbering of amino acids herein
corresponds to the conventioanl system of numbering from the
beginning methionine of the plasminogen molecule.
[0101] The term "substantially similar," when used in reference to
angiostatin amino acid sequences, means an amino acid sequence
having anti-angiogenic activity and having a molecular weight of
approximately 38 kD to 45 kD, which also has a high degree of
sequence homology to the protein fragment of mouse plasminogen
beginning approximately at amino acid number 98 in mouse
plasminogen and weighing 38 kD to 45 kD. A high degree of homology
means at least approximately 60% amino acid homology, desirably at
least approximately 70% amino acid homology, and more desirably at
least approximately 80% amino acid homology. The term "endothelial
inhibiting activity" as used herein means the capability of a
molecule to inhibit angiogenesis in general and, for example, to
inhibit the growth of bovine capillary endothelial cells in culture
in the presence of fibroblast growth factor.
[0102] The amino acid sequence of the complete murine plasminogen
molecule is shown in FIG. 1 and in SEQ ID NO: 1. The sequence for
angiostatin protein can begin approximately at amino acid 98.
Active human angiostatin, howvere, can also begin at a variety of
alternative positions. The examples demonstrate that genetic
constructs encoding active angiostatin protein can begin at amino
acid 93 or 102, for example.
[0103] The amino acid sequence of the first 339 amino acids of an
angiostatin from mouse is shown in FIG. 2, (SEQ ID NO:2), and is
compared with the sequences of corresponding plasminogen protein
fragments from human (SEQ ID NO:3, Rhesus monkey (SEQ ID NO:4),
porcine (SEQ ID NO:5) and bovine (SEQ ID NO:6) plasminogen. Given
that these sequences are identical in well over 50% of their amino
acids, it is to be understood that the amino acid sequence of the
angiostatin is substantially similar among species. The total
number of amino acids in angiostatin is not known precisely but is
defined by the molecular weight of the active molecule. The amino
acid sequence of the angiostatin of the present invention may vary
depending upon from which species the plasminogen molecule is
derived. Thus, although the angiostatin of the present invention
that is derived from human plasminogen has a slightly different
sequence than angiostatin derived from mouse, it has
anti-angiogenic activity as shown in a mouse tumor model.
[0104] Angiostatin has been shown to be capable of inhibiting the
growth of endothelial cells in vitro. Angiostatin does not inhibit
the growth of cell lines derived from other cell types.
Specifically, angiostatin has no effect on Lewis lung carcinoma
cell lines, mink lung epithelium, 3T3 fibroblasts, bovine aortic
smooth muscle cells, bovine retinal pigment epithelium, MDCk cells
(canine renal epithelium), W138 cells (human fetal lung
fibroblasts) EFN cells (murine fetal fibroblasts) and LM cells
(murine connective tissue). Endogenous angiostatin in a tumor
bering mouse is effective at inhibiting metastases at a systemic
concentration of approximately 10 mg angiostatin/kg body
weight.
[0105] Angiostatin has a specific three dimensional conformation
that is defined by the kringle regions of the plasminogen molecule.
(Robbins, K. C., "The plasminogen-plasmin enzyme system" Hemostasis
and Thrombosis, Basic Principles and Practice, 2nd Edition, ed. by
Colman, R. W. et al. J. B. Lippincott Company, pp. 340-357, 1987)
There are five such kringle regions, which are conformationally
related motifs and have substantial sequence homology, in the
NH.sub.2 terminal portion of the plasminogen molecule. The three
dimensional conformation of functional angiostatin is believed to
encompass plasminogen kringle regions 1 through 5. Each kringle
region of the plasminogen molecule contains approximately 80 amino
acids and contains 3 disulfide bonds. This cysteine motif is known
to exist in other biologically active proteins. These proteins
include, but are not limited to, prothrombin, hepatocyte growth
factor, scatter factor and macrophage stimulating protein.
(Yoshimura, T, et al., "Cloning, sequencing, and expression of
human macrophage stimulating protein (MSP, MST1) confirms MSP as a
member of the family of kringle proteins and locates the MSP gene
on Chromosome 3" J. Biol. Chem., Vol. 268, No. 21, pp. 15461-15468,
1993). It is contemplated that any isolated protein or protein
having a three dimensional kringle-like conformation or cysteine
motif that has anti-angiogenic activity in vivo, is part of the
present invention.
[0106] The present invention also includes the detection of the
angiostatin in body fluids and tissues for the purpose of diagnosis
or prognosis of diseases such as cancer. The present invention also
includes the detection of angiostatin binding sites and receptors
in cells and tissues. The present invention also includes methods
of treating or preventing angiogenic diseases and processes
including, but not limited to, arthritis and tumors by stimulating
the production of angiostatin, and/or by administering
substantially purified angiostatin, or angiostatin agonists or
antagonists, and/or angiostatin antisera or antisera directed
against angiostatin antisera to a patient. Additional treatment
methods include administration of angiostatin, angiostatin
fragments, angiostatin analogs, angiostatin antisera, or
angiostatin receptor agonists and antagonists linked to cytotoxic
agents. It is to be understood that the angiostatin can be animal
or human in origin. Angiostatin can also be produced synthetically
by chemical reaction or by recombinant techniques in conjunction
with expression systems. Angiostatin can also be produced by
enzymatically cleaving isolated plasminogen or plasmin to generate
proteins having anti-angiogenic activity. Angiostatin may also be
produced by compounds that mimic the action of endogenous enzymes
that cleave plasminogen to angiostatin. Angiostatin production may
also be modulated by compounds that affect the activity of
plasminogen cleaving enxymes.
[0107] Passive antibody therapy using antibodies that specifically
bind angiostatin can be employed to modulate angiogenic-dependent
processes such as reproduction, development, and wound healing and
tissue repair. In addition, antisera directed to the Fab regions of
angiostatin antibodies can be administered to block the ability of
endogenous angiostatin antisera to bind angiostatin.
[0108] The present invention also encompasses gene therapy whereby
the gene encoding angiostatin is regulated in a patient. Various
methods of transferring or delivering DNA to cells for expression
of the gene product protein, otherwise referred to as gene therapy,
are disclosed in Gene Transfer into Mammalian Somatic Cells in
vivo, N. Yang, Crit. Rev. Biotechn. 12(4): 335-356 (1992), which is
hereby incorporated by reference. Gene therapy encompasses
incorporation of DNA sequences into somatic cells or germ line
cells for use in either ex vivo or in vivo therapy. Gene therapy
functions to replace genes, augment normal or abnormal gene
function, and to combat infectious diseases and other
pathologies.
[0109] Strategies for treating these medical problems with gene
therapy include therapeutic strategies such as identifying the
defective gene and then adding a functional gene to either replace
the function of the defective gene or to augment a slightly
functional gene; or prophylactic strategies, such as adding a gene
for the product protein that will treat the condition or that will
make the tissue or organ more susceptible to a treatment regimen.
As an example of a prophylactic strategy, a gene such as
angiostatin may be placed in a patient and thus prevent occurrence
of angiogenesis; or a gene that makes tumor cells more susceptible
to radiation could be inserted and then radiation of the tumor
would cause increased killing of the tumor cells.
[0110] Many protocols for transfer of angiostatin DNA or
angiostatin regulatory sequences are envisioned in this invention.
Transfection of promoter sequences, other than one normally found
specifically associated with angiostatin, or other sequences which
would increase production of angiostatin protein are also
envisioned as methods of gene therapy. An example of this
technology is found in Transkaryotic Therapies, Inc., of Cambridge,
Mass., using homologous recombination to insert a "genetic switch"
that turns on an erythropoietin gene in cells. See Genetic
Engineering News, Apr. 15, 1994. Such "genetic switches" could be
used to activate angiostatin (or the angiostatin receptor) in cells
not normally expressing angiostatin (or the angiostatin receptor)
.
[0111] Gene transfer methods for gene therapy fall into three broad
categories-physical (e.g., electroporation, direct gene transfer
and particle bombardment), chemical (lipid-based carriers, or other
non-viral vectors) and biological (virus-derived vector and
receptor uptake). For example, non-viral vectors may be used which
include liposomes coated with DNA. Such liposome/DNA complexes may
be directly injected intravenously into the patient. It is believed
that the liposome/DNA complexes are concentrated in the liver where
they deliver the DNA to macrophages and Kupffer cells. These cells
are long lived and thus provide long term expression of the
delivered DNA. Additionally, vectors or the "naked" DNA of the gene
may be directly injected into the desired organ, tissue or tumor
for targeted delivery of the therapeutic DNA.
[0112] Gene therapy methodologies can also be described by delivery
site. Fundamental ways to deliver genes include ex vivo gene
transfer, in vivo gene transfer, and in vitro gene transfer. In ex
vivo gene transfer, cells are taken from the patient and grown in
cell culture. The DNA is transfected into the cells, the
transfected cells are expanded in number and then reimplanted in
the patient. In in vitro gene transfer, the transformed cells are
cells growing in culture, such as tissue culture cells, and not
particular cells from a particular patient. These "laboratory
cells" are transfected, the transfected cells are selected and
expanded for either implantation into a patient or for other
uses.
[0113] In vivo gene transfer involves introducing the DNA into the
cells of the patient when the cells are within the patient. Methods
include using virally mediated gene transfer using a noninfectious
virus to deliver the gene in the patient or injecting naked DNA
into a site in the patient and the DNA is taken up by a percentage
of cells in which the gene product protein is expressed.
Additionally, the other methods described herein, such as use of a
"gene gun," may be used for in vitro insertion of angiostatin DNA
or angiostatin regulatory sequences.
[0114] Chemical methods of gene therapy may involve a lipid based
compound, not necessarily a liposome, to ferry the DNA across the
cell membrane. Lipofectins or cytofectins, lipid-based positive
ions that bind to negatively charged DNA, make a complex that can
cross the cell membrane and provide the DNA into the interior of
the cell. Another chemical method uses receptor-based endocytosis,
which involves binding a specific ligand to a cell surface receptor
and enveloping and transporting it across the cell membrane. The
ligand binds to the DNA and the whole complex is transported into
the cell. The ligand gene complex is injected into the blood stream
and then target cells that have the receptor will specifically bind
the ligand and transport the ligand-DNA complex into the cell.
[0115] Many gene therapy methodologies employ viral vectors to
insert genes into cells. For example, altered retrovirus vectors
have been used in ex vivo methods to introduce genes into
peripheral and tumor-infiltrating lymphocytes, hepatocytes,
epidermal cells, myocytes, or other somatic cells. These altered
cells are then introduced into the patient to provide the gene
product from the inserted DNA.
[0116] Viral vectors have also been used to insert genes into cells
using in vivo protocols. To direct tissue-specific expression of
foreign genes, cis-acting regulatory elements or promoters that are
known to be tissue specific can be used. Alternatively, this can be
achieved using in situ delivery of DNA or viral vectors to specific
anatomical sites in vivo. For example, gene transfer to blood
vessels in vivo was achieved by implanting in vitro transduced
endothelial cells in chosen sites on arterial walls. The virus
infected surrounding cells which also expressed the gene product. A
viral vector can be delivered directly to the in vivo site, by a
catheter for example, thus allowing only certain areas to be
infected by the virus, and providing long-term, site specific gene
expression. In vivo gene transfer using retrovirus vectors has also
been demonstrated in mammary tissue and hepatic tissue by injection
of the altered virus into blood vessels leading to the organs.
[0117] Viral vectors that have been used for gene therapy protocols
include but are not limited to, retroviruses, other RNA viruses
such as poliovirus or Sindbis virus , adenovirus, adeno-associated
virus, herpes viruses, SV 40, vaccinia and other DNA viruses.
Replication-defective murine retroviral vectors are the most widely
utilized gene transfer vectors. Murine leukemia retroviruses are
composed of a single strand RNA complexed with a nuclear core
protein and polymerase (pol) enzymes, encased by a protein core
(gag) and surrounded by a glycoprotein envelope (env) that
determines host range. The genomic structure of retroviruses
include the gag, pol, and env genes enclosed at by the 5' and 3'
long terminal repeats (LTR). Retroviral vector systems exploit the
fact that a minimal vector containing the 5' and 3' LTRs and the
packaging signal are sufficient to allow vector packaging,
infection and integration into target cells providing that the
viral structural proteins are supplied in trans in the packaging
cell line. Fundamental advantages of retroviral vectors for gene
transfer include efficient infection and gene expression in most
cell types, precise single copy vector integration into target cell
chromosomal DNA, and ease of manipulation of the retroviral
genome.
[0118] The adenovirus is composed of linear, double stranded DNA
complexed with core proteins and surrounded with capsid proteins.
Advances in molecular virology have led to the ability to exploit
the biology of these organisms to create vectors capable of
transducing novel genetic sequences into target cells in vivo.
Adenoviral-based vectors will express gene product proteins at high
levels. Adenoviral vectors have high efficiencies of infectivity,
even with low titers of virus. Additionally, the virus is fully
infective as a cell free virion so injection of producer cell lines
are not necessary. Another potential advantage to adenoviral
vectors is the ability to achieve long term expression of
heterologous genes in vivo.
[0119] Mechanical methods of DNA delivery include fusogenic lipid
vesicles such as liposomes or other vesicles for membrane fusion,
lipid particles of DNA incorporating cationic lipid such as
lipofectin, polylysine-mediated transfer of DNA, direct injection
of DNA, such as microinjection of DNA into germ or somatic cells,
pneumatically delivered DNA-coated particles, such as the gold
particles used in a "gene gun," and inorganic chemical approaches
such as calcium phosphate transfection. Another method,
ligand-mediated gene therapy, involves complexing the DNA with
specific ligands to form ligand-DNA conjugates, to direct the DNA
to a specific cell or tissue.
[0120] It has been found that injecting plasmid DNA into muscle
cells yields high percentage of the cells which are transfected and
have sustained expression of marker genes. The DNA of the plasmid
may or may not integrate into the genome of the cells.
Non-integration of the transfected DNA would allow the transfection
and expression of gene product proteins in terminally
differentiated, non-proliferative tissues for a prolonged period of
time without fear of mutational insertions, deletions, or
alterations in the cellular or mitochondrial genome. Long-term, but
not necessarily permanent, transfer of therapeutic genes into
specific cells may provide treatments for genetic diseases or for
prophylactic use. The DNA could be reinjected periodically to
maintain the gene product level without mutations occurring in the
genomes of the recipient cells. Non-integration of exogenous DNAs
may allow for the presence of several different exogenous DNA
constructs within one cell with all of the constructs expressing
various gene products.
[0121] Particle-mediated gene transfer methods were first used in
transforming plant tissue. With a particle bombardment device, or
"gene gun," a motive force is generated to accelerate DNA-coated
high density particles (such as gold or tungsten) to a high
velocity that allows penetration of the target organs, tissues or
cells. Particle bombardment can be used in in vitro systems, or
with ex vivo or in vivo techniques to introduce DNA into cells,
tissues or organs.
[0122] Electroporation for gene transfer uses an electrical current
to make cells or tissues susceptible to electroporation-mediated
gene transfer. A brief electric impulse with a given field strength
is used to increase the permeability of a membrane in such a way
that DNA molecules can penetrate into the cells. This technique can
be used in in vitro systems, or with ex vivo or in vivo techniques
to introduce DNA into cells, tissues or organs.
[0123] Carrier mediated gene transfer in vivo can be used to
transfect foreign DNA into cells. The carrier-DNA complex can be
conveniently introduced into body fluids or the bloodstream and
then site specifically directed to the target organ or tissue in
the body. Both liposomes and polycations, such as polylysine,
lipofectins or cytofectins, can be used. Liposomes can be developed
which are cell specific or organ specific and thus the foreign DNA
carried by the liposome will be taken up by target cells. Injection
of immunoliposomes that are targeted to a specific receptor on
certain cells can be used as a convenient method of inserting the
DNA into the cells bearing the receptor. Another carrier system
that has been used is the asialoglycoportein/polylysine conjugate
system for carrying DNA to hepatocytes for in vivo gene
transfer.
[0124] The transfected DNA may also be complexed with other kinds
of carriers so that the DNA is carried to the recipient cell and
then resides in the cytoplasm or in the nucleoplasm. DNA can be
coupled to carrier nuclear proteins in specifically engineered
vesicle complexes and carried directly into the nucleus.
[0125] Gene regulation of angiostatin may be accomplished by
administering compounds that bind to the angiostatin gene, or
control regions associated with the angiostatin gene, or its
corresponding RNA transcript to modify the rate of transcription or
translation. Additionally, cells transfected with a DNA sequence
encoding angiostatin may be administered to a patient to provide an
in vivo source of angiostatin. For example, cells may be
transfected with a vector containing a nucleic acid sequence
encoding angiostatin.
[0126] The term "vector" as used herein means a carrier that can
contain or associate with specific nucleic acid sequences, which
functions to transport the specific nucleic acid sequences into a
cell. Examples of vectors include plasmids and infective
microorganisms such as viruses, or non-viral vectors such as
ligand-DNA conjugates, liposomes, lipid-DNA complexes. It may be
desirable that a recombinant DNA molecule comprising an angiostatin
DNA sequence is operatively linked to an expression control
sequence to form an expression vector capable of expressing
angiostatin. The transfected cells may be cells derived from the
patient's normal tissue, the patient's diseased tissue, or may be
non-patient cells.
[0127] For example, tumor cells removed from a patient can be
transfected with a vector capable of expressing the angiostatin
protein of the present invention, and re-introduced into the
patient. The transfected tumor cells produce angiostatin levels in
the patient that inhibit the growth of the tumor. Patients may be
human or non-human animals. Cells may also be transfected by
non-vector, or physical or chemical methods known in the art such
as electroporation, ionoporation, or via a "gene gun."
Additionally, angiostatin DNA may be directly injected, without the
aid of a carrier, into a patient. In particular, angiostatin DNA
may be injected into skin, muscle or blood.
[0128] The gene therapy protocol for transfecting angiostatin into
a patient may either be through integration of the angiostatin DNA
into the genome of the cells, into minichromosomes or as a separate
replicating or non-replicating DNA construct in the cytoplasm or
nucleoplasm of the cell. Angiostatin expression may continue for a
long-period of time or may be reinjected periodically to maintain a
desired level of the angiostatin protein in the cell, the tissue or
organ or a determined blood level.
[0129] Angiostatin can be isolated on an HPLC C4 column (see Table
3). The angiostatin protein is eluted at 30 to 35% in an
acetonitrile gradient. On a sodium dodecyl sulfate polyacrylamide
gel electrophoresis (PAGE) gel under reducing conditions, the
protein band with activity eluted as a single peak at approximately
38 kilodaltons.
[0130] The inventors have shown that a growing primary tumor is
associated with the release into the blood stream of specific
inhibitor(s) of endothelial cell proliferation, including
angiostatin which can suppress angiogenesis within a metastasis and
thereby inhibit the growth of the metastasis itself. The source of
the angiostatin associated with the primary tumor is not known. The
compound may be produced by degradation of plasminogen by a
specific protease, or angiostatin could be produced by expression
of a specific gene coding for angiostatin.
[0131] The angiogenic phenotype of a primary tumor depends on
production of angiogenic proteins in excess of endothelial cell
inhibitors which are elaborated by normal cells, but are believed
to be down-regulated during transformation to neoplasia. While
production of angiostatin may be down-regulated in an individual
tumor cell relative to production by its parent cell type, the
total amount of inhibitor elaborated by the whole tumor may be
sufficient to enter the circulation and suppress endothelial growth
at remote sites of micrometastases. Angiostatin remains in the
circulation for a significantly longer time than the angiogenic
protein(s) released by a primary tumor. Thus, the angiogenic
proteins appear to act locally, whereas angiostatin acts globally
and circulates in the blood with a relatively long half-life. The
half-life of the angiostatin is approximately 12 hours to 5
days.
[0132] Although not wanting to be bound by the following
hypothesis, it is believed that when a tumor becomes angiogenic it
releases one or more angiogenic proteins (e.g., aFGF, bFGF, VEGF,
IL-8, GM-CSF, etc.), which act locally, target endothelium in the
neighborhood of a primary tumor from an extravascular direction,
and do not circulate (or circulate with a short half-life). These
angiogenic proteins must be produced in an amount sufficient to
overcome the action of endothelial cell inhibitor (inhibitors of
angiogenesis) for a primary tumor to continue to expand its
population. Once such a primary tumor is growing well, it continues
to release endothelial cell inhibitors into the circulation.
According to this hypothesis, these inhibitors act remotely at a
distance from the primary tumor, target capillary endothelium of a
metastasis from an intravascular direction, and continue to
circulate. Thus, just at the time when a remote metastasis might
begin to initiate angiogenesis, the capillary endothelium in its
neighborhood could be inhibited by incoming angiostatin.
[0133] Once a primary tumor has reached sufficient size to cause
angiostatin to be released continuously into the circulation, it is
difficult for a second tumor implant (or a micrometastasis) to
initiate or increase its own angiogenesis. If a second tumor
implant (e.g., into the subcutaneous space, or into the cornea, or
intravenously to the lung) occurs shortly after the primary tumor
is implanted, the primary tumor will not be able to suppress the
secondary tumor (because angiogenesis in the secondary tumor will
already be well underway). If two tumors are implanted
simultaneously (e.g., in opposite flanks), the inhibitors may have
an equivalent inhibiting effect on each other.
[0134] The angiostatin of the present invention can be:
[0135] (i) Administered to tumor-bearing humans or animals as
anti-angiogenic therapy;
[0136] (ii) Monitored in human or animal serum, urine, or tissues
as prognostic markers; and
[0137] (iii) Used as the basis to analyze serum and urine of cancer
patients for similar angiostatic molecules.
[0138] It is contemplated as part of the present invention that
angiostatin can be isolated from a body fluid such as blood or
urine of patients or the angiostatin can be produced by recombinant
DNA methods or synthetic protein chemical methods that are well
known to those of ordinary skill in the art. Protein purification
methods are well known in the art and a specific example of a
method for purifying angiostatin, and assaying for inhibitor
activity is provided in the examples below. Isolation of human
endogenous angiostatin is accomplished using similar
techniques.
[0139] One example of a method of producing angiostatin using
recombinant DNA techniques entails the steps of (1) identifying and
purifying angiostatin as discussed above, and as more fully
described below, (2) determining the N-terminal amino acid sequence
of the purified inhibitor, (3) synthetically generating 5' and 3'
DNA oligonucleotide primers for the angiostatin sequence, (4)
amplifying the angiostatin gene sequence using polymerase, (5)
inserting the amplified sequence into an appropriate vector such as
an expression vector, (6) inserting the gene containing vector into
a microorganism or other expression system capable of expressing
the inhibitor gene, and (7) isolating the recombinantly produced
inhibitor. Appropriate vectors include viral, bacterial and
eukaryotic (such as yeast) expression vectors. The above techniques
are more fully described in laboratory manuals such as "Molecular
Cloning: A Laboratory Manual" Second Edition by Sambrook et al.,
Cold Spring Harbor Press, 1989. The DNA sequence of human
plasminogen has been published (Browne, M. J., et al., "Expression
of recombinant human plasminogen and aglycoplasminogen in HeLa
cells" Fibrinolysis Vol. 5 (4). 257-260, 1991) and is incorporated
herein by reference
[0140] The gene for angiostatin may also be isolated from cells or
tissue (such as tumor cells) that express high levels of
angiostatin by (1) isolating messenger RNA from the tissue, (2)
using reverse transcriptase to generate the corresponding DNA
sequence and then (3) using the polymerase chain reaction (PCR)
with the appropriate primers to amplify the DNA sequence coding for
the active angiostatin amino acid sequence.
[0141] Yet another method of producing angiostatin, or biologically
active fragments thereof, is by protein synthesis. Once a
biologically active fragment of an angiostatin is found using the
assay system described more fully below, it can be sequenced, for
example by automated protein sequencing methods. Alternatively,
once the gene or DNA sequence which codes for angiostatin is
isolated, for example by the methods described above, the DNA
sequence can be determined using manual or automated sequencing
methods well know in the art. The nucleic acid sequence in turn
provides information regarding the amino acid sequence. Thus, if
the biologically active fragment is generated by specific methods,
such as tryptic digests, or if the fragment is N-terminal
sequenced, the remaining amino acid sequence can be determined from
the corresponding DNA sequence.
[0142] Once the amino acid sequence of the protein is known, the
fragment can be synthesized by techniques well known in the art, as
exemplified by "Solid Phase Protein Synthesis: A Practical
Approach" E. Atherton and R. C. Sheppard, IRL Press, Oxford,
England. Similarly, multiple fragments can be synthesized which are
subsequently linked together to form larger fragments. These
synthetic protein fragments can also be made with amino acid
substitutions at specific locations to test for agonistic and
antagonistic activity in vitro and in vivo. Protein fragments that
possess high affinity binding to tissues can be used to isolate the
angiostatin receptor on affinity columns. Isolation and
purification of the angiostatin receptor is a fundamental step
towards elucidating the mechanism of action of angiostatin.
Isolation of an angiostatin receptor and identification of
angiostatin agonists and antagonists will facilitate development of
drugs to modulate the activity of the angiostatin receptor, the
final pathway to biological activity. Isolation of the receptor
enables the construction of nucleotide probes to monitor the
location and synthesis of the receptor, using in situ and solution
hybridization technology. Further, the gene for the angiostatin
receptor can be isolated, incorporated into an expression vector
and transfected into cells, such as patient tumor cells to increase
the ability of a cell type, tissue or tumor to bind angiostatin and
inhibit local angiogenesis.
[0143] Angiostatin is effective in treating diseases or processes
that are mediated by, or involve, angiogenesis. The present
invention includes the method of treating an angiogenesis mediated
disease with an effective amount of angiostatin, or a biologically
active fragment thereof, or combinations of angiostatin fragmetns
that collectively possess anti-angiogenic activity, or angiostatin
agonists and antagonists. The angiogenesis mediated diseases
include, but are not limited to, solid tumors; blood born tumors
such as leukemias; tumor metastasis; benign tumors, for example
hemangiomas, acoustic neuromas, neurofibromas, trachomas, and
pyogenic granulomas; rheumatoid arthritis; psoriasis; ocular
angiogenic diseases, for example, diabetic retinopathy, retinopathy
of prematurity, macular degeneration, corneal graft rejection,
neovascular glaucoma, retrolental fibroplasia, rubeosis;
Osler-Webber Syndrome; myocardial angiogenesis; plaque
neovascularization; telangiectasia; hemophiliac joints;
angiofibroma; and wound granulation. Angiostatin is useful in the
treatment of disease of excessive or abnormal stimulation of
endothelial cells. These diseases include, but are not limited to,
intestinal adhesions, Crohn's disease, atherosclerosis,
scleroderma, and hypertrophic scars, i.e., keloids. Angiostatin can
be used as a birth control agent by preventing vascularization
required for embryo implantation. Angiostatin is useful in the
treatment of diseases that have angiogenesis as a pathologic
consequence such as cat scratch disease (Rochele minalia quintosa)
and ulcers (Helicobacter pylori).
[0144] The synthetic protein fragments of angiostatin have a
variety of uses. The protein that binds to the angiostatin receptor
with high specificity and avidity is radiolabeled and employed for
visualization and quantitation of binding sites using
autoradiographic and membrane binding techniques. This application
provides important diagnostic and research tools. Knowledge of the
binding properties of the angiostatin receptor facilitates
investigation of the transduction mechanisms linked to the
receptor.
[0145] In addition, labeling angiostatin proteins with short lived
isotopes enables visualization of receptor binding sites in vivo
using positron emission tomography or other modern radiographic
techniques to locate tumors with angiostatin binding sites.
[0146] Systematic substitution of amino acids within these
synthesized proteins yields high affinity protein agonists and
antagonists to the angiostatin receptor that enhance or diminish
angiostatin binding to its receptor. Such agonists are used to
suppress the growth of micrometastases, thereby limiting the spread
of cancer. Antagonists to angiostatin are applied in situations of
inadequate vascularization, to block the inhibitory effects of
angiostatin and promote angiogenesis. For example, this treatment
may have therapeutic effects to promote wound healing in
diabetics.
[0147] Angiostatin proteins are employed to develop affinity
columns for isolation of the angiostatin receptor from cultured
tumor cells. Isolation and purification of the angiostatin receptor
is followed by amino acid sequencing. Using this information the
gene or genes coding for the angiostatin receptor can be identified
and isolated. Next, cloned nucleic acid sequences are developed for
insertion into vectors capable of expressing the receptor. These
techniques are well known to those skilled in the art. Transfection
of the nucleic acid sequence(s) coding for angiostatin receptor
into tumor cells, and expression of the receptor by the transfected
tumor cells enhances the responsiveness of these cells to
endogenous or exogenous angiostatin and thereby decreasing the rate
of metastatic growth.
[0148] Cytotoxic agents such as ricin, are linked to angiostatin,
and high affinity angiostatin protein fragments, thereby providing
a tool for destruction of cells that bind angiostatin. These cells
may be found in many locations, including but not limited to,
micrometastases and primary tumors. Proteins linked to cytotoxic
agents are infused in a manner designed to maximize delivery to the
desired location. For example, ricin-linked high affinity
angiostatin fragments are delivered through a cannula into vessels
supplying the target site or directly into the target. Such agents
are also delivered in a controlled manner through osmotic pumps
coupled to infusion cannulae. A combination of angiostatin
antagonists may be co-applied with stimulators of angiogenesis to
increase vascularization of tissue. This therapeutic regimen
provides an effective means of destroying metastatic cancer.
[0149] Angiostatin may be used in combination with other
compositions and procedures for the treatment of diseases. For
example, a tumor may be treated conventionally with surgery,
radiation or chemotherapy combined with angiostatin and then
angiostatin may be subsequently administered to the patient to
extend the dormancy of micrometastases and to stabilize and inhibit
the growth of any residual primary tumor. Additionally,
angiostatin, angiostatin fragments, angiostatin antisera,
angiostatin receptor agonists, angiostatin receptor antagonists, or
combinations thereof, are combined with pharmaceutically acceptable
excipients, and optionally sustained-release matrix, such as
biodegradable polymers, to form therapeutic compositions.
[0150] A sustained-release matrix, as used herein, is a matrix made
of materials, usually polymers, which are degradable by enzymatic
or acid/base hydrolysis or by dissolution. Once inserted into the
body, the matrix is acted upon by enzymes and body fluids. The
sustained-release matrix desirably is chosen from biocompatible
materials such as liposomes, polylactides (polylactic acid),
polyglycolide (polymer of glycolic acid), polylactide co-glycolide
(co-polymers of lactic acid and glycolic acid) polyanhydrides,
poly(ortho)esters, polyproteins, hyaluronic acid, collagen,
chondroitin sulfate, carboxylic acids, fatty acids, phospholipids,
polysaccharides, nucleic acids, polyamino acids, amino acids such
as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl
propylene, polyvinylpyrrolidone and silicone. A preferred
biodegradable matrix is a matrix of one of either polylactide,
polyglycolide, or polylactide co-glycolide (co-polymers of lactic
acid and glycolic acid).
[0151] The angiogenesis-modulating therapeutic composition of the
present invention may be a solid, liquid or aerosol and may be
administered by any known route of administration. Examples of
solid therapeutic compositions include pills, creams, and
implantable dosage units. The pills may be administered orally, the
therapeutic creams may be administered topically. The implantable
dosage unitst may be administered locally, for example at a tumor
site, or which may be implanted for systemic release of the
therapeutic angiogenesis-modulating composition, for example
subcutaneously. Examples of liquid composition include formulations
adapted for injection subcutaneously, intravenously,
intraarterially, and formulations for topical and intraocular
administration. Examples of aersol formulation include inhaler
formulation for administration to the lungs.
[0152] The angiostatin of the present invention also can be used to
generate antibodies that are specific for the inhibitor and its
receptor. The antibodies can be either polyclonal antibodies or
monoclonal antibodies. These antibodies that specifically bind to
the angiostatin or angiostatin receptors can be used in diagnostic
methods and kits that are well known to those of ordinary skill in
the art to detect or quantify the angiostatin or angiostatin
receptors in a body fluid or tissue. Results from these tests can
be used to diagnose or predict the occurrence or recurrence of a
cancer and other angiogenic mediated diseases.
[0153] The angiostatin also can be used in a diagnostic method and
kit to detect and quantify antibodies capable of binding
angiostatin. These kits would permit detection of circulating
angiostatin antibodies which indicates the spread of
micrometastases in the presence of angiostatin secreted by primary
tumors in situ. Patients that have such circulating
anti-angiostatin antibodies may be more likely to develop multiple
tumors and cancers, and may be more likely to have recurrences of
cancer after treatments or periods of remission. The Fab fragments
of these anti-angiostatin antibodies may be used as antigens to
generate anti-angiostatin Fab-fragment antisera which can be used
to neutralize anti-angiostatin antibodies. Such a method would
reduce the removal of circulating angiostatin by anti-angiostatin
antibodies, thereby effectively elevating circulating angiostatin
levels.
[0154] Another aspect of the present invention is a method of
blocking the action of excess endogenous angiostatin. This can be
done by passively immunizing a human or animal with antibodies
specific for the undesired angiostatin in the system. This
treatment can be important in treating abnormal ovulation,
menstruation and placentation, and vasculogenesis. This provides a
useful tool to examine the effects of angiostatin removal on
metastatic processes. The Fab fragment of angiostatin antibodies
contains the binding site for angiostatin. This fragment is
isolated from angiostatin antibodies using techniques known to
those skilled in the art. The Fab fragments of angiostatin antisera
are used as antigens to generate production of anti-Fab fragment
serum. Infusion of this antiserum against the Fab fragments of
angiostatin prevents angiostatin from binding to angiostatin
antibodies. Therapeutic benefit is obtained by neutralizing
endogenous anti-angiostatin antibodies by blocking the binding of
angiostatin to the Fab fragments of anti-angiostatin. The net
effect of this treatment is to facilitate the ability of endogenous
circulating angiostatin to reach target cells, thereby decreasing
the spread of metastases.
[0155] It is to be understood that the present invention is
contemplated to include any derivatives of the angiostatin that
have endothelial inhibitory activity. The present invention
includes the entire angiostatin protein, derivatives of the
angiostatin protein and biologically-active fragments of the
angiostatin protein. These include proteins with angiostatin
activity that have amino acid substitutions or have sugars or other
molecules attached to amino acid functional groups. The present
invention also includes genes that code for angiostatin and the
angiostatin receptor, and to proteins that are expressed by those
genes.
[0156] The proteins and protein fragments with the angiostatin
activity described above can be provided as isolated and
substantially purified proteins and protein fragments in
pharmaceutically acceptable formulations using formulation methods
known to those of ordinary skill in the art. These formulations can
be administered by standard routes. In general, the combinations
may be administered by the topical, transdermal, intraperitoneal,
intracranial, intracerebroventricular, intracerebral, intravaginal,
intrauterine, oral, rectal or parenteral (e.g., intravenous,
intraspinal, subcutaneous or intramuscular) route. In addition, the
angiostatin may be incorporated into biodegradable polymers
allowing for sustained release of the compound, the polymers being
implanted in the vicinity of where drug delivery is desired, for
example, at the site of a tumor or implanted so that the
angiostatin is slowly released systemically. Osmotic minipumps may
also be used to provide controlled delivery of high concentrations
of angiostatin through cannulae to the site of interest, such as
directly into a metastatic growth or into the vascular supply to
that tumor. The biodegradable polymers and their use are described,
for example, in detail in Brem et al., J. Neurosurg. 74:441-446
(1991), which is hereby incorporated by reference in its
entirety.
[0157] The dosage of the angiostatin of the present invention will
depend on the disease state or condition being treated and other
clinical factors such as weight and condition of the human or
animal and the route of administration of the compound. For
treating humans or animals, between approximately 0.5 mg/kilogram
to 500 mg/kilogram of the angiostatin can be administered.
Depending upon the half-life of the angiostatin in the particular
animal or human, the angiostatin can be administered between
several times per day to once a week. It is to be understood that
the present invention has application for both human and veterinary
use. The methods of the present invention contemplate single as
well as multiple administrations, given either simultaneously or
over an extended period of time.
[0158] The angiostatin formulations include those suitable for
oral, rectal, ophthalmic (including intravitreal or intracameral),
nasal, topical (including buccal and sublingual), intrauterine,
vaginal or parenteral (including subcutaneous, intraperitoneal,
intramuscular, intravenous, intradermal, intracranial,
intratracheal, and epidural) administration.- The angiostatin
formulations may conveniently be presented in unit dosage form and
may be prepared by conventional pharmaceutical techniques. Such
techniques include the step of bringing into association the active
ingredient and the pharmaceutical carrier(s) or excipient(s). In
general, the formulations are prepared by uniformly and intimately
bringing into association the active ingredient with liquid
carriers or finely divided solid carriers or both, and then, if
necessary, shaping the product.
[0159] Formulations suitable for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may
contain anti-oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
may include suspending agents and thickening agents. The
formulations may be presented in unit-dose or multi-dose
containers, for example, sealed ampules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example, water for
injections, immediately prior to use. Extemporaneous injection
solutions and suspensions may be prepared from sterile powders,
granules and tablets of the kind previously described.
[0160] Preferred unit dosage formulations are those containing a
daily dose or unit, daily sub-dose, or an appropriate fraction
thereof, of the administered ingredient. It should be understood
that in addition to the ingredients, particularly mentioned above,
the formulations of the present invention may include other agents
conventional in the art having regard to the type of formulation in
question. Optionally, cytotoxic agents may be incorporated or
otherwise combined with angiostatin proteins, or biologically
functional protein fragements thereof, to provide dual therapy to
the patient.
[0161] Angiogenesis inhibiting proteins of the present invention
can be synthesized in a standard microchemical facility and purity
checked with HPLC and mass spectrophotometry. Methods of protein
synthesis, HPLC purification and mass spectrophotometry are
commonly known to those skilled in these arts. Angiostatin proteins
and angiostatin receptors proteins are also produced in recombinant
E. coli or yeast expression systems, and purified with column
chromatography.
[0162] Different protein fragments of the intact angiostatin
molecule can be synthesized for use in several applications
including, but not limited to the following; as antigens for the
development of specific antisera, as agonists and antagonists
active at angiostatin binding sites, as proteins to be linked to,
or used in combination with, cytotoxic agents for targeted killing
of cells that bind angiostatin. The amino acid sequences that
comprise these proteins are selected on the basis of their position
on the exterior regions of the molecule and are accessible for
binding to antisera. The amino and carboxyl termini of angiostatin,
as well as the mid-region of the molecule are' represented
separately among the fragments to be synthesized.
[0163] These protein sequences are compared to known sequences
using protein sequence databases such as GenBank, Brookhaven
Protein, SWISS-PROT, and PIR to determine potential sequence
homologies. This information facilitates elimination of sequences
that exhibit a high degree of sequence homology to other molecules,
thereby enhancing the potential for high specificity in the
development of antisera, agonists and antagonists to
angiostatin.
[0164] Angiostatin and angiostatin derived proteins can be coupled
to other molecules using standard methods. The amino and carboxyl
termini of angiostatin both contain tyrosine and lysine residues
and are isotopically and nonisotopically labeled with many
techniques, for example radiolabeling using conventional techniques
(tyrosine residues-chloramine T, iodogen, lactoperoxidase; lysine
residues-Bolton-Hunter reagent). These coupling techniques are well
known to those skilled in the art. Alternatively, tyrosine or
lysine is added to fragments that do not have these residues to
facilitate labeling of reactive amino and hydroxyl groups on the
protein. The coupling technique is chosen on the basis of the
functional groups available on the amino acids including, but not
limited to amino, sulfhydral, carboxyl, amide, phenol, and
imidazole. Various reagents used to effect these couplings include
among others, glutaraldehyde, diazotized benzidine, carbodiimide,
and p-benzoquinone.
[0165] Angiostatin proteins are chemically coupled to isotopes,
enzymes, carrier proteins, cytotoxic agents, fluorescent molecules,
chemiluminescent, bioluminescent and other compounds for a variety
of applications. The efficiency of the coupling reaction is
determined using different techniques appropriate for the specific
reaction. For example, radiolabeling of an angiostatin protein with
.sup.125I is accomplished using chloramine T and Na .sup.125I of
high specific activity. The reaction is terminated with sodium
metabisulfite and the mixture is desalted on disposable columns.
The labeled protein is eluted from the column and fractions are
collected. Aliquots are removed from each fraction and
radioactivity measured in a gamma counter. In this manner, the
unreacted Na.sup.125I is separated from the labeled angiostatin
protein. The protein fractions with the highest specific
radioactivity are stored for -subsequent use such as analysis of
the ability to bind to angiostatin antisera.
[0166] Another application of protein conjugation is for production
of polyclonal antisera. For example, angiostatin proteins
containing lysine residues are linked to purified bovine serum
albumin using glutaraldehyde. The efficiency of the reaction is
determined by measuring the incorporation of radiolabeled protein.
Unreacted glutaraldehyde and protein are separated by dialysis. The
conjugate is stored for subsequent use.
[0167] Antiserum against angiostatin, angiostatin analogs, protein
fragments of angiostatin and the angiostatin receptor can be
generated. After protein synthesis and purification, both
monoclonal and polyclonal antisera are raised using established
techniques known to those skilled in the art. For example,
polyclonal antisera may be raised in rabbits, sheep, goats or other
animals. Angiostatin proteins conjugated to a carrier molecule such
as bovine serum albumin, or angiostatin itself, is combined with an
adjuvant mixture, emulsified and injected subcutaneously at
multiple sites on the back, neck, flanks, and sometimes in the
footpads. Booster injections are made at regular intervals, such as
every 2 to 4 weeks. Blood samples are obtained by venipuncture, for
example using the marginal ear veins after dilation, approximately
7 to 10 days after each injection. The blood samples are allowed to
clot overnight at 4C and are centrifuged at approximately
2400.times.g at 4C for about 30 minutes. The serum is removed,
aliquoted, and stored at 4C for immediate use or at -20 to -90C for
subsequent analysis.
[0168] All serum samples from generation of polyclonal antisera or
media samples from production of monoclonal antisera are analyzed
for determination of antibody titer. Titer is established through
several means, for example, using dot blots and density analysis,
and also with precipitation of radiolabeled protein-antibody
complexes using protein A, secondary antisera, cold ethanol or
charcoal-dextran followed by activity measurement with a gamma
counter. The highest titer antisera are also purified on affinity
columns which are commercially available. Angiostatin proteins are
coupled to the gel in the affinity column. Antiserum samples are
passed through the column and anti-angiostatin antibodies remain
bound to the column. These antibodies are subsequently eluted,
collected and evaluated for determination of titer and
specificity.
[0169] The highest titer angiostatin antisera is tested to
establish the following; a) optimal antiserum dilution for highest
specific binding of the antigen and lowest non-specific binding, b)
the ability to bind increasing amounts of angiostatin protein in a
standard displacement curve, c) potential cross-reactivity with
related proteins and proteins, including plasminogen and also
angiostatin of related species, d) ability to detect angiostatin
proteins in extracts of plasma, urine, tissues, and in cell culture
media.
[0170] Kits for measurement of angiostatin, and the angiostatin
receptor, are also contemplated as part of the present invention.
Antisera that possess the highest titer and specificity and can
detect angiostatin proteins in extracts of plasma, urine, tissues,
and in cell culture media are further examined to establish easy to
use kits for rapid, reliable, sensitive, and specific measurement
and localization of angiostatin. These assay kits include but are
not limited to the following techniques; competitive and
non-competitive assays, radioimmunoassay, bioluminescence and
chemiluminescence assays, fluorometric assays, sandwich assays,
immunoradiometric assays, dot blots, enzyme linked assays including
ELISA, microtiter plates, antibody coated strips or dipsticks for
rapid monitoring of urine or blood, and immunocytochemistry. For
each kit the range, sensitivity, precision, reliability,
specificity and reproducibility of the assay are established.
Intraassay and interassay variation is established at 20%, 50% and
80% points on the standard curves of displacement or activity.
[0171] One example of an assay kit commonly used in research and in
the clinic is a radioimmunoassay (RIA) kit. An angiostatin RIA is
illustrated below. After successful radioiodination and
purification of angiostatin or an angiostatin protein, the
antiserum possessing the highest titer is added at several
dilutions to tubes containing a relatively constant amount of
radioactivity, such as 10,000 cpm, in a suitable buffer system.
Other tubes contain buffer or preimmune serum to determine the
non-specific binding. After incubation at 4C for 24 hours, protein
A is added and the tubes are vortexed, incubated at room
temperature for 90 minutes, and centrifuged at approximately 2000-
2500.times.g at 4C to precipitate the complexes of antibody bound
to labeled antigen. The supernatant is removed by aspiration and
the radioactivity in the pellets counted in a gamma counter. The
antiserum dilution that binds approximately 10 to 40% of the
labeled protein after subtraction of the non-specific binding is
further characterized.
[0172] Next, a dilution range (approximately 0.1 pg to 10 ng) of
the angiostatin protein used for development of the antiserum is
evaluated by adding known amounts of the protein to tubes
containing radiolabeled protein and antiserum. After an additional
incubation period, for example, 24 to 48 hours, protein A is added
and the tubes centrifuged, supernatant removed and the
radioactivity in the pellet counted. The displacement of the
binding of radiolabeled angiostatin protein by the unlabeled
angiostatin protein (standard) provides a standard curve. Several
concentrations of other angiostatin protein fragments, plasminogen,
angiostatin from different species, and homologous proteins are
added to the assay tubes to characterize the specificity of the
angiostatin antiserum.
[0173] Extracts of various tissues, including but not limited to
primary and secondary tumors, Lewis lung carcinoma, cultures of
angiostatin producing cells, placenta, uterus, and other tissues
such as brain, liver, and intestine, are prepared using extraction
techniques that have been successfully employed to extract
angiostatin. After lyophilization or Speed Vac of the tisssue
extracts, assay buffer is added and different aliquots are placed
into the RIA tubes. Extracts of known angiostatin producing cells
produce displacement curves that are parallel to the standard
curve, whereas extracts of tissues that do not produce angiostatin
do not displace radiolabeled angiostatin from the angiostatin
antiserum. In addition, extracts of urine, plasma, and
cerebrospinal fluid from animals with Lewis lung carcinoma are
added to the assay tubes in increasing amounts. Parallel
displacement curves indicate the utility of the angiostatin assay
to measure angiostatin in tissues and body fluids.
[0174] Tissue extracts that contain angiostatin are additionally
characterized by subjecting aliquots to reverse phase HPLC. Eluate
fractions are collected, dried in Speed Vac, reconstituted in RIA
buffer and analyzed in the angiostatin RIA. The maximal amount of
angiostatin immunoreactivity is located in the fractions
corresponding to the elution position of angiostatin.
[0175] The assay kit provides instructions, antiserum, angiostatin
or angiostatin protein, and possibly radiolabeled angiostatin
and/or reagents for precipitation of bound angiostatin-angiostatin
antibody complexes. The kit is useful for the measurement of
angiostatin in biological fluids and tissue extracts of animals and
humans with and without tumors.
[0176] Another kit is used for localization of angiostatin in
tissues and cells. This angiostatin immunohistochemistry kit
provides instructions, angiostatin antiserum, and possibly blocking
serum and secondary antiserum linked to a fluorescent molecule such
as fluorescein isothiocyanate, or to some other reagent used to
visualize the primary antiserum. Immunohistochemistry techniques
are well known to those skilled in the art. This angiostatin
immunohistochemistry kit permits localization of angiostatin in
tissue sections and cultured cells using both light and electron
microscopy. It is used for both research and clinical purposes. For
example, tumors are biopsied or collected and tissue sections cut
with a microtome to examine sites of angiostatin production. Such
information is useful for diagnostic and possibly therapeutic
purposes in the detection and treatment of cancer. Another method
to visualize sites of angiostatin biosynthesis involves
radiolabeling nucleic acids for use in in situ hybridization to
probe for angiostatin messenger RNA. Similarly, the angiostatin
receptor can be localized, visualized and quantitated with
immunohistochemistry techniques.
[0177] This invention is further illustrated by the following
examples, which are not to be construed in any way as imposing
limitations upon the scope thereof. On the contrary, it is to be
clearly understood that resort may be had to various other
embodiments, modifications, and equivalents thereof which, after
reading the description herein, may suggest themselves to those
skilled in the art without departing from the spirit of the present
invention and/or the scope of the appended claims.
EXAMPLE 1
[0178] Choice of an animal-tumor system in which growth of
metastasis is inhibited by the primary tumor and is accelerated
after removal of the primary tumor.
[0179] By screening a variety of murine tumors capable of
inhibiting their own metastases, a Lewis lung carcinoma was
selected in which the primary tumor most efficiently inhibited lung
metastasis. Syngeneic C57BI6/J six-week-old male mice were injected
(subcutaneous dorsum) with 1.times.10.sup.6 tumor cells. Visible
tumors first appeared after 3-4 days. When tumors were
approximately 1500 mm.sup.3 in size, mice were randomized into two
groups. The primary tumor was completely excised in the first group
and left intact in the second group after a sham operation.
Although tumors from 500 mm.sup.3 to 3000 mm.sup.3 inhibited growth
of metastases, 1500 mm.sup.3 was the largest primary tumor that
could be safely resected with high survival and no local
recurrence.
[0180] After 21 days, all mice were sacrificed and autopsied. In
mice with an intact primary tumor, there were four +2 visible
metastases, compared to fifty +5 metastases in the mice in which
the tumor had been removed (p<0.0001). These data were confirmed
by lung weight, which correlates closely with tumor burden, as has
been previously demonstrated. There was a 400% increase in wet lung
weight in the mice that had their tumors removed compared to mice
in which the tumor remained intact (p<0.0001).
[0181] This experimental model gave reproducible data and the
experiment described is reproducible. This tumor is labeled "Lewis
lung carcinoma-low metastatic" (LLC-Low). The tumor also suppressed
metastases in a nearly identical pattern in SCID mice, which are
deficient in both B and T lymphocytes.
EXAMPLE 2
[0182] Isolation of a variant of Lewis lung carcinoma tumor that is
highly metastatic, whether or not the primary tumor is removed.
[0183] A highly metastatic variant of Lewis lung carcinoma arose
spontaneously from the LLC-Low cell line of EXAMPLE 1 in one group
of mice and has been isolated according to the methods described in
EXAMPLE 1 and repeatedly transplanted. This tumor (LLC-High) forms
more than 30 visible lung metastases whether or not the primary
tumor is present.
EXAMPLE 3
[0184] Size of metastases and proliferation rate of tumor cells
within them. Effect of the primary tumor that inhibits metastases
(LLC-Low).
[0185] C57BI6/J mice were used in all experiments. Mice were
inoculated subcutaneously with LLC-Low cells, and 14 days later the
primary tumor was removed in half of the mice. At 5, 10 and 15 days
after the tumor had been removed, mice were sacrificed.
Histological sections of lung metastases were obtained. Mice with
an intact primary tumor had micrometastases in the lung which were
not neovascularized. These metastases were restricted to a diameter
of 12-15 cell layers and did not show a significant size increase
even 15 days after tumor removal. In contrast, animals from which
the primary tumor was removed, revealed large vascularized
metastases as early as 5 days after operation. These metastases
underwent a further 4-fold increase in volume by the 15th day after
the tumor was removed (as reflected by lung weight and histology).
Approximately 50% of the animals who had a primary tumor removed
died of lung metastases before the end of the experiment. All
animals with an intact primary tumor survived to the end of the
experiment.
[0186] Replication rate of tumor cells within metastases was
determined by counting nuclei stained with BrdU which had been
previously injected into the mice. The high percentage of tumor
cells incorporating BrdU in small, avascular metastases of animals
with an intact primary tumor was equivalent to the BrdU
incorporation of tumor cells in the large vascularized metastases
of mice from which the primary tumor had been removed (FIG. 3).
This finding suggests that the presence of a primary tumor has no
direct effect on the replication rate of tumor cells within a
metastasis.
[0187] In FIG. 3, the left panel shows BrdU labeling index of tumor
cells in the lung in the presence or absence of a primary tumor.
Before immunohistochemical staining, sections were permeabilized
with 0.2 M HCl for 10 minutes and digested with 1 .mu.g/ml
proteinase K (Boehringer Mannheim GmbH, Mannheim, Germany) in 0.2 M
Tris-HCl, 2 mM CaCl.sub.2 at 37.degree. C. for 15 minutes. Labeling
index was estimated by counting percentage of positive nuclei at
250 power. The right panel of FIG. 3 depicts an analysis of total
lung weight of tumors with primary tumors intact or removed 5, 10
and 15 days after operation. Animals were sacrificed 6 hours after
intraperitoneal injection of BrdU (0.75 mg/mouse).
EXAMPLE 4
[0188] Inhibition of angiogenesis in lung metastases in the
presence of an intact primary tumor.
[0189] To measure the degree of vascularization in lung metastases,
tissues were stained with antibodies against von Willebrand factor
(an endothelial specific marker, available from Dako Inc.,
Carpenteria, Calif.). Metastases from animals with intact tumors
formed a thin cuff (8-12 tumor cell layers) around existing
pulmonary vessels. Except for the endothelial cells of the vessel
lining, no or few cells were positive for von Willebrand factor. In
contrast, lung metastases of animals 5 days after removal of the
primary tumor were not only larger but were also infiltrated with
capillary sprouts containing endothelial cells which stained
strongly for von Willebrand factor.
[0190] In immunohistochemical analysis of the presence of
endothelial cells in lung metastases, a lung metastasis with the
primary lung tumor intact 19 days after inoculation, had a cuff of
tumor cells around a pre-existing microvessel in the lung. The
metastasis was limited to 8 to 12 cell layers. There was no
evidence of neovascularization around the microvessel, and it did
not contain any new microvessels. This was typical of the maximum
size of an avascular pre-angiogenic metastasis.
[0191] In an immunohistochemical analysis of tissue collected five
days after the primary tumor was resected (19 days after
inoculation of the primary tumor), the metastasis surrounded a
pre-existing vessel in the lung. In contrast, in the sample where
the primary tumor was not resected, the tumor was neovascularized.
Thus, an intact primary tumor inhibits formation of new capillary
blood vessels in metastases, but proliferation of tumor cells
within a metastasis are not affected by the primary tumor.
EXAMPLE 5
[0192] A primary tumor inhibits angiogenesis of a second tumor
implanted in the mouse cornea. Growth of this second tumor is
inhibited.
[0193] A 0.25 to 0.5 mm.sup.2 Lewis lung tumor (LLC-Low) was
implanted in the mouse cornea on-day 0. (Muthukkaruppan Vr., et
al., Angiogenesis in the mouse cornea. Science 205:1416-1418, 1979)
A primary tumor was formed by inoculating 1.times.10.sup.6 LLC-Low
cells subcutaneously in the dorsum, either 4 or 7 days before the
corneal implant; or on the day of the comeal implant; or 4 or 7
days after the corneal implant. Control mice received the corneal
implant but not the subcutaneous tumor. Other control mice received
the corneal implant and an inoculation of LLC-High tumor cells in
the dorsum 4 days before the corneal implant. The corneas were
evaluated daily by slit-lamp stereomicroscopy for the growth of the
corneal tumor (measured by an ocular micrometer) and for the growth
of new capillary vessels from the edge of the corneal limbus.
[0194] In control mice not bearing a primary subcutaneous tumor, a
majority of corneas (6/8) developed neovascularization starting at
day 6 to 7 days after corneal implantation and continuing to day
10. By day 10, the vascularized corneal tumors had reached
approximately a quarter of the volume of the whole eye. In the
presence of the primary subcutaneous LLC-Low tumor, the corneal
implants did not become vascularized if the primary tumor was in
place by at least 4 days or more before the corneal implant (Table
1). In the absence of neovascularization, corneal tumors grew
slowly as thin, white, avascular discs within the cornea.
[0195] However, if the primary tumor was not implanted until 4 days
after the corneal implant, corneas became vascularized and
{fraction (3/3)} corneal tumors grew at similar rates as the
non-tumor bearing controls. In the presence of the primary
subcutaneous LLC-High tumor, the majority of corneas (2/3)
developed neovascularization starting at day 7 after corneal
implantation and continuing to day 10. By day 10, the vascularized
corneal tumors again had reached approximately a quarter of the
volume of the whole eye.
1TABLE 1 Inhibition of tumor angiogenesis in the cornea by a
primary subcutaneous tumor. [All primary tumors are LLC- Low except
(*) which is LLC-High]. Day of eye implant 0 0 0 0 0 0 0 Day of
primary tumor -7 -4 -4* 0 none +4 +7 implant Number of mice with
new 2/10 0/9 2/3 2/3 6/8 3/3 2/3 corneal vessels at day 10
[0196] It would be expected that 0/10 corneas would show
neovascularization when the primary LLC-Low subcutaneous tumor was
implanted 7 days before the eye tumor implant (i.e.--7). However, 2
of the tumors ({fraction (2/10)}) had become necrotic because they
were too large (>3 cm.sup.3).
EXAMPLE 6
[0197] Primary intact tumor inhibits angiogenesis induced by a
secondary subcutaneous implant of basic fibroblast growth factor
(bFGF.).
[0198] Although the experiments described in EXAMPLEs V and VI show
that a primary tumor inhibits angiogenesis in a secondary
metastasis, these studies do not reveal whether the primary tumor:
(i) inhibits endothelial proliferation (or angiogenesis) directly,
or (ii) indirectly by down-regulating the angiogenic activity of
the metastatic tumor cells. To distinguish between these two
possibilities, a focus of subcutaneous angiogenesis was induced by
an implant of matrigel containing basic fibroblast growth factor
(bFGF). (Passaniti A, et al., A simple, quantitative method for
assessing angiogenesis. and anti-angiogenic agents using
reconstituted basement membrane, heparin and fibroblast growth
factor. Lab. Invest. 67:519, 1992)
[0199] Matrigel (an extract of basement membrane proteins),
containing either 25 or 50 ng/ml bFGF in the presence of heparin,
was injected subcutaneously on the ventral surface of normal and
tumor-bearing mice (LLC-Low). Mice were sacrificed 4 days later and
hemoglobin concentration in the gel was measured to quantify blood
vessel formation. It has previously been shown that the number of
new vessels which enter the matrigel is correlated with hemoglobin
concentration. (Folkman J., Angiogenesis and its inhibitors in
"Important Advances in Oncology 1985", V T DeVita, S. Hellman and
S. Rosenberg, editors, J. B. Lippincott, Philadelphia 1985) Some
gels were also prepared for histological examination. In normal
mice, matrigel pellets which contained 50 ng/ml bFGF were
completely red. They were heavily invaded by new capillary vessels,
and contained 2.4 g/dl hemoglobin. Matrigel which lacked bFGF was
translucent and gray and contained only 0.4 g/dl hemoglobin (a
6-fold difference). In contrast, matrigel from mice with a primary
tumor contained only 0.5 g/dl (FIG. 4).
[0200] The near complete inhibition of angiogenesis in this
experiment suggests that the presence of a Lewis lung primary tumor
can inhibit bFGF-induced angiogenesis directly.
EXAMPLE 7
[0201] Transfer of serum from a tumor-bearing animal to an animal
from which the primary tumor has been removed suppresses
metastases.
[0202] Mice were implanted with Lewis lung carcinoma as described
above. After 15 days, when tumors were approximately 1500 mm.sup.3,
the mice were randomized into four groups. Three groups underwent
complete surgical resection of the primary tumor; in one group the
tumors were left in place (after a sham surgical procedure). The
mice in the three resection groups then received daily
intraperitoneal injections of saline, serum from normal nontumor
bearing mice, or serum from mice with 1500 mm.sup.3 Lewis lung
carcinomas. The group of mice with the tumors left intact received
intraperitoneal saline injections. All mice were treated for 21
days, after which the animals were euthanized and lung metastases
were counted (Table 2).
2 TABLE 2 Primary Primary Tumor Removed Tumor Treatment Serum from
Intact (Intraperitoneal Serum from tumor-bearing Saline Injections)
Saline normal mice mice Injections Number of Lung 55 .+-. 5 50 .+-.
4 7 .+-. 2 3 .+-. 1 Metastases:
[0203] These results were confirmed by lung weight. p=<0.0001
for the difference between the two groups [(55 & 50) vs. (7
& 3)]. Similar results have been obtained using angiostatin
from the urine of tumor-bearing animals.
EXAMPLE 8
[0204] Bovine capillary endothelial (BCE) cell assay
[0205] BCE cells are used between passages 9 and 14 only. At day 0,
BCE cells are plated onto gelatinized (1.5% gelatin in PBS at 370,
10% CO.sub.2 for 24 hours and then rinsed with 0.5 ml PBS) 24 well
plates at a concentration of 12,500 cells/well. Cell counts are
performed using a hemocytometer. Cells are plated in 500 .mu.l DMEM
with 10% heat-inactivated (56.degree. C. for 20 minutes) bovine
calf serum and 1% glutamine-pen-strep (GPS).
[0206] BCE cells are challenged-as follows: Media is removed and
replaced with 250 .mu.l of DMEM/5% BCS/1% GPS. The sample to be
tested is then added to wells. (The amount varies depending on the
sample being tested) Plates are placed at 37.degree. C./10%
CO.sub.2 for approximately 10 minutes. 250 .mu.l of DMEM/5% BCS/1%
GPS with 2 ng/ml bFGF is added to each well. The final media is 500
.mu.l of DMEM/5% BCS/1% GPS/with 1 ng/ml bFGF. The plate is
returned to 37.degree. C./10% CO.sub.2 incubator for 72 hours.
[0207] At day 4, cells are counted by removing the medium and then
trypsinizing all wells (0.5 ml trypsin/EDTA) for 2 to 3 minutes.
The suspended cells are then transferred to scintillation vials
with 9.5 ml Hemetall and counted using a Coulter counter. A unit of
activity is that amount of serum containing angiostatin that is
capable of producing half-maximal inhibition of capillary
endothelial proliferation when endothelial cells are incubated in
bFGF 1 ng/ml for 72 hours.
EXAMPLE 9
[0208] Serum from mice bearing the low metastatic Lewis lung tumor
(LLC-Low) inhibits capillary endothelial cell proliferation in
vitro.
[0209] Bovine capillary endothelial cells were stimulated by basic
fibroblast growth factor (bFGF 1 ng/ml), in a 72-hour proliferation
assay. The serum of tumor-bearing mice added to these cultures
inhibited endothelial cell proliferation in a dose-dependent and
reversible manner. Normal serum was not inhibitory (FIG. 5).
Endothelial cell proliferation was inhibited in a similar manner
(relative to controls) by serum obtained from tumor-bearing nu/nu
mice and SCID mice. After the primary tumor was removed,
angiostatin activity disappeared from the serum by 3-5 days.
[0210] Tumor-bearing serum also inhibited bovine aortic endothelial
cells and endothelial cells derived from a spontaneous mouse
hemangioendothelioma, (Obeso, et al., "Methods in Laboratory
Investigation, A Hemangioendothelioma-derived cell line; Its use as
a Model for the Study of Endothelial Cell Biology," Lab Invest.,
63(2), pgs 259-269, 1990) but did not inhibit Lewis lung tumor
cells, 3T3 fibroblasts, aortic smooth muscle cells, mink lung
epithelium, or W138 human fetal lung fibroblasts.
EXAMPLE 10
[0211] Serum from mice bearing the Lewis lung tumor (LLC-High) that
does not inhibit metastases, does not inhibit capillary endothelial
cell proliferation in vitro.
[0212] Serum from mice bearing a primary tumor of the LLC-High did
not significantly inhibit proliferation of bFGF-stimulated bovine
capillary endothelial cells relative to controls. Also, when this
serum was subjected to the first two steps of purification
(heparin-Sepharose chromatography and gel filtration), angiostatin
activity was not found in any fractions.
EXAMPLE 11
[0213] Ascites from Lewis lung carcinoma (low metastatic), also
generates angiostatin serum.
[0214] Mice received intraperitoneal injections of either LLC-Low
or LLC-High tumor cells (10.sup.6), and one week later, 1-2 ml of
bloody ascites was obtained from each of 10-20 mice. Mesenteric
tumor seeding was seen. The mice were then euthanized. Serum was
obtained by cardiac puncture. Serum was also obtained from normal,
non-tumor-bearing mice as a control. Serum and ascites were
centrifuged to remove cells, and the supemate was assayed on bovine
capillary endothelial cells stimulated by bFGF (1 ng/ml) (see
EXAMPLE IX). Ascites originating from both tumor types stimulated
significant proliferation of capillary endothelial cells (e.g.,
100% proliferation) over controls after 72 hours (FIG. 6). In
contrast, serum from the low metastatic mice inhibited endothelial
cell proliferation (inhibition to 79% of controls). The serum from
the high metastatic line was stimulatory by 200%.
[0215] These data show that the ascites of the low metastatic line
contains a predominance of endothelial growth stimulator over
angiostatin. This condition is analogous to a solid primary tumor.
Furthermore, angiostatin activity appears in the serum, as though
it were unopposed by stimulatory activity. This pattern is similar
to the solid primary tumor (LLC-Low). The ascites from the high
metastatic tumor (LLC-High) also appears to contain a predominance
of endothelial cell stimulator, but angiostatin cannot be
identified in the serum.
EXAMPLE 12
[0216] Fractionation of angiostatin from serum by column
chromatography and analysis of growth-inhibitory fractions by
SDS-PAGE.
[0217] To purify the angiostatin(s), serum was pooled from
tumor-bearing mice. The inhibitory activity, assayed according the
above-described in vitro inhibitor activity assay, was sequentially
chromatographed using heparin-Sepharose, Biogel AO0.5mm agarose,
and several cycles of C4-reverse phase high performance liquid
chromatography (HPLC). SDS-PAGE of the HPLC fraction which
contained endothelial inhibitory activity, revealed a discrete band
of apparent reduced M.sub.r of 38,000 Daltons, which was purified
approximately 1 million-fold (see Table 3) to a specific activity
of approximately 2.times.10.sup.7. At different stages of the
purification, pooled fractions were tested with specific antibodies
for the presence of known endothelial inhibitors. Platelet
factor-4, thrombospondin, or transforming growth factor beta, were
not found in the partially purified or purified fractions.
3 TABLE 3 Specific activity (units*/mg) Fold purification Serum
1.69 1 Heparin Sepharose 14.92 8.8 Bio-gel AO .5 m 69.96 41.4
HPLC/C4 2 .times. 10.sup.7 1.2 .times. 10.sup.6 *A unit of activity
is that amount of serum containing angiostatin that is capable of
producing half-maximal # inhibition of capillary endothelial
proliferation when endothelial cells are incubated in bFGF 1 ng/ml
for 72 hours.
EXAMPLE 13
[0218] Fractionation of angiostatin from urine by column
chromatography and analysis of growth-inhibitory fractions by
SDS-PAGE.
[0219] Purification of the endothelial cell inhibitor(s) from serum
is hampered by the small volume of serum that can be obtained from
each mouse and by the large amount of protein in the serum.
[0220] Urine from tumor bearing mice was analyzed and found that it
contains an inhibitor of endothelial cell proliferation that is
absent from the urine of non-tumor bearing mice and from mice with
LLC-high tumors. Purification of the endothelial cell inhibitory
activity was carried out by the same strategy that was employed for
purification of serum (described above) (FIG. 7).
[0221] FIG. 7 shows C4 reverse phase chromatography of partially
purified serum or urine from tumor-bearing animals. All fractions
were assayed on bovine capillary endothelial cells with bFGF in a
72-hour proliferation assay as described in EXAMPLE IX. A discrete
peak of inhibition was seen in both cases eluting at 30- 35%
acetonitrile in fraction 23. SDS-polyacrylamide gel electrophoresis
of inhibitory fraction from the third cycle of C4 reverse phase
chromatography of serum from tumor-bearing animals showed a single
band at about 38,000 Daltons.
EXAMPLE 14
[0222] Characterization of circulating angiostatin.
[0223] Endothelial inhibition was assayed according to the
procedure described in EXAMPLE 9. Angiostatin was isolated on a
Synchropak HPLC C4 column. (Synchrom, Inc. Lafayette, Ind.) The
inhibitor was eluted at 30 to 35% acetonitrile gradient. On a
sodium dodecyl sulfate polyacrylamide gel electrophoresis (PAGE)
gel under reducing conditions (b-mercaptoethanol(5% v/v), the
protein band with activity eluted at 38 kilodaltons. Under
non-reducing conditions, the protein with activity eluted at 28
kilodaltons. The activity is found at similar points whether the
initial sample was isolated from urine or from serum. Activity was
not detected with any other bands.
[0224] Activity associated with the bands was lost when heated
(100.degree. C. for 10 minutes) or treated with trypsin. When the
band with activity was extracted with a water/chloroform mixture
(1:1), the activity was found in the aqueous phase only.
EXAMPLE 15
[0225] Purification of inhibitory fragments from human
plasminogen:
[0226] Plasminogen lysine binding site I was obtained from Sigma
Chemical Company. The preparation is purified human plasminogen
after digestion with elastase. Lysine binding site I obtained in
this manner is a population of proteins that contain, in aggregate,
at least the first three triple-loop structures (numbers 1 through
3) in the plasmin A-chain (Kringle 1+2+3). (Sotrrup-Jensen, L., et
al. in Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3,
191, Davidson, J. F., et al. eds. Raven Press, New York 1978 and
Wiman, B., et al., Biochemica et Biophysica Acta, 579, 142 (1979)).
Plasminogen lysine binding site I (Sigma Chemical Company, St.
Louis, Mo.) was resuspended in water and applied to a C4-reversed
phase column that had been equilibrated with HPLC-grade water/0.1%
TFA. The column was eluted with a gradient of water/0. 1% TFA to
acetonitrile/0.1% TFA and fractions were collected into
polypropylene tubes. An aliquot of each was evaporated in a speed
vac, resuspended with water, and applied to BCEs in a proliferation
assay. This procedure was repeated two times for the inhibitory
fractions using a similar gradient for elution. The inhibitory
activity eluted at 30-35% acetonitrile in the final run of the C4
column. SDS-PAGE of the inhibitory fraction revealed 3 discrete
bands of apparent reduced molecular mass of 40, 42.5, and 45 kd.
SDS-PAGE under non-reducing conditions revealed three bands of
molecular mass 30, 32.5, and 35 kd respectively.
EXAMPLE 16
[0227] Extraction of inhibitory activity from SDS-PAGE
[0228] Purified inhibitory fractions from human plasminogen based
purifications were resolved by SDS-PAGE under non-denaturing
conditions. Areas of the gel corresponding to bands seen in
neighboring lanes loaded with the same samples by silver staining
were cut from the gel and incubated in 1 ml of phosphate buffered
saline at 4.degree. C. for 12 hours in polypropylene tubes. The
supernatant was removed and dialyzed twice against saline for 6
hours (MWCO=6-8000) and twice against distilled water for 6 hours.
The dialysate was evaporated by vacuum centrifugation. The product
was resuspended in saline and applied to bovine capillary
endothelial cells stimulated by 1 ng/ml basic fibroblast growth
factor in a 72 hour assay. Protein extracted from each of the three
bands inhibited the capillary endothelial cells.
EXAMPLE 17
[0229] Plasminogen Fragment Treatment Studies
[0230] Mice were implanted with Lewis lung carcinomas and underwent
resections when the tumors were 1500-2000 mm.sup.3. On the day of
operation, mice were randomized into 6 groups of 6 mice each. The
mice received daily intraperitoneal injections with the three
purified inhibitory fragments of human plasminogen, whole human
plasminogen, urine from tumor-bearing animals, urine from normal
mice, or saline. One group of tumor-bearing animals that had only a
sham procedure was treated with saline injections. Immediately
after removal of the primary tumor, the mice receive an
intraperitoneal injection of 24 .mu.g (1.2 mg/kg/day/mouse) of the
inhibitory plasminogen fragments as a loading dose. They then
receive a daily intraperitoneal injections of 12 .mu.g of the
inhibitory fragment (0.6 mg/kg/day/mouse) for the duration of the
experiment. Control mice receive the same dose of the whole
plasminogen molecule after tumor removal. For the urine treatments,
the urine of normal or tumor bearing mice is filtered, dialyzed
extensively, lyophilized, and then resuspended in sterile water to
obtain a 250 fold concentration. The mice are given 0.8 ml of the
dialyzed urine concentrate, either from tumor bearing mice or
normal mice, in two intraperitoneal injections on the day of
removal of the primary tumor as a loading dose. They then receive
daily intraperitoneal injections of 0.4 ml of the dialyzed and
concentrated urine for the course of the experiment. Treatments
were continued for 13 days at which point all mice were sacrificed
and autopsied.
[0231] The results of the experiment are shown in FIGS. 8 and 9.
FIG. 8 shows surface lung metastases after the 13 day treatment.
Surface lung metastases refers to the number of metastases seen in
the lungs of the mice at autopsy. A stereomicroscope was used to
count the metastases. FIG. 8 shows the mean number of surface lung
metastases that was counted and the standard error of the mean. As
shown, the group of mice with the primary tumor present showed no
metastases. The mice in which the primary tumor was resected and
were treated with saline showed extensive metastases. The mice
treated with the human derived plasminogen fragment showed no
metastases. The mice treated with whole plasminogen showed
extensive metastases indicating that the whole plasminogen molecule
has no endothelial inhibitory activity. Those mice treated with
dialyzed and concentrated urine from tumor bearing mice showed no
metastases. Mice treated with concentrated urine from normal mice
showed extensive metastases. When the weight of the lung was
measured, similar results were obtained (FIG. 9).
EXAMPLE 18
[0232] Amino acid sequence of murine and human angiostatin.
[0233] The amino acid sequence of angiostatin isolated from mouse
urine and angiostatin isolated from the human lysine binding site I
fragment preparation was determined on an Applied Biosystem Model
477A protein sequencer. Phenylthiohydantoin amino acid fractions
were identified with an on-line ABI Model 120A HPLC. The amino acid
sequence determined from the N-terminal sequence and the tryptic
digests of the murine and human angiostatin indicate that the
sequence of the angiostatin is similar to the sequence beginning at
amino acid number 98 of murine plasminogen. Thus, the amino acid
sequence of the angiostatin is a molecule comprising a protein
having a molecular weight of between approximately 38 kilodaltons
and 45 kilodaltons as determined by reducing polyacrylamide gel
electrophoresis and having an amino acid sequence substantially
similar to that of a murine plasminogen fragment beginning at amino
acid number 98 of an intact murine plasminogen molecule. The
beginning amino acid sequence of the murine angiostatin (SEQ ID
NO:2) is shown in FIG. 1. The length of the amino acid sequence may
be slightly longer or shorter than that shown in the FIG. 1.
[0234] N terminal amino acid analysis and tryptic digests of the
active fraction of human lysine binding site I (See EXAMPLE 15)
show that the sequence of the fraction begins at approximately
amino acid 97 or 99 of human plasminogen and the human angiostatin
is homologous with the murine angiostatin. The beginning amino acid
sequence of the human angiostatin (starting at amino acid 98) is
shown in FIG. 2, (SEQ ID NO:3). The amino acid sequence of murine
and human angiostatin is compared in FIG. 2 to corresponding
internal amino acid sequences from plasminogen of other species
including porcine, bovine, and Rhesus monkey plasminogen,
indicating the presence of angiostatin in those species.
EXAMPLE 19
[0235] Expression of human angiostatin in E. coli.
[0236] The pTrcHisA vector (Invitrogen) (FIG. 10) was used to
obtain high-level, regulated transcription from the trc promoter
for enhanced translation efficiency of eukaryotic genes in E. coli.
Angiostatin is expressed fused to an N-terminal nickel-binding
poly-histidine tail for one-step purification using metal affinity
resins. The enterokinase cleavage recognition site in the fusion
protein allows for subsequent removal of the N-terminal histidine
fusion protein from the purified recombinant protein. The
recombinant human angioststin protein was found to bind lysine; is
cross-reactive with monoclonal antibodies specific for kringle
regions 1, 2 and 3, and inhibits bFGF-driven endothelial cell
proliferation in vitro.
[0237] To construct the insert, the gene fragment encoding human
angiostatin is obtained from human liver mRNA which is reverse
transcribed and amplified using the polymerase chain reaction (PCR)
and specific primers. The product of 1131 base pairs encodes amino
acids 93 to 470 of human plasminogen. The amplified fragment was
cloned into the XhoI/KpnI site of pTrcHisA, and the resultant
construct transformed into XL-1B (available from Stratagene) E.
coli host cells. A control clone containing the plasmid vector
pTrcHisA alone was transformed inot XL-1B E. coli host cells as
well. This clone is referred to as the vector control clone. Both
clones were purified identically as described below.
[0238] Expressing colonies were selected in the following manner.
Colony lifts of E. coli transformed with the gene encoding
angiostatin were grown on IPTG impregnated nitrocellulose filters
and overlaid on an LB agar plate. Following IPTG induction of
expression, colonies were lysed on nitrocellulose filters. The
nitrocellulose lifts were blocked, rinsed and probed with two
separate monoclonal antibodies (mAbs Dcd and Vap; gift of S. G.
McCance and F. J. Castellino, University of Notre Dame) which
recognize specific conformations of angiostatin. Strongly
expressing colonies recognized by the mAbs were selected.
[0239] To identify the optimal time for maximal expression, cells
were collected at various times before and after IPTG induction and
exposed to repeated freeze-thaw cycles, followed by analysis with
SDS-PAGE, immunoblotting and probing with mAbs Dcd and Vap.
[0240] From these, clone pTrcHisA/HAsH4 was selected. Induction
with IPTG was for 4 hours after which the cell pellet was collected
and resuspended in 50 mM Tris pH 8.0, 2 mM EDTA, 5% glycerol and
200 mg/ml lysozyme and stirred for 30 min. at 4.degree. C. The
slurry was centrifuged at 14,000 rpm for 25 min. and the pellet
resuspended in 50 mM Tris pH 8.0, 2 mM EDTA, 5% glycerol and 0.1%
DOC. This suspension was stirred for 1 hr. at 4.degree. C., and
then centrifuged at 14,000 rpm for 25 min. The supernatant fraction
at this step contains expressed angiostatin. The E. coli expressed
human angiostatin was found to possess the physical property of
native angiostatin, that is the ability to bind lysine. The E. coli
expressed angiostatin was thus purified over a lysine-sepharose
(Pharmacia or Sigma) column in a single step. Elution of
angiostatin from the column was with 0.2M epsilon-amino-n-caproic
acid pH7.5.
[0241] Subsequent to these experiments, scale-up 10 L fermentation
batches of clone pTrcHisA/HAsH4 was performed. The cells obtained
from this scaled-up induction were pelleted and resuspended in50 mM
Tris pH7.5, cracked at 10,000 psi thrice chilling at 10.degree. C.
in-between passes. The lysate obtained was clarified by
centrifugation at 10,000 rpm for 30 min at 4.degree. C., and
expressed angiostatin isolated over lysine-sepharose (FIG. 11).
[0242] Purified E. coli expressed human angiostatin was dialysed
exhaustively against water and lyophilized. The expressed human
angiostatin was resuspended in media (DMEM, 5% BCS, 1%
Gentamycin/penicillin/streptomycin) to an estimated concentration
of 3 ug/ml, and used in bovine capillary endothelial (BCE) cell
assays in vitro, as described in EXAMPLE 8, pg.39. Similarly, the
control clone containing the vector alone was treated in the
identical fashion as the clone pTrcHisA/HAsH4. It was induced with
IPTG identically, and the bacterial lysate used to bind lysine,
eluted with 0.2 M amino caproic acid, dialysed exhaustively and
lyophilized. This control preparation was resuspended in media also
at an estimated concentration of 3 ug/ml. The samples of
recombinant angiostatin, and controls were obtained from different
induction and fermentation batches as well as seperate purification
runs, and were all coded at EntreMed, Maryland. BCE assays were
performed with these coded samples in a blinded fashion at
Children's Hospital, Boston.
[0243] The results of BCE assays of recombinant human angiostatin
showed that human angiostatin expressed in E.coli inhibited the
proliferation of BCE cells due to bFGF (used at 1 ng/ml) (FIG. 12).
The stock recombinant angiostatin in media (at about 3 ug/ml) was
used at a 1:5, 1:10 and 1:20 dilution. Percent inhibition was
calculated as follows: 1 1 - number of cells with angiostatin -
number of cells at day 0 number of cells with bFGF alone - number
of cells at day 0
[0244] The percent inhibition of BCE cell proliferation was
comparable or higher to that of plasminogen derived angiostatin at
similar concentrations. The results from a repeat run of the BCE
assay are depicted in FIG. 13, where at a 1:5 dilution of the
stock, recombinant angiostatin gave similar percent inhibitions to
those obtained with plasminogen derived angiostatin. FIG. 13 shows
the surprising result that human recombinant angiostatin protein
inhibits over 60%, and as much as over 75% of BCE proliferation in
culture.
EXAMPLE 20
[0245] Angiostatin maintains dormancy of micrometastases by
increasing the rate of apoptosis.
[0246] Following subcutaneous inoculation of C57 BL6/J mice with
Lewis lung carcinoma cells (1.times.10.sup.6), primary tumors of
approximately 1.5 cm.sup.3 developed. Animals were subject to
either surgical removal of the primary tumor or sham surgery. At 5,
10 and 15 days after surgery, mice were sacrificed and their lungs
prepared for histological examination. Animals with resected
primary tumors showed massive proliferation of micrometastases
compared to sham operated controls (FIG. 14). These changes were
accompanied by a significant increase in lung weight.
[0247] Analysis of tumor cell proliferation, as measured by uptake
of bromo-deoxyuridine (BrdU) showed no differences between animals
with intact primary tumors or resected tumors at 5, 9 and 13 days,
indicating that the increase in tumor mass could not be explained
by increased proliferation (FIG. 15). Accordingly, cell death was
examined in these animals. Apoptosis, a process of cell death that
is dependent on changes in gene expression and accounts for
elimination of cells during development and in rapidly
proliferating tissues such as the small intestine, was examined by
immunohistochemically labeling fragmented DNA with the terminal
deoxynucleotidyl transferase (TdT) technique. The apoptotic index
was determined at each time of sacrifice. The removal of primary
tumors caused a statistically significant increase (approximately 3
to 4 fold) in the apoptotic index at all times examined (FIG.
15).
[0248] Supporting evidence was obtained by treating mice with
removed primary tumors with an exogenous suppressor of
angiogenesis. This substance, TNP-1470 (O-chloroacetylcarbamoyl
fumagillol, previously named AGM-1470), is an analogue of
fumagillin with reported anti-angiogenic activity. Subcutaneous
injection of TNP-1470 (30 mg/kg every two days) produced results
that were strikingly similar to those described above for animals
that had intact primary tumors. These animals displayed a lower
lung weight, equivalent proliferative index and increased apoptotic
index compared to saline-injected controls (FIG. 16).
[0249] These data indicate that metastases remain dormant when
tumor cell proliferation is balanced by an equivalent rate of cell
death. The removal of the primary tumor causes a rapid increase in
the growth of metastases, probably due to the removal of
angiogenesis inhibitors (angiostatin) which control metastatic
growth by increasing apoptosis in tumor cells. These effects are
similar to those seen following removal of primary tumors and
administration of an exogenous inhibitor of angiogenesis. Taken
together, these data suggest that the primary tumor releases
angiostatin which maintains dormancy of micrometastases.
EXAMPLE 21
[0250] Treatment of primary tumors with angiostatin in vivo.
[0251] Angiostatin was purified from human plasminogen by limited
elastase digestion as described in EXAMPLE 15 above. Angiostatin
was resuspended in phosphate-buffered saline for administration
into six week old male C57BI6/J mice. Animals were implanted
subcutaneously with 1.times.10.sup.6 tumor cells of either the
Lewis lung carcinoma or T241 fibrosarcoma. Treatment with
angiostatin is begun after four days when tumors are 80-160 mm in
size. Mice received angiostatin injections in either a single
injection of 40 mg/kg or two 80 mg/kg injections via
intraperitoneal (ip) or subcutaneous (sc) routes. Animals were
sacrificed at various times after treatment extending to 19
days.
[0252] Angiostatin, administered at a daily dose of 40 mg/kg ip,
produced a highly significant inhibition of the growth of T241
primary tumors (FIG. 17). This inhibitory effect on growth was
visibly evident within 2 days and increased in magnitude throughout
the time course of the study. By day 18, angiostatin-treated mice
had tumors that were approximately 38% of the volume of the saline
injected controls. This difference was statistically significant
(p<0.001, Students t-test).
[0253] Angiostatin treatment (total dose of 80 mg/kg/day,
administered twice daily at 40 mg/kg ip or sc) also significantly
reduced the growth rate of LLC-LM primary tumors (FIG. 17). This
inhibitory effect was evident at 4 days and increased in magnitude
at all subsequent times examined. On the last day of the experiment
(day 19), angiostatin-treated mice possessed a mean tumor volume
that was only 20% of the saline-injected controls which was
significantly different (p<0.001 Students t-test).
[0254] In another series of experiments angiostatin was
administered (50 mg/kg q12 h) to mice implanted with T241
fibrosarcoma, Lewis lung carcinoma (LM) or reticulum cell sarcoma
cells. For each tumor cell type, the mice receiving angiostatin had
substantially reduced tumor size. FIG. 19 demonstrates that for
T241 fibrosarcoma, the angiostatin treated mice had mean tumor
volumes that were only 15% of the untreated mice at day 24. FIG. 20
demonstrates that for Lewis lung carcinoma (LM), the angiostatin
treated mice had mean tumor volumes that were only 13% of the
untreated mice at day 24. FIG. 21 demonstrates that for reticulum
sacroma, the angiostatin treated mice had mean tumor volumes that
were only 19% of the untreated mice at day 24. The data represent
the average of 4 mice at each time point.
[0255] These results demonstrate that angiostatin is an extremely
potent inhibitor of the growth of three different primary tumors in
vivo.
EXAMPLE 22
[0256] Treatment of human cell-derived primary tumors in mice with
angiostatin in vivo.
[0257] The effect of angiostatin on two human tumor cell lines,
human prostate carcinoma PC-3 and human breast carcinoma MDA-MB,
was studied. Immunodeficient SCID mice were implanted with human
tumor cells, and the mice treated with 50 mg/kg angiostatin every
12 hours essentially as described in EXAMPLE 21. The results
demonstrate that the angiostatin protein of the present invention
is a potent inhibitor of human tumor cell growth. FIG. 22 shows
that for human prostate carcinoma PC-3, the angiostatin treated
mice had only 2% of the mean tumor volume compared to the untreated
control mice at day 24. FIG. 23 shows that for human breast
carcinoma MDA-MB, he angiostatin treated mice had only 8% of the
mean tumor volume compared to the untreated control mice at day
24.
EXAMPLE 23
[0258] Gene Therapy--Effect of transfection of the angiostatin gene
on tumor volume.
[0259] A 1380 base pair DNA sequence for angiostatin derived from
mouse plasminogen cDNA (obtained from American Type Culture
Collection (ATCC)), coding for mouse plasminogen amino acids 1-
460, was generated using PCR and inserted into an expression
vector. The expression vector was transfected into T241
fibrosarcoma cells and the transfected cells were implanted into
mice. Control mice received either non-transfected T241 cells, or
T241 cells transfected with the vector only (i.e. non-angiostatin
expressing transfected cells). Three angiostatin-expressing
transfected cell clones were used in the experiment. Mean tumor
volume determined over time. The results show the surprising and
dramatic reduction in mean tumor volume in mice for the
angiostatin-expressing cells clones as compared with the
non-transfected and non-expressing control cells.
[0260] The mouse DNA sequence coding for mouse angiostatin protein
is derived from mouse plasminogen cDNA. The mouse angiostatin
encompasses mouse plasminogen kringle regions 1-4. The schematic
for constructing this clone is shown in FIG. 24.
[0261] The mouse angiostatin protein clones were transfected into
T241 fibrosarcoma cells using the LIPOFECTIN.TM. transfection
system (available from Life Technologies, Gaithersburg, Md.). The
LIPOFECTIN.TM. reagent is a 1:1 (w/w) liposome formulation of the
cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium
chloride (DOTMA), and diolecoyl phosphotidylethanolamine (DOPE) in
membrane filtered water.
[0262] The procedure for transient transfection of cells is as
follows:
[0263] 1. T241 cells are grown in 60 cm.sup.2 tissue culture
dishes, seed .apprxeq.1-2.times.10.sup.5 cells in 2 ml of the
appropriate growth medium supplemented with serum.
[0264] 2. Incubate the cells at 37.degree. C. in a CO.sub.2
incubator until the cells are 40-70% confluent. will usually take
18-24 h, but the time will vary among cell types. The T241 tumor
cells confluency was approximately 70%.
[0265] 3. Prepare the following solutions in 12.times.75 mm sterile
tubes:
[0266] Solution A: For each transfection, dilute 5 .mu.g of DNA in
100 .mu.l of serum-free OPTI-MEM I Reduced Serum Medium (available
from Life Technologies) (tissue culture grade deionized water can
also be used).
[0267] Solution B: For each transfection, dilute 30 .mu.g of
LIPOFECTIN in 100 .mu.l OPTI-MEM medium.
[0268] 4. Combine the two solutions, mix gently, and incubate at
room temperature for 10-15 min.
[0269] 5. Wash cells twice with serum-free medium.
[0270] 6. For each transfection, add 0.8 ml serum-free medium to
each tube containing the LIPOFECTIN.TM. reagent-DNA complexes. Mix
gently and overlay the complex onto cells.
[0271] 7. Incubate the cells for approximately. 12 h at 37.degree.
C. in a CO.sub.2 incubator.
[0272] 8. Replace the DNA containing medium with 1 mg/ml selection
medium containing serum and incubate cells at 37.degree. C. in a
CO.sub.2 incubator for a total of 48-72 h.
[0273] 9. Assay cell extracts for gene activity at 48-72 h post
transfection.
[0274] Transfected cells can be assayed for expression of
angiostatin protein using angiostatin-specific antibodies.
Alternatively, after about 10-14 days, G418 resistant colonies
appeared in the CMV-angiostatin transfected T241 cells. Also, a
number of clones were seen in the vector alone transfected clones
but not in the untransfected clones. The G418 resistant clones were
selected for their expression of angiostatin, using a
immunofluorence method.
[0275] Interestingly, the in vitro cell growth T241 cells and Lewis
lung cells transfected with angiostatin was not inhibited or
otherwise adversely affected, as shown in FIGS. 25 and 26.
[0276] FIG. 27 depicts the results of the transfection experiment.
All three of the angiostatin-expressing T241 transfected clones
produced mean tumor volumes in mice that were substantially reduced
relative to the tumor volume in contol mice. The mean tumor volume
of the mice implanted with Clone 37 was only 13% of the control,
while Clone 31 and Clone 25 tumor volumes were only 21% and 34% of
the control tumor volumes, respectively. These results demonstrate
that the DNA sequences coding for angiostatin can be transfected
into cells, that the transfected DNA sequences are capable of
expressing angiostatin protein by implanted cells, and that the
expressed angiostatin functions in vivo to reduce tumor growth.
EXAMPLE 24
[0277] Localization of in vivo site of angiostatin expression
[0278] To localize the in vivo site of expression of angiostatin
protein, total RNA from various cell types, Lewis lung carcinoma
cells (mouse), T241 fibrosarcoma (mouse), and Burkitt's lymphoma
cells (human), both from fresh tumor or cell culture after several
passages were analysed to determine the presence of angiostatin
transcripts. Northern analysis of samples showed an absence of any
signal hybridizing with thn sequence from all samples except that
of normal mouse liver RNA showing a single signal of approximately
2.4 kb corresponding to mouse plasminogen. Northern analysis of
human samles show an absence of any signal hybridizing with human
angiostatin sequence from all samples except that of normal human
liver RNA showing a single signal of approximately 2.4 kb
corresponding to human plasminogen.
[0279] Reverse transcription polymerase chain reaction (RT-PCR)
analysis showed an absence of any product from all samples probed
with mouse angiostatin sequences except that of the normal mouse
liver. RT-PCR analysis showed an absence of any product from all
human samples probed with human angiostatin sequences except that
of the normal human liver (expected size of 1050 bp for mouse and
1134 bp for human).
[0280] Thus it appears that mouse angiostatin transcripts (assuming
identity with amino acids 97 to 450 of mouse plasminogen) are not
produced by all the above mouse samples and human angiostatin
transcripts (assuming identity with amino acids 93 to 470 of human
plasminogen) are not produced by the above human samples. The
positive signals obtained in normal mouse/human liver is from
hybridization with plasminogen.
EXAMPLE 25
[0281] Expression of Angiostatin in Yeast
[0282] The gene fragment encoding amino acids 93 to 470 of human
plasminogen was cloned into the XhoI/EcoRI site of
pHIL-SI(Invitrogen) which allows the secreted expression of
proteins using the PHO1 secretion signal in the yeast Pichia
pastoris. Similarly, the gene fragment encoding amino acids 93 to
470 of human plasminogen was cloned into the SnaBI/EcoRI site of
pPIC9 (Invitrogen) which allows the secreted expression of proteins
using the a-factor secretion signal in the yeast Pichia pastiris.
The expressed human angiostatin proteins in these systems will have
many advantages over those expressed in E. coli such as protein
processing, protein folding and posttranslational modification
inclusive of glycosylation.
[0283] Expression of gene in P. pastiris : is described in )
Sreekrishna, K. et al. (1988) High level expression of heterologous
proteins in methylotropic yeast Pichia pastiris. J. Basic
Microbiol. 29 (4): 265-278, and Clare, J. J. et al. (1991)
Production of epidermal growth factor in yeast: High-level
secretion using Pichia pastiris strains containing multiple gene
copies, Gene 105:205-212, both of which are hereby incorporated
herein by reference.
EXAMPLE 26
[0284] Expression of angiostatin proteins in transgenic animals and
plants
[0285] Transgenic animals such as of the bovine or procine family
are created which express the angiostatin gene transcript. The
transgenic animal express angiostatin protein for example in the
milk of these animals. Additionally edible transgenic plants which
express the angiostatin gene transcript are constructed.
[0286] Constructing transgenic animals that express foreign DNA is
described in Smith H. Phytochrome transgenics: functional,
ecological and biotechnical applications, Semin. Cell. Biol. 1994
5(5):315-325, which is hereby incorporated herein by reference.
EXAMPLE 27
[0287] Characterization of Endothelial Cell Proliferation
Inhibiting Angiostatin Fragments
[0288] The following example characterizes the activity of
individual and combinational angiostatin fragments. The data
suggests that a functional difference exists among individual
kringle structures, and potent anti-endothelial, and hence
anti-angiogenic, activity can be obtained from such protein
fragments of angiostatin.
[0289] As used herein, "angiostatin fragment" means a protein
derivative of angiostain, or plasminogen, having an endothelial
cell proliferation inhibiting activity. Angiostatin fragments are
useful for treating angiogenic-mediated diseases or conditions. For
example, angiostatin fragments can be used to inhibit or suppress
tumor growth. The amino acid sequence of such an angiostatin
fragment, for example, can be selected from a portion of murine
plasminogen (SEQ ID NO:1), murine angiostatin (SEQ ID NO:2); human
angiostatin (SEQ ID NO:3), Rhesus angiostatin (SEQ ID NO:4),
porcine angiostatin (SEQ ID NO:5), and bovine angiostatin (SEQ ID
NO:6), unless indicated otherwise by the context in which it is
used.
[0290] As used herein, "kringle 1" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 1, exemplified by, but
not limited to that of murine kringle 1 (SEQ ID NO:7), human
kringle 1 (SEQ ID NO:8), Rhesus kringle 1 (SEQ ID NO:9), porcine
kringle 1 (SEQ ID NO:10), and bovine kringle 1 (SEQ ID NO:11),
unless indicated otherwise by the context in which it is used.
Murine kringle 1 (SEQ ID NO:7) corresponds to amino acid positions
103 to 181 (inclusive) of murine plasminogen of SEQ ID NO:1, and
corresponds to amino acid positions 6 to 84 (inclusive) of murine
angiostatin of SEQ ID NO:2. Human kringle 1 (SEQ ID NO:8), Rhesus
kringle 1 (SEQ ID NO:9), porcine kringle 1 (SEQ ID NO:10), and
bovine kringle 1 (SEQ ID NO:11) correspond to amino acid positions
6 to 84 (inclusive) of angiostatin of SEQ ID NO:3, SEQ ID NO:4, SEQ
ID NO:5, and SEQ ID NO:6, respectively.
[0291] As used herein, "kringle 2" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 2, exemplified by, but
not limited to that of murine kringle 2 (SEQ ID NO:12), human
kringle 2 (SEQ ID NO:13), Rhesus kringle 2 (SEQ ID NO:14), porcine
kringle 2 (SEQ ID NO:15), and bovine kringle 2 (SEQ ID NO:16),
unless indicated otherwise by the context in which it is used.
Murine kringle 2 (SEQ ID NO:12) corresponds to amino acid positions
185 to 262 (inclusive) of murine plasminogen of SEQ ID NO:1, and
corresponds to amino acid positions 88 to 165 (inclusive) of murine
angiostatin of SEQ ID NO:2. Human kringle 2 (SEQ ID NO:13), Rhesus
kringle 2 (SEQ ID NO: 14), porcine kringle 2 (SEQ ID NO:15), and
bovine kringle 2 (SEQ ID NO:16) correspond to amino acid positions
88 to 165 (inclusive) of angiostatin of SEQ ID NO:3, SEQ ID NO:4,
SEQ ID NO:5, and SEQ ID NO:6, respectively.
[0292] As used herein, "kringle 3" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 3, exemplified by, but
not limited to that of murine kringle 3 (SEQ ID NO:17), human
kringle 3 (SEQ ID NO:18), Rhesus kringle 3 (SEQ ID NO:19), porcine
kringle 3 (SEQ ID NO:20), and bovine kringle 3 (SEQ ID NO:21).
Murine kringle 3 (SEQ ID NO:17) corresponds to amino acid positions
275 to 352 (inclusive) of murine plasminogen of SEQ ID NO:1, and
corresponds to amino acid positions 178 to 255 (inclusive) of
murine angiostatin of SEQ ID NO:2. Human kringle 3 (SEQ ID NO:18),
Rhesus kringle 3 (SEQ ID NO:19), porcine kringle 3 (SEQ ID NO:20),
and bovine kringle 3 (SEQ ID NO:21) correspond to amino acid
positions 178 to 255 (inclusive) of angiostatin of SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively.
[0293] As used herein, "kringle 4" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 4, exemplified by, but
not limited to that of murine kringle 4 (SEQ ID NO:22) and human
kringle 4 (SEQ ID NO:23), unless indicated otherwise by the context
in which it is used. Murine kringle 4 (SEQ ID NO:22) corresponds to
amino acid positions 377 to 454 (inclusive) of murine plasminogen
of SEQ ID NO:1.
[0294] As used herein, "kringle 2-3" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 2-3, exemplified by,
but not limited to that of murine kringle 2-3 (SEQ ID NO:24), human
kringle 2-3 (SEQ ID NO:25), Rhesus kringle 2-3 (SEQ ID NO:26),
porcine kringle 2-3 (SEQ ID NO:27), and bovine kringle 2-3 (SEQ ID
NO:28), unless indicated otherwise by the context in which it is
used. Murine kringle 2-3 (SEQ ID NO:24) corresponds to amino acid
positions 185 to 352 (inclusive) of murine plasminogen of SEQ ID
NO:1, and corresponds to amino acid positions 88 to 255 (inclusive)
of murine angiostatin of SEQ ID NO:2. Human kringle 2-3 (SEQ ID
NO:25), Rhesus kringle 2-3 (SEQ ID NO:26), porcine kringle 2-3 (SEQ
ID NO:27), and bovine kringle 2-3 (SEQ ID NO:28) correspond to
amino acid positions 88 to 255 (inclusive) of angiostatin of SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively.
[0295] As used herein, "kringle 1-3" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 1-3, exemplified by,
but not limited to that of murine kringle 1-3 (SEQ ID NO:29), human
kringle 1 (SEQ ID NO:30), Rhesus kringle 1-3 (SEQ ID NO:31),
porcine kringle 1-3 (SEQ ID NO:32), and bovine kringle 1-3 (SEQ ID
NO:33), unless indicated otherwise by the context in which it is
used. Murine kringle 1-3 (SEQ ID NO:29) corresponds to amino acid
positions 103 to 352 (inclusive) of murine plasminogen of SEQ ID
NO:1, and corresponds to amino acid positions 6 to 255 (inclusive)
of murine angiostatin of SEQ ID NO:2. Human kringle 1-3 (SEQ ID
NO:30), Rhesus kringle 1-3 (SEQ ID NO:31), porcine kringle 1-3 (SEQ
ID NO:32), and bovine kringle 1-3 (SEQ ID NO:33) correspond to
amino acid positions 6 to 255 (inclusive) of angiostatin of SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively.
[0296] As used herein, "kringle 1-2" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 1-2, exemplified by,
but not limited to that of murine kringle 1-2 (SEQ ID NO:34), human
kringle 1-2 (SEQ ID NO:35), Rhesus kringle 1-2 (SEQ ID NO:36),
porcine kringle 1-2 (SEQ ID NO:37), and bovine kringle 1-2 (SEQ ID
NO:38), unless indicated otherwise by the context in which it is
used. Murine kringle 1-2 (SEQ ID NO:34) corresponds to amino acid
positions 103 to 262 (inclusive) of murine plasminogen of SEQ ID
NO:1, and corresponds to amino acid positions 6 to 165 (inclusive)
of murine angiostatin of SEQ ID NO:2. Human kringle 1-2 (SEQ ID
NO:35), Rhesus kringle 1-2 (SEQ ID NO:36), porcine kringle 1-2 (SEQ
ID NO:37), and bovine kringle 1-2 (SEQ ID NO:38) correspond to
amino acid positions 6 to 165 (inclusive) of angiostatin of SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively.
[0297] As used herein, "kringle 1-4" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 1-4, exemplified by,
but not limited to that of murine kringle 1-4 (SEQ ID NO:39) and
human kringle 1-4 (SEQ ID NO:40), unless indicated otherwise by the
context in which it is used. Murine kringle 1-4 (SEQ ID NO:39)
corresponds to amino acid positions 103 to 454 (inclusive) of
murine plasminogen of SEQ ID NO:1.
[0298] Kringle 1, kringle 2, kringle 3, kringle 4, kringle 2-3,
kringle 1-3, kringle 1-2 and kringle 1-4 amino acid sequences are
respectively homologous to the specific kringle sequences
identified above. Preferably, the amino acid sequences have a
degree of homology to the disclosed sequences of at least 60%, more
preferably at least 70%, and more preferably at least 80%. It
should be understood that a variety of amino acid substitutions,
additions, deletions or other modifications to the above listed
fragments may be made to improve or modify the endothelial cell
proliferation inhibiting activity or anti-angiogenic activity of
the angiostatin fragments. Such modifications are not intended to
exceed the scope and spirit of the claims. For example, to avoid
homodimerization by formation of inter-kringle disulfide bridges,
the cysteine residues C4 in recombinant human kringle 2 (SEQ ID
NO:13) and C42 in recombinant kringle 3 (SEQ ID NO:18) were mutated
to serines. Furthermore, it is understood that a variety of amino
acid substitutions, additions, deletions or other modifications can
be made in the above identified angiostatin fragments, which do not
significantly alter the fragments'endothelial cell proliferation
inhibiting activity, and which are, therefore, not intended to
exceed the scope of the claims. By "not significantly alter" is
meant that the angiostatin fragment has at least 60%, more
preferably at least 70%, and more preferably at least 80% of the
endothelial cell proliferation inhibiting activity compared to that
of the closest homologous angiostatin fragment disclosed
herein.
[0299] Gene Construction and Expression
[0300] A PCR-based method was used to generate the cDNA fragments
coding for kringle 1 (K1), kringle 2 (K2), kringle 3 (K3), kringle
4 (K4) and kringle 2-3 (K2-3) of human plasminogen (HPg).
Recombinant kringle 1 (rK1), kringle 2 (rK2), kringle 3 (rK3),
kringle 4 (rK4) and kringle 2-3 (rK2-3) were expressed in E. coli
as previously described (Menhart, N., Shel, L. C., Kelly, R. F.,
and Castellino, F. J. (1991) Biochem. 30, 1948-1957; Marti, D.,
Schaller, J., Ochensberger, B., and Rickli, E. E. (1994) Eur. J.
Biochem. 219, 455-462; Sohndel, S., Hu, C. -K., Marti, D.,
Affolter, M., Schaller, J., Llinas, M., and Rickli, E. E. (1996)
Biochem. in press; Rejante, M. R., Byeon, I. -J.L., and Llinas, M.
(1991) Biochem. 30, 11081-11092). To avoid homodimerization by
formation of inter-kringle disulfide bridges as shown in FIG. 32B,
the cysteine residues C169 and rK2 and C297 in rK3 were mutated to
serines as seen in SEQ ID NO.s 13 and 18, at positions 4 and 42,
respectively. (Sohndel, S., Hu, C. -K., Marti, D., Affolter, M.,
Schaller, J., Llinas, M., and Rickli, E. E. (1996) Biochem. in
press). The rK3 and rK2-3 contained an N-terminal hexa-histidine
tag which was used for protein purification (not shown).
[0301] Proteolytic Digestion
[0302] The fragments of K1-3, K1-4 and K4 were prepared by
digestion of Lys-HPg (Abbott Labs) with porcine elastase (Sigma) as
previously described (Powell, J. R., and Castellino, F. J. (1983)
Biochem. 22, 923-927). Briefly, 1.5 mg elastase was incubated at
room temperature with 200 mg of human plasminogen in 50 mM Tris-HCl
pH 8.0 overnight with shaking. The reaction was terminated by the
addition of diisopropyl fluorophosphate (DFP) (Sigma) to a final
concentration of 1 mM. The mixture was rocked for an additional 30
minutes at room temperature and dialyzed overnight against 50 mM
Tris-HC1, pH 8.0.
[0303] Protein Purification
[0304] Recombinant K1 was expressed in DH5.alpha.E. coli bacterial
cells using a pSTII plasmid vector. This protein was purified to
homogeneity by chromatography using lysine-Sepharose 4B (Pharmacia)
and Mono Q (BioRad) columns. E. coli bacterial cells (strain HB101)
expressing rK2 and rK3 were grown to an OD.sub.600 of approximately
0.8 at 3.degree. C. in 2.times.YT medium containing 100 mg/ml
ampicillin and 25 mg/ml kanamycin. IPTG
(isopropyl-b-D-thiogalactopyranoside) was added to a final
concentration of 0.1 mM and cells were grown for an additional 4.5
hours at 37.degree. C. to induce the production of recombinant
proteins. The cells were harvested by centrifugation and the
pellets were stored at -80.degree. C. The thawed cell lysates were
re-suspended in the extraction buffer (6 M guanidine hydrochloride
in 0.1 M sodium phosphate, pH 8.0). The suspension was centrifuged
at 15,000.times.g for 30 minutes and b-mercaptoethanol was added to
the supernatant at a final concentration of 10 mM. The supernatant
was then loaded on a Ni.sup.2+-NTA agarose column (1.5 cm.times.5
cm) pre-equilibrated with the extraction buffer. The column was
washed successively with extraction buffer at pH 8.0 and pH 6.3,
respectively. Recombinant K2 and K3 were eluted with extraction
buffer at pH 50.
[0305] The proteolytically cleaved fragments of K1-3, K1-4 and K4
were purified using a lysine-Sepharose 4B column (2.5 cm.times.15
cm) equilibrated with 50 mM Tris-HCl, pH 8.0 until an absorbance at
180 nm reached 0.005. The absorbed kringle fragments were eluted
with Tris buffer containing 200 mM c-aminocaproic acid, pH 8.0. The
eluted samples were the dialyzed overnight against 20 mM Tris-HC1,
pH 5.0, and were applied to a BioRad Mono-S column equilibrated
with the same buffer. The fragments of K4, K1-3 and K1-4 were
eluted with 0-20%, 20-50% and 50-70% step-gradients of 20 mM
phosphate/l M KC1, pH 5.0. Most K1-3 and K1-4 fragments were eluted
from the column with 0.5 M KC1 as determined by SDS-PAGE. All
fractions were dialyzed overnight against 20 mM Tris-HC1, pH 8.0.
After dialysis, K1-3 and K1-4 fragments were further purified using
a heparin-Sepharose column (5 cm.times.10 cm) (Sigma)
pre-equilibrated with 20 mM Tris-HCl buffer, pH 8.0. The K1-3
fragment was eluted with 350 mM KC1 and K1-4 was recovered from the
flow-through fraction. The purified kringle fragments were analyzed
on SDS-gels follows by silver-staining, by Western immunoblotting
analysis with anti-human K4 and K1-3 polyclonal antibodies, and by
amino-terminal sequencing analysis.
[0306] In vitro re-folding
[0307] The re-folding of rK2, rK3 and rK2-3 was performed according
to a standard protocol (Cleary, S., Mulkerrin, M. G., and Kelley,
R. R. (1989) Biochem. 28, 1884-1891). The purified proteins were
adjusted to pH 8.0 and dithiotreitol (DTT) was added to a final
concentration of 5 mM. After an overnight incubation, the solution
was diluted with 4 volumes of 50 mM Tris-HCl, pH 8.0, containing
1.25 mM reduced glutathione. After 1 hour of incubation, oxidized
glutathione was added to a final concentration of 1.25 mM and
incubated for 6 hours at 4.degree. C. The renatured protein was
dialyzed initially against H.sub.2O for 2 days and for an
additional two days against 50 mM phosphate-buffered saline, pH
8.0. The solution was then loaded onto a lysine-Bio-Gel column (2
cm.times.13 cm) equilibrated with the same phosphate-buffered
saline. The column was washed with phosphate-buffered saline and
protein was eluted with a phosphate buffer containing 50 mM 6-AHA
(6-aminohexanoic acid). Reverse-phase HPLC was performed on an
Aquapore Butyl column (2.1.times.100 mm, widepore 30 nm, 7 mm,
Applied Biosystems) and a Hewlett Packard liquid chromatography was
used with acetonitrile gradients.
[0308] Reduction and Alkylation
[0309] The reduction and alkylation of kringle fragments were
performed according to a standard protocol (Cao, Y., and
Pettersson, R.F., (1990) Growth Factors 3, 1013). Approximately
20-80 mg of purified proteins in 300-500 ml DME medium in the
absence of serum were incubated at room temperature with 15 ml of
0.5 M DTT for 15 minutes. After incubation, 30 ml of 0.5 M
iodoacetamide was added to the reaction. The protein solution was
dialyzed at 4.degree. C. overnight initially against 20 volumes of
DMEM. The solution was further dialyzed at 4.degree. C. for an
additional 4 hours against 20 volumes of fresh DMEM. After
dialysis, the samples were analyzed on a SDS-gel and assayed for
their inhibitory activities on endothelial cell proliferation.
[0310] Endothelial Proliferation Assay
[0311] Bovine capillary endothelial (BCE) cells were isolated as
previously described (Folkman, J., Haudenschild, C. C., and Zetter,
B. R. (1979) Proc. Natl. Acad. Sci USA. 76, 5217-5121) and
maintained in DMEM supplemented with 10% heat-inactivated bovine
calf serum (BCS), antibiotics, and 3 ng/ml recombinant human bFGF
(Scios Nova, Mountainview, Calif.). Monolayers of BCE cells growing
in 6-well plates were dispersed in a 0.05% trypsin solution. Cells
were re-suspended with DMEM containing 10% BCS. Approximately
12,500 cells in 0.5 ml were added to each well of gelatinized
24-well tissue culture plates and incubated at 37.degree. C. (in
10% CO.sub.2) for 24 hours. The medium was replaced with 500 ml of
fresh DMEM containing 5% BCS and samples of individual or
combinatorial kringle fragments in triplicates were added to each
well. After 30 minutes of incubation, bFGF was added to a final
concentration of 1 ng/ml. After 72 hours of incubation, cells were
trypsinized, re-suspended in Hematall (Fisher Scientific,
Pittsburg, Pa.) and counted with a Coulter counter.
[0312] Purification and Characterization of Kringle Fragment of
Human Plasminogen
[0313] The cDNA fragments coding for individual kringles (K1, K2,
K3, and K4) and kringles 2-3 (K2-3) of human plasminogen were
amplified by a PCR-based method (FIG. 28). The PCR-amplified cDNA
fragments were cloned into a bacterial expression vector.
Recombinant proteins expressed from Escherichia coli were refolded
in vitro and were purified to >98% homogeneity using
HPLC-coupled chromatography (FIG. 29). Under reducing conditions,
recombinant K2, K3 and K4 migrated with molecular weights of 12-13
kDa (FIG. 29A, lanes 2-4), corresponding to the predicted molecular
weights of each kringle fragment. Recombinant K1 migrating with a
higher molecular weight of 17 kDa was identified by SDS-gel
electrophoresis. The fragments of K1-4 and K1-3 were obtained by
proteolytic digestion of human Lys-plasminogen (Lys-HPg) with
elastase as previously described (Powell, J. R., and Castellino, F.
J. (1983) Biochem. 22, 923-927; Brockway, W. J., and Castellino, F.
J. (1972) Arch. Biochem. Biophys). These two fragments (FIG. 29B,
lanes 1 and 2) with predicted molecular weights of 43 kDa and 35
kDa, respectively, were also purified to homogeneity. N-terminal
amino acid sequence analysis of the purified fragments yielded an
identical sequence, -YLSE-, followed by SEQ ID NO:30 and SEQ ID
NO:40, for K1-3 and K1-4, respectively. The N-terminal sequence for
K4 produced -VVQD- with approximately 20% -VQD-, followed by SEQ ID
NO:23, each of which is predicted from the expected sequence
beginning with Valine.sup.176 and Valine.sup.177 of human
angiostatin (SEQ ID NO:3).
[0314] Anti-Endothelial Cell Proliferative Activity of Individual
Kringles
[0315] Individual recombinant kringle fragments of angiostatin were
assayed for the inhibitory activities on bovine capillary
endothelial (BCE) cell growth stimulated by bFGF. As shown in FIG.
30A, rK1 inhibited BCE cell proliferation in a dose-dependent
fashion. The concentration of rK1 required to reach 50% inhibition
(ED.sub.50) was about 320 nM (Table 4). In contrast, rK4 exhibited
little or no inhibitory effect on endothelial cell proliferation.
Recombinant K2 and rK3, two non-lysine binding kringle fragments,
also produced a dose-dependent inhibition of endothelial cell
proliferation (FIG. 30B). However, the inhibitory potency of rK2
was substantially lower than rK1 and rK3 (ED.sub.50=460) (FIG. 30
and Table 4). No cytotoxicity or distinct morphology associated
with apoptotic endothelial cells such as rounding, detachment, and
fragmentation of cells could be detected, even after incubation
with a high concentration of these kringle fragments. These data
suggest that the anti-endothelial growth activity of angiostatin
may be shared by fragments of K1, K2 and K3, and lesser so by
K4.
4TABLE 4 Inhibitory activity on capillary endothelial cell
proliferation. Fragments ED.sub.50 (nM) Kringle 1 320 Kringle 2 --
Kringle 3 460 Kringle 4 -- Kringle 2-3 -- Kringle 1-3 70 Kringle
1-4 (Angiostatin) 135 Anti-Endothelial Cell Proliferative Activity
of K 1-3 and K 1-4 Fragments
[0316] To evaluate the anti-endothelial cell proliferative effect
of combined kringle fragments, purified proteolytic fragments of
human K1-4, K1-3 and rK2-3 were assayed on BCE cells. In agreement
with previous findings (O'Reilly, M. S., Holmgren, L., Shing, Y.,
Chen, C., Rosenthal, R. A., Moses, J., Lane, W. S., Cao, Y., Sage,
E. H., and Folkman, J. (1994) Cell 79, 315-328), BCE cell
proliferation, as shown in FIG. 31, was significantly inhibited by
angiostatin-like fragment K1-4 (ED.sub.50=135 nM) (Table 4). An
increase of anti-endothelial growth activity was obtained with K1-3
fragment (ED.sub.50=70 nM) (Table 4). The inhibition of endothelial
cell proliferation occurred in a dose-dependent manner. These
results indicate that removal of K4 from angiostatin potentiates
anti-endothelial growth activity.
[0317] Additive Inhibition by rK2 and rK3
[0318] The fragment of rK2-3 displayed only weak inhibitory
activity which was similar to that of rK2 alone (FIG. 31). However,
both rK2 and rK3 inhibited endothelial cell proliferation (FIG.
30B). This finding suggested that the inhibitory effect of K3 was
hidden in the structure of K2-3. Previous structural studies showed
that an inter-kringle disulfide bond was present between K2
(cysteine169) and K3 (cysteine.sup.297) of human plasminogen,
corresponding to cysteine.sup.91 and cysteine.sup.219 of SEQ ID
NO:3 (Sohndel, S., Hu, C. -K., Marti, D., Affolter, M., Schaller,
J., Llinas, M., and Rickli, E. E. (1996) Biochem. in press) See
FIG. 32B. The inhibitory effect of rK2 and rK3 in combination was
tested. Interestingly, an additive inhibition was seen when
individual rK2 and rK3 fragments were added together to BCE cells.
See FIG. 32A. These results imply that it is preferable to open the
interdisulfide bridge between K2 and K3 in order to obtain the
maximal inhibitory effect of K2-3.
[0319] Appropriate Folding of Kringle Structures is Required for
the Anti-Endothelial Activity of Angiostatin
[0320] To study whether the folding of kringle structures is
required for the anti-endothelial proliferation activity, native
angiostatin was reduced with DTT and assayed on bovine capillary
endothelial cells. After reduction, angiostatin was further
alkylated with iodoacetamide and analyzed by SDS gel
electrophoresis. As shown in FIG. 34A, the DTT-treated protein
migrated at a higher position with molecular weight of about 42 kDa
(lane 2) as compared to the native angiostatin with molecular
weight of 33 kDa (lane 1), suggesting that angiostatin was
completely reduced. The anti-proliferation activity of angiostatin
was largely abolished after reduction (FIG. 34B). From these
results, we conclude that the correct folding of angiostatin
through the intra-kringle disulfide bonds is preferable to maintain
its potent effect on inhibition of endothelial cell
proliferation.
[0321] Amino acid sequence alignment of the kringle domains of
human plasminogen shows that K1, K2, K3 and K4 display identical
gross architecture and remarkable sequence homology (56-82%
identify) as seen in FIG. 35. Among these structures, the
high-affinity lysine binding kringle, K1, is the most potent
inhibitory segment of endothelial cell proliferation'. Of interest,
the intermediate-affinity lysine binding fragment, K4, lacks
inhibitory activity. These data suggest that the lysine binding
site of the kringle structures may not be directly involved in the
inhibitory activity. The amino acid conservation and functional
divergence of these kringle structures provide an ideal system to
study the role mutations caused by DNA replication during
evolution. Similar divergent activities relative to the regulation
of angiogenesis exhibited by a group of structurally related
proteins are also found in the --C--X--C-- chemokine and
prolactin-growth hormone families (Maione, T. E., Gray, G. S.,
Petro, A. J., Hunt, A. L., and Donner, S. I. (1990) Science 247,
77-79.; Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L.
A., DiPietro, L. A., Elner, V. M., Elner, S. J., and Strieter, R.
M. (1992) Science 258, 1798-1801.; Cao, Y., Chen, C., Weatherbee,
J. A., Tsang, M., and Folkman, J. (1995) J. Exp. Med. 182, 2069-20
77.; Strieter, R. M., Polverini, P. J., Arenberg, D. A., and
Kunkel, S. L. (1995) Shock 4, 155-160.; Jackson, D., Volpert, O.
V., Bouck, N., and Linzer, D. I. H. (1994) Science 266,
1581-1584).
[0322] Further sequence analysis reveals that K4 contains two
positively charged lysine residues adjacent to cysteines 22 and 78
(FIG. 35). .sup.1H nuclear magnetic resonance (NMR) analysis shows
that these 4 lysines, together with lysine 57, form the core of a
positively charged domain in K4 (Llinas M, unpublished data),
whereas other kringle structures lack such a positively charged
domain. Whether this lysine-enriched domain contributes to the loss
of inhibitory activity of kringle 4 of human plasminogen remains to
be studied. K4 was previously reported to stimulate proliferation
of other cell types and to increase the release of intracellular
calcium (Donate, L. E., Gherardi, E., Srinivasan, N., Sowdhamini,
R., Aporicio, S., and Blundell, T. L. (1994) Prot. Sci. 3,
2378-2394). The fact that removal of K4 from angiostatin
potentiates its inhibitory activity on endothelial cells suggests
that this structure may prevent some of the inhibitory effect of
K1-3.
[0323] The mechanism underlying how angiostatin and its related
kringle fragments specifically inhibit endothelial cell growth
remains uncharacterized. It is not yet clear whether the inhibition
is mediated by a receptor that is specifically expressed in
proliferating endothelial cells, or if angiostatin is internalized
by endothelial cells and subsequently inhibits cell proliferation.
Alternatively, angiostatin may interact with an endothelial cell
adhesion receptor such as integrin a.sub.vb.sub.3, blocking
integrin-mediated angiogenesis (Brooks, P. C., Montgomery, A. M.,
Rosenfeld, M., Reisfeld R. A., Hu, T. Klier, G., and Cheresh, D. A.
(1994) Cell 79, 1157-1164). Of interest, Friedlander et. al.
(Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M.,
Varner, J. A., and Cheresh, D. A. (1995) 270, 1502) reported
recently that in vivo angiogenesis in cornea or chorioallantoic
membrane models (induced by bFGF and by tumor necrosis factor) was
a.sub.vb.sub.3 integrin dependent. However, angiogenesis stimulated
by VEGF, transforming growth factor a, or phorbol esters was
dependent on a.sub.vb.sub.5. Antibodies to the individual integrins
specifically blocked one of these pathways, and a cyclic protein
antagonist of both integrins blocked angiogenesis induced by each
cytokine (Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid,
C. M., Varner, J. A., and Cheresh, D. A. (1995) 270, 1502). Because
bFGF- and VEGF- induced angiogenesis are inhibited by angiostatin,
it may block a common pathway for these integrin-mediated
angiogenesis.
[0324] An increasing number of endogenous angiogenesis inhibitors
have been identified in the last few decades (Folkman, J. (1995) N.
Engl. J. Med. 333, 1757-1763). Of the nine characterized
endothelial cell suppressors, several inhibitors are proteolytic
fragments. For example, the 16 kDa N-terminal fragment of human
prolactin inhibits endothelial cell proliferation and blocks
angiogenesis in vivo (Clapp, C., Martial, J. A., Guzman, R. C.,
Rentierdelrue, F., and Weiner, R. I. (1993) Endorinology 133,
1292-1299). In a recent paper, D'Angelo et. al. reported that the
antiangiogenic 16 kDa N-terminal fragment inhibited the activation
of mitogen-activated protein kinase (MAPK) by VEGF and bFGF in
capillary endothelial cells (D'Angelo, G., Struman, I., Martial,
J., and Weiner, R. (1995) Proc. Natl. Acad. Sci. 92, 6374-6378).
Similar to angiostatin, the intact parental molecule of prolactin
does not inhibit endothelial cell proliferation nor is it an
angiogenesis inhibitor. Platelet factor 4 (PF-4) inhibits
angiogenesis at high concentrations (Maione, T. E., Gray, G. S.,
Petro, A. J., Hunt, A. L., and Donner, S. I. (1990) Science 247,
77-79; Cao, Y., Chen, C., Weatherbee, J. A., Tsang, M., and
Folkman, J. (1995) J. Exp. Med. 182, 2069-20 77). However, the
N-terminally truncated proteolytically cleaved PF-4 fragment
exhibits a 30- to 50-fold increase in its anti-proliferative
activity over the intact PF-4 molecule (Gupta, S. K., Hassel, T.,
and Singh, J. P. (1995) Proc. Natl. Acad. Sci. 92, 7799-7803).
Smaller protein fragments of fibronectin, murine epidermal growth
factor, and thrombospondin have also been shown to specifically
inhibit endothelial cell growth (Homandberg, G. A., Williams, J.
E., Grant, D., Schumacher, B., and Eisenstein, R. (1985) Am. J.
Pathol. 120, 327-332; Nelson, J., Allen, W. E., Scott, W. N.,
Bailie, J. R., Walker, B., McFerran, N. V., and Wilson, D. J.
(1995) Cancer Res. 55, 3772-3776; Tolsma, S. S., Volpert, O. V.,
Good, D. J., Frazer, W. A., Polverini, P. J., and Bouck, N. (1993)
J. Cell Biol. 122, 497-511). Proteolytic processing of a large
protein may change the conformational structure of the original
molecule or expose new epitopes that are antiangiogenic. Thus,
protease(s) may play a critical role in the regulation of
angiogenesis. To date, little is known about the regulation of
these protease activities in vivo.
[0325] The data also show that the disulfide bond mediated folding
of the kringle structures in angiostatin is preferable to maintain
its inhibitory activity on endothelial cell growth. Kringle
structures analogous to those in plasminogen are also found in a
variety of other proteins. For example, apolipoprotein (a) has as
many as 37 repeats of plasminogen kringle 4 (McLean, J. W.,
Tomlinson, J. E., Kuang, W. -J., Eaton, D. L., Chen, E. Y., Fless,
G. M., Scanu, A. M., and Lawn, R. M. (1987) Nature 330, 132-137).
The amino terminal portion of prothrombin also contains two
kringles that are homologous to those of plasminogen (Walz, D. A.,
Hewett-Emmett, D., and Seegers, W. H. (1977) Proc. Natl. Acad. Sci.
74, 1969-1973). Urokinase has been shown to possess a kringle
structure that shares extensive homology with plasminogen (Gunzler,
W. A., J., S. G., Otting, F., Kim, S. -M. A., Frankus, E., and
Flohe, L. (1982) Hoppe-Seyler's A. Physiol. Chem. 363, 1155-1165).
In addition, suffactant protein B and hepatocyte growth factor
(HGF), also carry kringle structures (Johansson, J., Curstedt, T.,
and Jormvall., H. (1991) Biochem. 30, 6917-6921; Lukker, N. A.,
Presta, L. G., and Godowski, P. J. (1994) Prot. Engin. 7,
895-903).
EXAMPLE 28
[0326] Suppression of Metastases and of Endothelial Cell
Proliferation by Angiostatin Fragments
[0327] The following example characterizes the activity of
additional angiostatin fragments. The data suggests that potent
anti-endothelial and tumor suppressive activity can be obtained
from such protein fragments of angiostatin.
[0328] As used herein, "kringle 1-4BKLS" means a protein derivative
of plasminogen having an endothelial cell inhibiting activity, and
having an amino acid sequence comprising a sequence homologous to
kringle 1-4BKLS, exemplified by, but not limited to that of murine
kringle 1-4BKLS (SEQ ID NO:41), and human kringle 1-4BKLS (SEQ ID
NO:42), unless indicated otherwise by the context in which it is
used. Murine kringle 1-4BKLS (SEQ ID NO:41) corresponds to amino
acid positions 93 to 470 (inclusive) of murine plasminogen of SEQ
ID NO:1. This example demonstrates that an "angiostatin fragment"
can be a plasminogen fragment and encompass an amino acid sequence
larger than the angiostatin presented in SEQ ID NO:3, for example,
and still have therapeutic endothelial cell proliferation
inhibiting activity or anti-angiogenic activity.
[0329] A kringle 1-4BLKS amino acid sequence is homologous to the
specific kringle 1-4BLKS sequences identified above. Preferably,
the amino acid sequences have a degree of homology to the disclosed
sequences of at least 60%, more preferably at least 70%, and more
preferably at least 80%. It should be understood that a variety of
amino acid substitutions, deletions and other modifications to the
above listed fragments may be made to improve or modify the
endothelial cell inhibiting activity of the fragments. Such
modifications are not intended to exceed the scope and spirit of
the claims. Furthermore, it is understood that a variety of silent
amino acid substitutions, additions, or deletions can be made in
the above identified kringle fragments, which do not significantly
alter the fragments' endothelial cell inhibiting activity, and
which are, therefore, not intended to exceed the scope of the
claims.
[0330] Cloning of Angiostatin in Pichia pastiris
[0331] Sequences encoding angiostatin were amplified by PCR using
Vent polymerase (New England Biolabs) and primers #154
[0332] (5'-ATCGCTCGAGCGTTATTTGAAAAGAAAGTG-3')
[0333] (SEQ ID NO:43) and #151
[0334] (5'- ATCGGAATTCAAGCAGGACAACAGGCGG-3')
[0335] (SEQ ID NO:44) containing linkers Xhol and Eco R1
respectively and using the plasmid pTrcHis/HAs as template. This
plasmid contained sequences encoding amino acids 93 to 470 of human
plasminogen (SEQ ID NO:42) for cloning into the Xho I/ECo R1 site
of pHIL-S1 expression vector using the P. pastoris native secretion
signal PHO 1. This same sequence was amplified in the same manner
using primers #156
[0336] (5'-ATCGTACGTATTATTTGAAAAGAAAGTG-3')
[0337] (SEQ ID NO:45) and #151 containing linkers Sna B1 and Eco R1
respectively, for cloning into the Sna B1/ECo R1 site of expression
vector pP1C9 with the alpha-factor secretory signal. The products
of the amplifications were gel purified, linkers were digested with
the appropriate enzymes, and again purified using gene-clean (Bio
101). These gene fragments were ligated into the appropriate
vectors. Resultant clones were selected and plasmid preparations of
clones were obtained and linearized to generate His.sup.+ Mut.sup.s
and His.sup.+ Mut.sup.+ recombinant strains when transformed into
P. pastoris host strain GS 115. Integration was confirmed by
PCR.
[0338] Both His.sup.+ and His.sup.+ Mut.sup.+recombinants were
induced with methanol and screened for high expression of
angiostatin using Coomassie stained SDS-PAGE gels and immunoblots
using mouse monoclonal antibody against kringles 1 to 3
(Castellino, Enzyme Research Laboratories, Inc., South Bend, Ind.).
From these, a GS115 transformed P. pastoris clone pHIL-S1/HAs18 was
selected and phenotypically characterized as His.sup.+
Mut.sup.s.
[0339] Expression of PHIL-S1/HAs18
[0340] Expression of angiostatin from pHIL-S1/HAs18 was typical for
a His.sup.+ Mut.sup.s clone. At induction in baffled shake flasks,
1L of OD.sub.600 cells were cultured in 150 ml of buffered metanol
complex medium containing 1% yeast extract, 2% peptone, 100 mM
potassium phosphate pH 6.0, 1.34% yeast nitrogen base with ammonium
sulfate, 0.00004% biotin and 0.5% methanol, in a 1L baffled flask.
Cells were constantly shaken at 30.degree. C., 250 rpm. Methanol
was batch fed at 24 hour intervals by addition of absolute methanol
to a final of 0.5%. After 120 hours cells were spun at 5,000 rpm
for 10 minutes, and supernatants were stored at -70.degree. C.
until used.
[0341] Purification of Angiostatin From P. pastoris Fermentation
Broth by Lysine-Sepharose Chromatography
[0342] All procedures are carried out at 4.degree. C. Crude
fermentation broth, typically 200 ml, containing angiostatin was
clarified by centrifugation at 14,000.times.g and concentrated by
Centriprep 30 (amicon) 30 kDa molecular weight cutoff membrane to
approximately one-fourth the original volume. One volume of 50 mM
phosphate buffer, pH 7.5, was added to the concentrated sample
which was again concentrated by Centriprep to one-fourth the
original sample volume. The sample was again diluted volume:volume
with 50 mM sodium phosphate buffer, pH 7.5. 60 g lysine-sepharose
4B (Pharmacia) was resuspended in 500 ml ice-cold 50 mM phosphate
buffer, pH 7.5 and used to pack a 48.times.100 mm column
(.about.180 ml packed volume). The column was washed overnight with
7.5 column volumes (CV) of 50 mM sodium phosphate buffer, pH 7.5,
at a flow rate of 1.5 mil/min. The sample was pumped onto the
column at a flow rate of 1.5 ml/min and the column washed with 1.5
CV of 50 mM sodium phosphate, pH 7.5, at a flow rate of 3 ml/min.
The column was then washed with 1.5 CV phosphate-buffered saline,
pH 7.4, at a flow rate of 3 ml/min: angiostatin was then eluted
with 0.2 M .epsilon.-amino-n-caproic acid, pH 7.4 at a flow rate of
3 ml/min. Fractions containing significant absorbance were pooled
and dialyzed for 24-48 hours against deionized water and
lyophilized. A typical recovery from a 100 mg total protein load is
10 mg angiostatin. Columns were regenerated using 5 column volumes
of 50 mM sodium phosphate/1 M NaCl, pH 7.5.
[0343] Bovine Capillary Endothelial Cell Proliferation Assay
[0344] Bovine capillary endothelial cells were obtained as
previously described. The cells are maintained in DMEM containing 3
mg/ml of recombinant human bFGF (Scios Nova, Mountainview, Calif.),
supplemented with 10% heat-inactivated bovine calf serum, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml fungizone
(BioWhittaker) in 75 cm.sup.2 cell-culture flasks. The assay was
performed as described previously.
[0345] Animal Studies
[0346] Six to eight week old male C57B1/6J mice (Jackson
Laboratories) were inoculated subcutaneously with murine Lewis lung
carcinoma-low metastatic (LLC-LM) line (1.times.10.sup.6
cells/injection). Approximately 14 days after implantation, when
primary tumor reached 1.5 cm.sup.3, animals were anaesthetized with
methoxyflurane and primary tumors were surgically excised. The
incision site was closed with simple interrupted sutures. Half the
animals in this group received a loading dose (3 mg/kg by the
subcutaneous route) of recombinant or plasminogen derived
angiostatin subcutaneously immediately after surgery, followed by
daily inoculations of 1.5 mg/kg for 14 days. A control group of
mice received an equal volume of PBS every day for 14 days
following surgery. All mice were sacrificed 14 days after primary
tumor removal (28 days after tumor implantation), lungs were
removed and weighed, and surface metastases were counted with
stereomicroscope.
[0347] Characteristics of Recombinant Human Angiostatin
Fragments
[0348] A gene fragment encoding human angiostatin including
kringles 1 to 4 of human plasminogen that contains a total of 26
cysteines, was expressed in Pichia pastiris, the methylotropic
yeast. P. pastoris expressed angiostatin binds lysine sepharose and
can be specifically eluted by .epsilon.-amino caproic acid. This
demonstrates that fully functional epsilon amino caproic
acid-binding kringle(s), which are physical properties of kringle 1
and 4 of plasminogen (Sottrup-Jensen, L. et al., Progress in
Chemical Fibrinolysis and Thrombolysis, Vol. 3 (1978) Ravens Press,
N.Y. p. 191), can be expressed and secreted by P. pastoris and
purified by techniques that do not require refolding (FIG. 36A and
B). Expressed angiostatin from P. pastoris as well as angiostatin
purified by elastase cleavage of plasminogen were recognized by a
conformationally dependent monoclonal antibody against kringle 1 to
3 (Castellino, Enzyme Research Laboratories, Inc., South Bend,
Ind.) (FIG. 36B). This antibody fails to recognize reduced forms of
plasminogen or angiostatin.
[0349] P. pastoris expressed angiostatin is seen as a doublet that
migrates at 49 kDa and 51.5 kDa on denatured unreduced SDS-PAGE
Coomassie stained gels. P. pastoris expressed proteins are
post-translationally modified with the majority of N-linked
glycosylation of the high-mannose type and insignificant O-linked
glycosylation. To evaluate the possibility of glycosylation in P.
pastoris expressed angiostatin, we digested the recombinant
angiostatin with endoglycosidase H specific for high mannose
structures, causing the 51.5 kDa band to migrate identically with
the band at 49 kDa (FIG. 37A and B). O-glycanase digestion with
prior neuraminidase treatment to remove sialic acid residues, did
not change the pattern of migration of the doublet (data not
shown). These results indicate that P. pastoris expressed
angiostatin in two forms: (1) with an N-linked complex chain
probably of the structure:
[0350] (Man).sub.2-150--Man
[0351] Man--GlcNAc---GlcNAc-Asn-(Man).sub.1-2-Man
[0352] and (2) without any glycosylation.
[0353] Inhibition of Bovine Capillary Endothelial Cells In
Vitro
[0354] To determine if recombinantly expressed angiostatin had the
potential for antiangiogenic activity, BCEs were cultured in the
presence of bFGF to determine if the addition of purified
recombinant angiostatin would inhibit the proliferation of BCEs.
Purified P. pastiris-expressed angiostatin inhibited the
bFGF-driven proliferation of bovine endothelial cells in vitro
(FIG. 38B) in a dose dependent manner (FIG. 38C). At 1 ug/ml of
recombinant angiostatin, inhibition was 80%. The 50% inhibition was
equivalent to that obtained with angiostatin derived from elastase
cleavage of human plasminogen.
[0355] Suppression of Metastases In Vivo
[0356] The transplantable murine LLC (LM) line from which
angiostatin was first identified was used. When implanted
subcutaneously in syngenic C57B1/6J mice, these tumors grow
rapidly, producing >1.5 cm.sup.3 tumors within 14 days.
Following primary tumor resection, the micometastases in the lungs
grow exponentially, to completely cover the surface of the lung.
These metastases are highly vascularized by day 14 after primary
tumor resection. If the primary tumor is left on, the
micrometastases remain dormant and are not macroscopically visible.
Recombinant angiostatin was administered systemically to mice
following primary tumor resection to test the suppression of the
growth of metastases. P. pastoris expressed angiostatin
administered systemically at 30 ug/mouse/day inhibited the growth
of metastases as quantitated by scoring of surface metastases (FIG.
39A) and total lung weight (FIG. 39B). The weights of lungs of mice
that had primary tumors resected and that received daily doses of
recombinant angiostatin or angiostatin obtained from elastase
cleavage of plasminogen were of comparable to those of normal mice
(190 to 200 mg). Lungs of mice that had their primary tumors
resected and subsequently treated with daily doses of recombinant
angiostatin were pink with minimal numbers of unvascularized
micrometastases (FIG. 40). In contrast, the mice treated with
saline after primary tumor resection had lungs covered with
vascularized metastases (FIG. 41). Also of notable importance was
an absence of systemic or local toxicity caused by P. pastoris
expressed angiostatin at the dosage and regimen used in this study.
There was no evidence of inflammation or bleeding in all treated
nice.
[0357] Angiostatin protein expressed by P. pastoris possesses two
important physical characteristics of the natural protein: (1) it
is recognized by a conformationally dependent monoclonal antibody
raised against kringle 1 to 3 of human plasminogen (FIG. 36B) and
(2) it binds lysine (FIG. 36A and B). These properties indicated
that the recombinant angiostatin protein was expressed with a
conformation that mimics the native molecule. P. pastoris expressed
angiostatin protein inhibits the proliferation of bovine capillary
endothelial cells stimulated by bFGF in vitro (FIG. 38). when
administered systemically, the recombinant angiostatin maintained
the otherwise lethal metastastic Lewis lung carcinoma in a
suppressed state (FIG. 39A and B and FIG. 40).
[0358] Preliminary data shows the absence of a detectable
transcript for angiostatin in Lewis lung tumors freshly resected
from mice or in LLC cells after 4 passages in in vitro culture.
Plasminogen, produced by the liver, is maintained in circulation at
a stable plasma concentration of 1.6.+-.0.2 .mu.M. It is possible
that LLC-LM tumors produce an enzyme that cleaves plasminogen,
bound or in circulation, to produce angiostatin. Alternatively
inflammatory cells attracted to the tumor site could produce such
an enzyme.
[0359] It is intriguing that both P. pastoris as well as native
human plasminogen is produced in a glycosylated and a
non-glycosylated form. In the case of human plasminogen, a single
transcript for a single gene can produce both forms. The molecular
mechanism of differential post-translational modifications of human
plasminogen, as well as that seen in TPA are unknown.
[0360] Angiostatin is highly expressed by P. pastiris. Supernatants
contain 100 mg/L of the protein. Therefore, the quantities required
for clinical trials should be straightforward to produce and purify
using standard technology well-known to those skilled in the art.
The development of this expression system, and the demonstration of
the in vitro and in vivo activity of purified recombinant
angiostatin against metastases provided the foundation for
assessment of the capacity of these fragments to inhibit tumor
growth and prolong life in cancer patients and others suffering
from angiogenic-mediated disease.
EXAMPLE 29
[0361] Kringle 1-5 Angiostatin Protein Fragment
[0362] The following example describes one method for the
production of kringle 1-5 angiostatin protein fragment.
[0363] As used herein, "kringle 1-5" means a protein derivative of
plasminogen having an endothelial cell inhibiting activity or
anti-angiogenic activity, and having an amino acid sequence
comprising a sequence homologous to kringle 1-5, exemplified by,
but not limited to that of murine kringle 1-5 corresponding to
amino acid positions 102 to 560 (inclusive) of murine plasminogen
of SEQ ID NO:1. Kringle 5 itself is represented in the murine
sequence of plasminogen of SEQ ID NO: 1 at amino acid positions
481-560 (inclusive). The amino acid and corresponding nucleotide
sequence of plasminogen is provided in Forsgren et al., "Molecular
cloning and characterization of a full-length cDNA clone for human
plasminogen," FEBS 213:2, pp.254-260 (1987), which is hereby
incorporated by reference.
[0364] Kringle 1-5 amino acid sequences are respectively homologous
to the specific kringle 1-5 sequence identified above. Preferably,
the amino acid sequences have a degree of homology to the disclosed
sequences of at least 60%, more preferably at least 70%, and more
preferably at least 80%. It should be understood that a variety of
amino acid substitutions, additions, deletions or other
modifications to the above listed fragments may be made to improve
or modify the endothelial cell proliferation inhibiting activity or
anti-angiogenic activity of the angiostatin fragments. Such
modifications are not intended to exceed the scope and spirit of
the claims. For example, to avoid homodimerization by formation of
inter-kringle disulfide bridges, the cysteine residues can be
mutated to serines. Furthermore, it is understood that a variety of
amino acid substitutions, additions, deletions or other
modifications can be made in the above identified angiostatin
fragments, which do not significantly alter the fragments'
endothelial cell proliferation inhibiting activity, and which are,
therefore, not intended to exceed the scope of the claims. By "not
significantly alter" is meant that the angiostatin fragment has at
least 60%, more preferably at least 70%, and more preferably at
least 80% of the endothelial cell proliferation inhibiting activity
compared to that of the closest homologous angiostatin fragment
disclosed herein.
[0365] Kringle 1-5 angiostatin protein fragment can be produced
according to the following method:
[0366] 1) Convert purified human palsminogen (Plg) to Lys Plg using
the enzyme plasmin.
[0367] 2) Digest Lys Plg with TPA or urokinase. This will result in
the heavy (A) and light (B) chains, but still linked together by 2
disulfide bonds.
[0368] 3) These bonds can be specifically reduced by common
reducing agents like beta mercaptoethanol to result in separate
heavy chain A and light chain B.
[0369] 4) Then block the cysteines so that they do not form bonds
again by making the A and B chains into S-carboxymethyl derivatives
(Robbins, K C, Bemabe P, Arzadon L, Summaria L. J. Biol. Chem.
247(21):6757-6762 (1972). "The primary structure of human
plasminogen. I. The NH2-terminal sequences of human plasminogen and
the s-carboxymethyl heavy (A) and light (B) chain derivatives of
plasmin.")
[0370] 5) Run the product of step 4 over a lysine-Sepharose column
to purify K1-5 from the rest.
[0371] QED.
[0372] The kringle 1-5 angiostatin protein fragment can be used to
inhibit endothelial cell proliferation and angiogenesis in vitro
and in vivo. In particular, the kringle 1-5 angiostatin protein
fragment can be used to inhibit angiogenesis in a cancerous
tumor.
[0373] It should be understood that the foregoing relates only to
preferred embodiments of the present invention, and that numerous
modifications or alterations may be made therein without departing
from the spirit and the scope of the invention as set forth in the
appended claims.
Sequence CWU 1
1
47 1 812 PRT Murinae gen. sp. misc_feature Plasminogen 1 Met Asp
His Lys Glu Val Ile Leu Leu Phe Leu Leu Leu Leu Lys Pro 1 5 10 15
Gly Gln Gly Asp Ser Leu Asp Gly Tyr Ile Ser Thr Gln Gly Ala Ser 20
25 30 Leu Phe Ser Leu Thr Lys Lys Gln Leu Ala Ala Gly Gly Val Ser
Asp 35 40 45 Cys Leu Ala Lys Cys Glu Gly Glu Thr Asp Phe Val Cys
Arg Ser Phe 50 55 60 Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile
Met Ala Glu Asn Ser 65 70 75 80 Lys Thr Ser Ser Ile Ile Arg Met Arg
Asp Val Ile Leu Phe Glu Lys 85 90 95 Arg Val Tyr Leu Ser Glu Cys
Lys Thr Gly Ile Gly Asn Gly Tyr Arg 100 105 110 Gly Thr Met Ser Arg
Thr Lys Ser Gly Val Ala Cys Gln Lys Trp Gly 115 120 125 Ala Thr Phe
Pro His Val Pro Asn Tyr Ser Pro Ser Thr His Pro Asn 130 135 140 Glu
Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Glu Gln 145 150
155 160 Gly Pro Trp Cys Tyr Thr Thr Asp Pro Asp Lys Arg Tyr Asp Tyr
Cys 165 170 175 Asn Ile Pro Glu Cys Glu Glu Glu Cys Met Tyr Cys Ser
Gly Glu Lys 180 185 190 Tyr Glu Gly Lys Ile Ser Lys Thr Met Ser Gly
Leu Asp Cys Gln Ala 195 200 205 Trp Asp Ser Gln Ser Pro His Ala His
Gly Tyr Ile Pro Ala Lys Phe 210 215 220 Pro Ser Lys Asn Leu Lys Met
Asn Tyr Cys His Asn Pro Asp Gly Glu 225 230 235 240 Pro Arg Pro Trp
Cys Phe Thr Thr Asp Pro Thr Lys Arg Trp Glu Tyr 245 250 255 Cys Asp
Ile Pro Arg Cys Thr Thr Pro Pro Pro Pro Pro Ser Pro Thr 260 265 270
Tyr Gln Cys Leu Lys Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val Ser 275
280 285 Val Thr Val Ser Gly Lys Thr Cys Gln Arg Trp Ser Glu Gln Thr
Pro 290 295 300 His Arg His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys
Asn Leu Glu 305 310 315 320 Glu Asn Tyr Cys Arg Asn Pro Asp Gly Glu
Thr Ala Pro Trp Cys Tyr 325 330 335 Thr Thr Asp Ser Gln Leu Arg Trp
Glu Tyr Cys Glu Ile Pro Ser Cys 340 345 350 Glu Ser Ser Ala Ser Pro
Asp Gln Ser Asp Ser Ser Val Pro Pro Glu 355 360 365 Glu Gln Thr Pro
Val Val Gln Glu Cys Tyr Gln Ser Asp Gly Gln Ser 370 375 380 Tyr Arg
Gly Thr Ser Ser Thr Thr Ile Thr Gly Lys Lys Cys Gln Ser 385 390 395
400 Trp Ala Ala Met Phe Pro His Arg His Ser Lys Thr Pro Glu Asn Phe
405 410 415 Pro Asp Ala Gly Leu Glu Met Asn Tyr Cys Arg Asn Pro Asp
Gly Asp 420 425 430 Lys Gly Pro Trp Cys Tyr Thr Thr Asp Pro Ser Val
Arg Trp Glu Tyr 435 440 445 Cys Asn Leu Lys Arg Cys Ser Glu Thr Gly
Gly Ser Val Val Glu Leu 450 455 460 Pro Thr Val Ser Gln Glu Pro Ser
Gly Pro Ser Asp Ser Glu Thr Asp 465 470 475 480 Cys Met Tyr Gly Asn
Gly Lys Asp Tyr Arg Gly Lys Thr Ala Val Thr 485 490 495 Ala Ala Gly
Thr Pro Cys Gln Gly Trp Ala Ala Gln Glu Pro His Arg 500 505 510 His
Ser Ile Phe Thr Pro Gln Thr Asn Pro Arg Ala Asp Leu Glu Lys 515 520
525 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Asn Gly Pro Trp Cys Tyr
530 535 540 Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Ile Pro
Leu Cys 545 550 555 560 Ala Ser Ala Ser Ser Phe Glu Cys Gly Lys Pro
Gln Val Glu Pro Lys 565 570 575 Lys Cys Pro Gly Arg Val Val Gly Gly
Cys Val Ala Asn Pro His Ser 580 585 590 Trp Pro Trp Gln Ile Ser Leu
Arg Thr Arg Phe Thr Gly Gln His Phe 595 600 605 Cys Gly Gly Thr Leu
Ile Ala Pro Glu Trp Val Leu Thr Ala Ala His 610 615 620 Cys Leu Glu
Lys Ser Ser Arg Pro Glu Phe Tyr Lys Val Ile Leu Gly 625 630 635 640
Ala His Glu Glu Tyr Ile Arg Gly Leu Asp Val Gln Glu Ile Ser Val 645
650 655 Ala Lys Leu Ile Leu Glu Pro Asn Asn Arg Asp Ile Ala Leu Leu
Lys 660 665 670 Leu Ser Arg Pro Ala Thr Ile Thr Asp Lys Val Ile Pro
Ala Cys Leu 675 680 685 Pro Ser Pro Asn Tyr Met Val Ala Asp Arg Thr
Ile Cys Tyr Ile Thr 690 695 700 Gly Trp Gly Glu Thr Gln Gly Thr Phe
Gly Ala Gly Arg Leu Lys Glu 705 710 715 720 Ala Gln Leu Pro Val Ile
Glu Asn Lys Val Cys Asn Arg Val Glu Tyr 725 730 735 Leu Asn Asn Arg
Val Lys Ser Thr Glu Leu Cys Ala Gly Gln Leu Ala 740 745 750 Gly Gly
Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys 755 760 765
Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu 770
775 780 Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser
Arg 785 790 795 800 Phe Val Asp Trp Ile Glu Arg Glu Met Arg Asn Asn
805 810 2 339 PRT Murinae gen. sp. 2 Val Tyr Leu Ser Glu Cys Lys
Thr Gly Ile Gly Asn Gly Tyr Arg Gly 1 5 10 15 Thr Met Ser Arg Thr
Lys Ser Gly Val Ala Cys Gln Lys Trp Gly Ala 20 25 30 Thr Phe Pro
His Val Pro Asn Tyr Ser Pro Ser Thr His Pro Asn Glu 35 40 45 Gly
Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Glu Gln Gly 50 55
60 Pro Trp Cys Tyr Thr Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys Asn
65 70 75 80 Ile Pro Glu Cys Glu Glu Glu Cys Met Tyr Cys Ser Gly Glu
Lys Tyr 85 90 95 Glu Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Asp
Cys Gln Ala Trp 100 105 110 Asp Ser Gln Ser Pro His Ala His Gly Tyr
Ile Pro Ala Lys Phe Pro 115 120 125 Ser Lys Asn Leu Lys Met Asn Tyr
Cys His Asn Pro Asp Gly Glu Pro 130 135 140 Arg Pro Trp Cys Phe Thr
Thr Asp Pro Thr Lys Arg Trp Glu Tyr Cys 145 150 155 160 Asp Ile Pro
Arg Cys Thr Thr Pro Pro Pro Pro Pro Ser Pro Thr Tyr 165 170 175 Gln
Cys Leu Lys Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val Ser Val 180 185
190 Thr Val Ser Gly Lys Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His
195 200 205 Arg His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu
Glu Glu 210 215 220 Asn Tyr Cys Arg Asn Pro Asp Gly Glu Thr Ala Pro
Trp Cys Tyr Thr 225 230 235 240 Thr Asp Ser Gln Leu Arg Trp Glu Tyr
Cys Glu Ile Pro Ser Cys Glu 245 250 255 Ser Ser Ala Ser Pro Asp Gln
Ser Asp Ser Ser Val Pro Pro Glu Glu 260 265 270 Gln Thr Pro Val Val
Gln Glu Cys Tyr Gln Ser Asp Gly Gln Ser Tyr 275 280 285 Arg Gly Thr
Ser Ser Thr Thr Ile Thr Gly Lys Lys Cys Gln Ser Trp 290 295 300 Ala
Ala Met Phe Pro His Arg His Ser Lys Thr Pro Glu Asn Phe Pro 305 310
315 320 Asp Ala Gly Leu Glu Met Asn Tyr Cys Arg Asn Pro Asp Gly Asp
Lys 325 330 335 Gly Pro Trp 3 339 PRT Homo sapiens 3 Val Tyr Leu
Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly 1 5 10 15 Thr
Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser 20 25
30 Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu
35 40 45 Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
Gln Gly 50 55 60 Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr
Asp Tyr Cys Asp 65 70 75 80 Ile Leu Glu Cys Glu Glu Glu Cys Met His
Cys Ser Gly Glu Asn Tyr 85 90 95 Asp Gly Lys Ile Ser Lys Thr Met
Ser Gly Leu Glu Cys Gln Ala Trp 100 105 110 Asp Ser Gln Ser Pro His
Ala His Gly Tyr Ile Pro Ser Lys Phe Pro 115 120 125 Asn Lys Asn Leu
Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu 130 135 140 Arg Pro
Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys 145 150 155
160 Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr
165 170 175 Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val
Ala Val 180 185 190 Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala
Gln Thr Pro His 195 200 205 Thr His Asn Arg Thr Pro Glu Asn Phe Pro
Cys Lys Asn Leu Asp Glu 210 215 220 Asn Tyr Cys Arg Asn Pro Asp Gly
Lys Arg Ala Pro Trp Cys His Thr 225 230 235 240 Thr Asn Ser Gln Val
Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp 245 250 255 Ser Ser Pro
Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu 260 265 270 Leu
Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr 275 280
285 Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp
290 295 300 Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn
Tyr Pro 305 310 315 320 Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn
Pro Asp Ala Asp Lys 325 330 335 Gly Pro Trp 4 339 PRT Macaca sp. 4
Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly 1 5
10 15 Thr Met Ser Lys Thr Arg Thr Gly Ile Thr Cys Gln Lys Trp Ser
Ser 20 25 30 Thr Ser Pro His Arg Pro Thr Phe Ser Pro Ala Thr His
Pro Ser Glu 35 40 45 Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp
Asn Asp Gly Gln Gly 50 55 60 Pro Trp Cys Tyr Thr Thr Asp Pro Glu
Glu Arg Phe Asp Tyr Cys Asp 65 70 75 80 Ile Pro Glu Cys Glu Asp Glu
Cys Met His Cys Ser Gly Glu Asn Tyr 85 90 95 Asp Gly Lys Ile Ser
Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp 100 105 110 Asp Ser Gln
Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro 115 120 125 Asn
Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro 130 135
140 Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys
145 150 155 160 Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly
Pro Thr Tyr 165 170 175 Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg
Gly Asp Val Ala Val 180 185 190 Thr Val Ser Gly His Thr Cys His Gly
Trp Ser Ala Gln Thr Pro His 195 200 205 Thr His Asn Arg Thr Pro Glu
Asn Phe Pro Cys Lys Asn Leu Asp Glu 210 215 220 Asn Tyr Cys Arg Asn
Pro Asp Gly Glu Lys Ala Pro Trp Cys Tyr Thr 225 230 235 240 Thr Asn
Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Glu 245 250 255
Ser Ser Pro Val Ser Thr Glu Pro Leu Asp Pro Thr Ala Pro Pro Glu 260
265 270 Leu Thr Pro Val Val Gln Glu Cys Tyr His Gly Asp Gly Gln Ser
Tyr 275 280 285 Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys
Gln Ser Trp 290 295 300 Ser Ser Met Thr Pro His Trp His Glu Lys Thr
Pro Glu Asn Phe Pro 305 310 315 320 Asn Ala Gly Leu Thr Met Asn Tyr
Cys Arg Asn Pro Asp Ala Asp Lys 325 330 335 Gly Pro Trp 5 339 PRT
Sus sp. 5 Ile Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
Arg Gly 1 5 10 15 Thr Thr Ser Lys Thr Lys Ser Gly Val Ile Cys Gln
Lys Trp Ser Val 20 25 30 Ser Ser Pro His Ile Pro Lys Tyr Ser Pro
Glu Lys Phe Pro Leu Ala 35 40 45 Gly Leu Glu Glu Asn Tyr Cys Arg
Asn Pro Asp Asn Asp Glu Lys Gly 50 55 60 Pro Trp Cys Tyr Thr Thr
Asp Pro Glu Thr Arg Phe Asp Tyr Cys Asp 65 70 75 80 Ile Pro Glu Cys
Glu Asp Glu Cys Met His Cys Ser Gly Glu His Tyr 85 90 95 Glu Gly
Lys Ile Ser Lys Thr Met Ser Gly Ile Glu Cys Gln Ser Trp 100 105 110
Gly Ser Gln Ser Pro His Ala His Gly Tyr Leu Pro Ser Lys Phe Pro 115
120 125 Asn Lys Asn Leu Lys Met Asn Tyr Cys Arg Asn Pro Asp Gly Glu
Pro 130 135 140 Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
Glu Phe Cys 145 150 155 160 Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro
Thr Ser Gly Pro Thr Tyr 165 170 175 Gln Cys Leu Lys Gly Arg Gly Glu
Asn Tyr Arg Gly Thr Val Ser Val 180 185 190 Thr Ala Ser Gly His Thr
Cys Gln Arg Trp Ser Ala Gln Ser Pro His 195 200 205 Lys His Asn Arg
Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu 210 215 220 Asn Tyr
Cys Arg Asn Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr 225 230 235
240 Thr Asp Ser Glu Val Arg Trp Asp Tyr Cys Lys Ile Pro Ser Cys Gly
245 250 255 Ser Ser Thr Thr Ser Thr Glu His Leu Asp Ala Pro Val Pro
Pro Glu 260 265 270 Gln Thr Pro Val Ala Gln Asp Cys Tyr Arg Gly Asn
Gly Glu Ser Tyr 275 280 285 Arg Gly Thr Ser Ser Thr Thr Ile Thr Gly
Arg Lys Cys Gln Ser Trp 290 295 300 Val Ser Met Thr Pro His Arg His
Glu Lys Thr Pro Gly Asn Phe Pro 305 310 315 320 Asn Ala Gly Leu Thr
Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys 325 330 335 Ser Pro Trp
6 339 PRT Bos sp. 6 Ile Tyr Leu Leu Glu Cys Lys Thr Gly Asn Gly Gln
Thr Tyr Arg Gly 1 5 10 15 Thr Thr Ala Glu Thr Lys Ser Gly Val Thr
Cys Gln Lys Trp Ser Ala 20 25 30 Thr Ser Pro His Val Pro Lys Phe
Ser Pro Glu Lys Phe Pro Leu Ala 35 40 45 Gly Leu Glu Glu Asn Tyr
Cys Arg Asn Pro Asp Asn Asp Glu Asn Gly 50 55 60 Pro Trp Cys Tyr
Thr Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys Asp 65 70 75 80 Ile Pro
Glu Cys Glu Asp Lys Cys Met His Cys Ser Gly Glu Asn Tyr 85 90 95
Glu Gly Lys Ile Ala Lys Thr Met Ser Gly Arg Asp Cys Gln Ala Trp 100
105 110 Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe
Pro 115 120 125 Asn Lys Asn Leu Lys Met Asn Tyr Cys Arg Asn Pro Asp
Gly Glu Pro 130 135 140 Arg Pro Trp Cys Phe Thr Thr Asp Pro Gln Lys
Arg Trp Glu Phe Cys 145 150 155 160 Asp Ile Pro Arg Cys Thr Thr Pro
Pro Pro Ser Ser Gly Pro Lys Tyr 165 170 175 Gln Cys Leu Lys Gly Thr
Gly Lys Asn Tyr Gly Gly Thr Val Ala Val 180 185 190 Thr Glu Ser Gly
His Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His 195 200 205 Lys His
Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu 210 215 220
Asn Tyr Cys Arg Asn Pro Asp Gly Glu Lys Ala Pro Trp Cys Tyr Thr 225
230 235 240 Thr Asn Ser Glu Val Arg Trp Glu Tyr Cys Thr Ile Pro Ser
Cys Glu 245 250 255 Ser Ser Pro Leu Ser Thr Glu
Arg Met Asp Val Pro Val Pro Pro Glu 260 265 270 Gln Thr Pro Val Pro
Gln Asp Cys Tyr His Gly Asn Gly Gln Ser Tyr 275 280 285 Arg Gly Thr
Ser Ser Thr Thr Ile Thr Gly Arg Lys Cys Gln Ser Trp 290 295 300 Ser
Ser Met Thr Pro His Arg His Leu Lys Thr Pro Glu Asn Tyr Pro 305 310
315 320 Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp
Lys 325 330 335 Ser Pro Trp 7 79 PRT Murinae gen. sp. misc_feature
Kringle 1 7 Cys Lys Thr Gly Ile Gly Asn Gly Thr Arg Gly Thr Met Ser
Arg Thr 1 5 10 15 Lys Ser Gly Val Ala Cys Gln Lys Trp Gly Ala Thr
Phe Pro His Val 20 25 30 Pro Asn Tyr Ser Pro Ser Thr His Pro Asn
Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn Asp
Glu Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp Pro Asp Lys Arg
Tyr Asp Tyr Cys Asn Ile Pro Glu Cys 65 70 75 8 79 PRT Homo sapiens
misc_feature Kringle 1 8 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
Gly Thr Met Ser Lys Thr 1 5 10 15 Lys Asn Gly Ile Thr Cys Gln Lys
Trp Ser Ser Thr Ser Pro His Arg 20 25 30 Pro Arg Phe Ser Pro Ala
Thr His Pro Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys 65 70 75 9 79
PRT Macaca sp. misc_feature Kringle 1 9 Cys Lys Thr Gly Asn Gly Lys
Asn Tyr Arg Gly Thr Met Ser Lys Thr 1 5 10 15 Arg Thr Gly Ile Thr
Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg 20 25 30 Pro Thr Phe
Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr
Cys Arg Asn Pro Asp Asn Asp Gly Gln Gly Pro Trp Cys Tyr Thr 50 55
60 Thr Asp Pro Glu Glu Arg Phe Asp Tyr Cys Asp Ile Pro Glu Cys 65
70 75 10 79 PRT Sus sp. misc_feature Kringle 1 10 Cys Lys Thr Gly
Asn Gly Lys Asn Tyr Arg Gly Thr Thr Ser Lys Thr 1 5 10 15 Lys Ser
Gly Val Ile Cys Gln Lys Trp Ser Val Ser Ser Pro His Ile 20 25 30
Pro Lys Tyr Ser Pro Glu Lys Phe Pro Leu Ala Gly Leu Glu Glu Asn 35
40 45 Tyr Cys Arg Asn Pro Asp Asn Asp Glu Lys Gly Pro Trp Cys Tyr
Thr 50 55 60 Thr Asp Pro Glu Thr Arg Phe Asp Tyr Cys Asp Ile Pro
Glu Cys 65 70 75 11 79 PRT Bos sp. misc_feature Kringle 1 11 Cys
Lys Thr Gly Asn Gly Gln Thr Tyr Arg Gly Thr Thr Ala Glu Thr 1 5 10
15 Lys Ser Gly Val Thr Cys Gln Lys Trp Ser Ala Thr Ser Pro His Val
20 25 30 Pro Lys Phe Ser Pro Glu Lys Phe Pro Leu Ala Gly Leu Glu
Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn Asp Glu Asn Gly Pro
Trp Cys Tyr Thr 50 55 60 Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys
Asp Ile Pro Glu Cys 65 70 75 12 78 PRT Murinae gen. sp.
misc_feature Kringle 2 12 Cys Met Tyr Cys Ser Gly Glu Lys Tyr Glu
Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser Gly Leu Asp Cys Gln Ala
Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His Gly Tyr Ile Pro Ala
Lys Phe Pro Ser Lys Asn Leu Lys Met Asn 35 40 45 Tyr Cys His Asn
Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr 50 55 60 Asp Pro
Thr Lys Arg Trp Glu Tyr Cys Asp Ile Pro Arg Cys 65 70 75 13 78 PRT
Homo sapiens misc_feature Kringle 2 13 Cys Met His Cys Ser Gly Glu
Asn Tyr Asp Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser Gly Leu Glu
Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His Gly Tyr
Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn 35 40 45 Tyr
Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr 50 55
60 Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys 65 70 75
14 78 PRT Macaca sp. misc_feature Kringle 2 14 Cys Met His Cys Ser
Gly Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser Gly
Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His
Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn 35 40
45 Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr
50 55 60 Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys 65
70 75 15 78 PRT Sus sp. misc_feature Kringle 2 15 Cys Met His Cys
Ser Gly Glu His Tyr Glu Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser
Gly Ile Glu Cys Gln Ser Trp Gly Ser Gln Ser Pro His Ala 20 25 30
His Gly Tyr Leu Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Met Asn 35
40 45 Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr
Thr 50 55 60 Asp Pro Asn Lys Arg Trp Glu Phe Cys Asp Ile Pro Arg
Cys 65 70 75 16 78 PRT Bos sp. misc_feature Kringle 2 16 Cys Met
His Cys Ser Gly Glu Asn Tyr Glu Gly Lys Ile Ala Lys Thr 1 5 10 15
Met Ser Gly Arg Asp Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala 20
25 30 His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Met
Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys
Phe Thr Thr 50 55 60 Asp Pro Gln Lys Arg Trp Glu Phe Cys Asp Ile
Pro Arg Cys 65 70 75 17 78 PRT Murinae gen. sp. misc_feature
Kringle 3 17 Cys Leu Lys Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val
Ser Val Thr 1 5 10 15 Val Ser Gly Lys Thr Cys Gln Arg Trp Ser Glu
Gln Thr Pro His Arg 20 25 30 His Asn Arg Thr Pro Glu Asn Phe Pro
Cys Lys Asn Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Gly
Glu Thr Ala Pro Trp Cys Tyr Thr Thr 50 55 60 Asp Ser Gln Leu Arg
Trp Glu Tyr Cys Glu Ile Pro Ser Cys 65 70 75 18 78 PRT Homo sapiens
misc_feature Kringle 3 18 Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg
Gly Asn Val Ala Val Thr 1 5 10 15 Val Ser Gly His Thr Cys Gln His
Trp Ser Ala Gln Thr Pro His Thr 20 25 30 His Asn Arg Thr Pro Glu
Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr 50 55 60 Asn Ser
Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys 65 70 75 19 78 PRT
Macaca sp. misc_feature Kringle 3 19 Cys Leu Lys Gly Thr Gly Glu
Asn Tyr Arg Gly Asp Val Ala Val Thr 1 5 10 15 Val Ser Gly His Thr
Cys His Gly Trp Ser Ala Gln Thr Pro His Thr 20 25 30 His Asn Arg
Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn 35 40 45 Tyr
Cys Arg Asn Pro Asp Gly Glu Lys Ala Pro Trp Cys Tyr Thr Thr 50 55
60 Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys 65 70 75
20 78 PRT Sus sp. misc_feature Kringle 3 20 Cys Leu Lys Gly Arg Gly
Glu Asn Tyr Arg Gly Thr Val Ser Val Thr 1 5 10 15 Ala Ser Gly His
Thr Cys Gln Arg Trp Ser Ala Gln Ser Pro His Lys 20 25 30 His Asn
Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn 35 40 45
Tyr Cys Arg Asn Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr 50
55 60 Asp Ser Glu Val Arg Trp Asp Tyr Cys Lys Ile Pro Ser Cys 65 70
75 21 78 PRT Bos sp. misc_feature Kringle 3 21 Cys Leu Lys Gly Thr
Gly Lys Asn Tyr Gly Gly Thr Val Ala Val Thr 1 5 10 15 Glu Ser Gly
His Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His Lys 20 25 30 His
Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn 35 40
45 Tyr Cys Arg Asn Pro Asp Gly Glu Lys Ala Pro Trp Cys Tyr Thr Thr
50 55 60 Asn Ser Glu Val Arg Trp Glu Tyr Cys Thr Ile Pro Ser Cys 65
70 75 22 78 PRT Murinae gen. sp. misc_feature Kringle 4 22 Cys Tyr
Gln Ser Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr 1 5 10 15
Ile Thr Gly Lys Lys Cys Gln Ser Trp Ala Ala Met Phe Pro His Arg 20
25 30 His Ser Lys Thr Pro Glu Asn Phe Pro Asp Ala Gly Leu Glu Met
Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Gly Asp Lys Gly Pro Trp Cys
Tyr Thr Thr 50 55 60 Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu
Lys Arg Cys 65 70 75 23 78 PRT Homo sapiens misc_feature Kringle 4
23 Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr
1 5 10 15 Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser Met Thr Pro
His Arg 20 25 30 His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly
Leu Thr Met Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly
Pro Trp Cys Phe Thr Thr 50 55 60 Asp Pro Ser Val Arg Trp Glu Tyr
Cys Asn Leu Lys Lys Cys 65 70 75 24 168 PRT Murinae gen. sp.
misc_feature Kringle 2-3 24 Cys Met Tyr Cys Ser Gly Glu Lys Tyr Glu
Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser Gly Leu Asp Cys Gln Ala
Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His Gly Tyr Ile Pro Ala
Lys Phe Pro Ser Lys Asn Leu Lys Met Asn 35 40 45 Tyr Cys His Asn
Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr 50 55 60 Asp Pro
Thr Lys Arg Trp Glu Tyr Cys Asp Ile Pro Arg Cys Thr Thr 65 70 75 80
Pro Pro Pro Pro Pro Ser Pro Thr Tyr Gln Cys Leu Lys Gly Arg Gly 85
90 95 Glu Asn Tyr Arg Gly Thr Val Ser Val Thr Val Ser Gly Lys Thr
Cys 100 105 110 Gln Arg Trp Ser Glu Gln Thr Pro His Arg His Asn Arg
Thr Pro Glu 115 120 125 Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr
Cys Arg Asn Pro Asp 130 135 140 Gly Glu Thr Ala Pro Trp Cys Tyr Thr
Thr Asp Ser Gln Leu Arg Trp 145 150 155 160 Glu Tyr Cys Glu Ile Pro
Ser Cys 165 25 168 PRT Homo sapiens misc_feature Kringle 2-3 25 Cys
Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr 1 5 10
15 Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala
20 25 30 His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys
Lys Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp
Cys Phe Thr Thr 50 55 60 Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp
Ile Pro Arg Cys Thr Thr 65 70 75 80 Pro Pro Pro Ser Ser Gly Pro Thr
Tyr Gln Cys Leu Lys Gly Thr Gly 85 90 95 Glu Asn Tyr Arg Gly Asn
Val Ala Val Thr Val Ser Gly His Thr Cys 100 105 110 Gln His Trp Ser
Ala Gln Thr Pro His Thr His Asn Arg Thr Pro Glu 115 120 125 Asn Phe
Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn Pro Asp 130 135 140
Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val Arg Trp 145
150 155 160 Glu Tyr Cys Lys Ile Pro Ser Cys 165 26 168 PRT Macaca
sp. misc_feature Kringle 2-3 26 Cys Met His Cys Ser Gly Glu Asn Tyr
Asp Gly Lys Ile Ser Lys Thr 1 5 10 15 Met Ser Gly Leu Glu Cys Gln
Ala Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His Gly Tyr Ile Pro
Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn 35 40 45 Tyr Cys Arg
Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr 50 55 60 Asp
Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys Thr Thr 65 70
75 80 Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly Thr
Gly 85 90 95 Glu Asn Tyr Arg Gly Asp Val Ala Val Thr Val Ser Gly
His Thr Cys 100 105 110 His Gly Trp Ser Ala Gln Thr Pro His Thr His
Asn Arg Thr Pro Glu 115 120 125 Asn Phe Pro Cys Lys Asn Leu Asp Glu
Asn Tyr Cys Arg Asn Pro Asp 130 135 140 Gly Glu Lys Ala Pro Trp Cys
Tyr Thr Thr Asn Ser Gln Val Arg Trp 145 150 155 160 Glu Tyr Cys Lys
Ile Pro Ser Cys 165 27 168 PRT Sus sp. misc_feature Kringle 2-3 27
Cys Met His Cys Ser Gly Glu His Tyr Glu Gly Lys Ile Ser Lys Thr 1 5
10 15 Met Ser Gly Ile Glu Cys Gln Ser Trp Gly Ser Gln Ser Pro His
Ala 20 25 30 His Gly Tyr Leu Pro Ser Lys Phe Pro Asn Lys Asn Leu
Lys Met Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro
Trp Cys Phe Thr Thr 50 55 60 Asp Pro Asn Lys Arg Trp Glu Phe Cys
Asp Ile Pro Arg Cys Thr Thr 65 70 75 80 Pro Pro Pro Thr Ser Gly Pro
Thr Tyr Gln Cys Leu Lys Gly Arg Gly 85 90 95 Glu Asn Tyr Arg Gly
Thr Val Ser Val Thr Ala Ser Gly His Thr Cys 100 105 110 Gln Arg Trp
Ser Ala Gln Ser Pro His Lys His Asn Arg Thr Pro Glu 115 120 125 Asn
Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp 130 135
140 Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr Asp Ser Glu Val Arg Trp
145 150 155 160 Asp Tyr Cys Lys Ile Pro Ser Cys 165 28 168 PRT Bos
sp. misc_feature Kringle 2-3 28 Cys Met His Cys Ser Gly Glu Asn Tyr
Glu Gly Lys Ile Ala Lys Thr 1 5 10 15 Met Ser Gly Arg Asp Cys Gln
Ala Trp Asp Ser Gln Ser Pro His Ala 20 25 30 His Gly Tyr Ile Pro
Ser Lys Phe Pro Asn Lys Asn Leu Lys Met Asn 35 40 45 Tyr Cys Arg
Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr 50 55 60 Asp
Pro Gln Lys Arg Trp Glu Phe Cys Asp Ile Pro Arg Cys Thr Thr 65 70
75 80 Pro Pro Pro Ser Ser Gly Pro Lys Tyr Gln Cys Leu Lys Gly Thr
Gly 85 90 95 Lys Asn Tyr Gly Gly Thr Val Ala Val Thr Glu Ser Gly
His Thr Cys 100 105 110 Gln Arg Trp Ser Glu Gln Thr Pro His Lys His
Asn Arg Thr Pro Glu 115 120 125 Asn Phe Pro Cys Lys Asn Leu Glu Glu
Asn Tyr Cys Arg Asn Pro Asp 130 135 140 Gly Glu Lys Ala Pro Trp Cys
Tyr Thr Thr Asn Ser Glu Val Arg Trp 145 150 155 160 Glu Tyr Cys Thr
Ile Pro Ser Cys 165 29 250 PRT Murinae gen. sp. misc_feature
Kringle 1-3 29 Cys Lys Thr Gly Ile Gly Asn Gly Tyr Arg Gly Thr Met
Ser Arg Thr 1 5 10 15 Lys Ser Gly Val Ala Cys Gln Lys Trp Gly Ala
Thr Phe Pro His Val 20 25 30 Pro Asn Tyr Ser Pro Ser Thr His Pro
Asn Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn
Asp Glu Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp Pro Asp Lys
Arg Tyr Asp Tyr Cys Asn Ile Pro Glu Cys Glu 65 70 75 80 Glu Glu Cys
Met Tyr Cys Ser Gly Glu Lys Tyr Glu Gly Lys Ile Ser
85 90 95 Lys Thr Met Ser Gly Leu Asp Cys Gln Ala Trp Asp Ser Gln
Ser Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ala Lys Phe Pro Ser
Lys Asn Leu Lys 115 120 125 Met Asn Tyr Cys His Asn Pro Asp Gly Glu
Pro Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Thr Lys Arg Trp
Glu Tyr Cys Asp Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro Pro Pro
Pro Pro Ser Pro Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Arg Gly Glu
Asn Tyr Arg Gly Thr Val Ser Val Thr Val Ser Gly Lys 180 185 190 Thr
Cys Gln Arg Trp Ser Glu Gln Thr Pro His Arg His Asn Arg Thr 195 200
205 Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr Cys Arg Asn
210 215 220 Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr Asp Ser
Gln Leu 225 230 235 240 Arg Trp Glu Tyr Cys Glu Ile Pro Ser Cys 245
250 30 250 PRT Homo sapien misc_feature Kringle 1-3 30 Cys Lys Thr
Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr 1 5 10 15 Lys
Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg 20 25
30 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn
35 40 45 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys
Tyr Thr 50 55 60 Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile
Leu Glu Cys Glu 65 70 75 80 Glu Glu Cys Met His Cys Ser Gly Glu Asn
Tyr Asp Gly Lys Ile Ser 85 90 95 Lys Thr Met Ser Gly Leu Glu Cys
Gln Ala Trp Asp Ser Gln Ser Pro 100 105 110 His Ala His Gly Tyr Ile
Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys 115 120 125 Lys Asn Tyr Cys
Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe 130 135 140 Thr Thr
Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys 145 150 155
160 Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly
165 170 175 Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser
Gly His 180 185 190 Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr
His Asn Arg Thr 195 200 205 Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp
Glu Asn Tyr Cys Arg Asn 210 215 220 Pro Asp Gly Lys Arg Ala Pro Trp
Cys His Thr Thr Asn Ser Gln Val 225 230 235 240 Arg Trp Glu Tyr Cys
Lys Ile Pro Ser Cys 245 250 31 250 PRT Macaca sp. misc_feature
Kringle 1-3 31 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met
Ser Lys Thr 1 5 10 15 Arg Thr Gly Ile Thr Cys Gln Lys Trp Ser Ser
Thr Ser Pro His Arg 20 25 30 Pro Thr Phe Ser Pro Ala Thr His Pro
Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn
Asp Gly Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp Pro Glu Glu
Arg Phe Asp Tyr Cys Asp Ile Pro Glu Cys Glu 65 70 75 80 Asp Glu Cys
Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser 85 90 95 Lys
Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro 100 105
110 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys
115 120 125 Lys Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp
Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp
Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro Pro Pro Ser Ser Gly Pro
Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Thr Gly Glu Asn Tyr Arg Gly
Asp Val Ala Val Thr Val Ser Gly His 180 185 190 Thr Cys His Gly Trp
Ser Ala Gln Thr Pro His Thr His Asn Arg Thr 195 200 205 Pro Glu Asn
Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn 210 215 220 Pro
Asp Gly Glu Lys Ala Pro Trp Cys Tyr Thr Thr Asn Ser Gln Val 225 230
235 240 Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys 245 250 32 250 PRT
Sus sp. misc_feature Kringle 1-3 32 Cys Lys Thr Gly Asn Gly Lys Asn
Tyr Arg Gly Thr Thr Ser Lys Thr 1 5 10 15 Lys Ser Gly Val Ile Cys
Gln Lys Trp Ser Val Ser Ser Pro His Ile 20 25 30 Pro Lys Tyr Ser
Pro Glu Lys Phe Pro Leu Ala Gly Leu Glu Glu Asn 35 40 45 Tyr Cys
Arg Asn Pro Asp Asn Asp Glu Lys Gly Pro Trp Cys Tyr Thr 50 55 60
Thr Asp Pro Glu Thr Arg Phe Asp Tyr Cys Asp Ile Pro Glu Cys Glu 65
70 75 80 Asp Glu Cys Met His Cys Ser Gly Glu His Tyr Glu Gly Lys
Ile Ser 85 90 95 Lys Thr Met Ser Gly Ile Glu Cys Gln Ser Trp Gly
Ser Gln Ser Pro 100 105 110 His Ala His Gly Tyr Leu Pro Ser Lys Phe
Pro Asn Lys Asn Leu Lys 115 120 125 Met Asn Tyr Cys Arg Asn Pro Asp
Gly Glu Pro Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys
Arg Trp Glu Phe Cys Asp Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro
Pro Pro Thr Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Arg
Gly Glu Asn Tyr Arg Gly Thr Val Ser Val Thr Ala Ser Gly His 180 185
190 Thr Cys Gln Arg Trp Ser Ala Gln Ser Pro His Lys His Asn Arg Thr
195 200 205 Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr Cys
Arg Asn 210 215 220 Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr
Asp Ser Glu Val 225 230 235 240 Arg Trp Asp Tyr Cys Lys Ile Pro Ser
Cys 245 250 33 250 PRT Bos sp. misc_feature Kringle 1-3 33 Cys Lys
Thr Gly Asn Gly Gln Thr Tyr Arg Gly Thr Thr Ala Glu Thr 1 5 10 15
Lys Ser Gly Val Thr Cys Gln Lys Trp Ser Ala Thr Ser Pro His Val 20
25 30 Pro Lys Phe Ser Pro Glu Lys Phe Pro Leu Ala Gly Leu Glu Glu
Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn Asp Glu Asn Gly Pro Trp
Cys Tyr Thr 50 55 60 Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys Asp
Ile Pro Glu Cys Glu 65 70 75 80 Asp Lys Cys Met His Cys Ser Gly Glu
Asn Tyr Glu Gly Lys Ile Ala 85 90 95 Lys Thr Met Ser Gly Arg Asp
Cys Gln Ala Trp Asp Ser Gln Ser Pro 100 105 110 His Ala His Gly Tyr
Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys 115 120 125 Met Asn Tyr
Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe 130 135 140 Thr
Thr Asp Pro Gln Lys Arg Trp Glu Phe Cys Asp Ile Pro Arg Cys 145 150
155 160 Thr Thr Pro Pro Pro Ser Ser Gly Pro Lys Tyr Gln Cys Leu Lys
Gly 165 170 175 Thr Gly Lys Asn Tyr Gly Gly Thr Val Ala Val Thr Glu
Ser Gly His 180 185 190 Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His
Lys His Asn Arg Thr 195 200 205 Pro Glu Asn Phe Pro Cys Lys Asn Leu
Glu Glu Asn Tyr Cys Arg Asn 210 215 220 Pro Asp Gly Glu Lys Ala Pro
Trp Cys Tyr Thr Thr Asn Ser Glu Val 225 230 235 240 Arg Trp Glu Tyr
Cys Thr Ile Pro Ser Cys 245 250 34 160 PRT Murinae gen. sp.
misc_feature Kringle 1-2 34 Cys Lys Thr Gly Ile Gly Asn Gly Tyr Arg
Gly Thr Met Ser Arg Thr 1 5 10 15 Lys Ser Gly Val Ala Cys Gln Lys
Trp Gly Ala Thr Phe Pro His Val 20 25 30 Pro Asn Tyr Ser Pro Ser
Thr His Pro Asn Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Glu Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Asp Lys Arg Tyr Asp Tyr Cys Asn Ile Pro Glu Cys Glu 65 70 75 80
Glu Glu Cys Met Tyr Cys Ser Gly Glu Lys Tyr Glu Gly Lys Ile Ser 85
90 95 Lys Thr Met Ser Gly Leu Asp Cys Gln Ala Trp Asp Ser Gln Ser
Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ala Lys Phe Pro Ser Lys
Asn Leu Lys 115 120 125 Met Asn Tyr Cys His Asn Pro Asp Gly Glu Pro
Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Thr Lys Arg Trp Glu
Tyr Cys Asp Ile Pro Arg Cys 145 150 155 160 35 160 PRT Homo sapiens
misc_feature Kringle 1-2 35 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
Gly Thr Met Ser Lys Thr 1 5 10 15 Lys Asn Gly Ile Thr Cys Gln Lys
Trp Ser Ser Thr Ser Pro His Arg 20 25 30 Pro Arg Phe Ser Pro Ala
Thr His Pro Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu 65 70 75 80
Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser 85
90 95 Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser
Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys
Asn Leu Lys 115 120 125 Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu
Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys Arg Trp Glu
Leu Cys Asp Ile Pro Arg Cys 145 150 155 160 36 160 PRT Macaca sp.
misc_feature Kringle 1-2 36 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
Gly Thr Met Ser Lys Thr 1 5 10 15 Arg Thr Gly Ile Thr Cys Gln Lys
Trp Ser Ser Thr Ser Pro His Arg 20 25 30 Pro Thr Phe Ser Pro Ala
Thr His Pro Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Gly Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Glu Glu Arg Phe Asp Tyr Cys Asp Ile Pro Glu Cys Glu 65 70 75 80
Asp Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser 85
90 95 Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser
Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys
Asn Leu Lys 115 120 125 Lys Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro
Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys Arg Trp Glu
Leu Cys Asp Ile Pro Arg Cys 145 150 155 160 37 160 PRT Sus sp.
misc_feature Kringle 1-2 37 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
Gly Thr Thr Ser Lys Thr 1 5 10 15 Lys Ser Gly Val Ile Cys Gln Lys
Trp Ser Val Ser Ser Pro His Ile 20 25 30 Pro Lys Tyr Ser Pro Glu
Lys Phe Pro Leu Ala Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Glu Lys Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Glu Thr Arg Phe Asp Tyr Cys Asp Ile Pro Glu Cys Glu 65 70 75 80
Asp Glu Cys Met His Cys Ser Gly Glu His Tyr Glu Gly Lys Ile Ser 85
90 95 Lys Thr Met Ser Gly Ile Glu Cys Gln Ser Trp Gly Ser Gln Ser
Pro 100 105 110 His Ala His Gly Tyr Leu Pro Ser Lys Phe Pro Asn Lys
Asn Leu Lys 115 120 125 Met Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro
Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys Arg Trp Glu
Phe Cys Asp Ile Pro Arg Cys 145 150 155 160 38 160 PRT Bos sp.
misc_feature Kringle 1-2 38 Cys Lys Thr Gly Asn Gly Gln Thr Tyr Arg
Gly Thr Thr Ala Glu Thr 1 5 10 15 Lys Ser Gly Val Thr Cys Gln Lys
Trp Ser Ala Thr Ser Pro His Val 20 25 30 Pro Lys Phe Ser Pro Glu
Lys Phe Pro Leu Ala Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn
Pro Asp Asn Asp Glu Asn Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp
Pro Asp Lys Arg Tyr Asp Tyr Cys Asp Ile Pro Glu Cys Glu 65 70 75 80
Asp Lys Cys Met His Cys Ser Gly Glu Asn Tyr Glu Gly Lys Ile Ala 85
90 95 Lys Thr Met Ser Gly Arg Asp Cys Gln Ala Trp Asp Ser Gln Ser
Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys
Asn Leu Lys 115 120 125 Met Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro
Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Gln Lys Arg Trp Glu
Phe Cys Asp Ile Pro Arg Cys 145 150 155 160 39 352 PRT Murinae gen.
sp. misc_feature Kringle 1-4 39 Cys Lys Thr Gly Ile Gly Asn Gly Tyr
Arg Gly Thr Met Ser Arg Thr 1 5 10 15 Lys Ser Gly Val Ala Cys Gln
Lys Trp Gly Ala Thr Phe Pro His Val 20 25 30 Pro Asn Tyr Ser Pro
Ser Thr His Pro Asn Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg
Asn Pro Asp Asn Asp Glu Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr
Asp Pro Asp Lys Arg Tyr Asp Tyr Cys Asn Ile Pro Glu Cys Glu 65 70
75 80 Glu Glu Cys Met Tyr Cys Ser Gly Glu Lys Tyr Glu Gly Lys Ile
Ser 85 90 95 Lys Thr Met Ser Gly Leu Asp Cys Gln Ala Trp Asp Ser
Gln Ser Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ala Lys Phe Pro
Ser Lys Asn Leu Lys 115 120 125 Met Asn Tyr Cys His Asn Pro Asp Gly
Glu Pro Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Thr Lys Arg
Trp Glu Tyr Cys Asp Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro Pro
Pro Pro Pro Ser Pro Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Arg Gly
Glu Asn Tyr Arg Gly Thr Val Ser Val Thr Val Ser Gly Lys 180 185 190
Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His Arg His Asn Arg Thr 195
200 205 Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr Cys Arg
Asn 210 215 220 Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr Asp
Ser Gln Leu 225 230 235 240 Arg Trp Glu Tyr Cys Glu Ile Pro Ser Cys
Glu Ser Ser Ala Ser Pro 245 250 255 Asp Gln Ser Asp Ser Ser Val Pro
Pro Glu Glu Gln Thr Pro Val Val 260 265 270 Gln Glu Cys Tyr Gln Ser
Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser 275 280 285 Thr Thr Ile Thr
Gly Lys Lys Cys Gln Ser Trp Ala Ala Met Phe Pro 290 295 300 His Arg
His Ser Lys Thr Pro Glu Asn Phe Pro Asp Ala Gly Leu Glu 305 310 315
320 Met Asn Tyr Cys Arg Asn Pro Asp Gly Asp Lys Gly Pro Trp Cys Tyr
325 330 335 Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys
Arg Cys 340 345 350 40 352 PRT Homo sapiens misc_feature Kringle
1-4 40 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys
Thr 1 5 10 15 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser
Pro His Arg 20 25 30 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu
Gly Leu Glu Glu Asn 35 40 45 Tyr Cys Arg Asn Pro Asp Asn Asp Pro
Gln Gly Pro Trp Cys Tyr Thr 50 55 60 Thr Asp Pro Glu
Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu 65 70 75 80 Glu Glu
Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser 85 90 95
Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro 100
105 110 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu
Lys 115 120 125 Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro
Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys
Asp Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro Pro Pro Ser Ser Gly
Pro Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Thr Gly Glu Asn Tyr Arg
Gly Asn Val Ala Val Thr Val Ser Gly His 180 185 190 Thr Cys Gln His
Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr 195 200 205 Pro Glu
Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn 210 215 220
Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val 225
230 235 240 Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro
Val Ser 245 250 255 Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu
Thr Pro Val Val 260 265 270 Gln Asp Cys Tyr His Gly Asp Gly Gln Ser
Tyr Arg Gly Thr Ser Ser 275 280 285 Thr Thr Thr Thr Gly Lys Lys Cys
Gln Ser Trp Ser Ser Met Thr Pro 290 295 300 His Arg His Gln Lys Thr
Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr 305 310 315 320 Met Asn Tyr
Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp Cys Phe 325 330 335 Thr
Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys Lys Cys 340 345
350 41 378 PRT Murinae gen. sp. misc_feature Kringle 1-4BKLS 41 Leu
Phe Glu Lys Arg Val Tyr Leu Ser Glu Cys Lys Thr Gly Ile Gly 1 5 10
15 Asn Gly Tyr Arg Gly Thr Met Ser Arg Thr Lys Ser Gly Val Ala Cys
20 25 30 Gln Lys Trp Gly Ala Thr Phe Pro His Val Pro Asn Tyr Ser
Pro Ser 35 40 45 Thr His Pro Asn Glu Gly Leu Glu Glu Asn Tyr Cys
Arg Asn Pro Asp 50 55 60 Asn Asp Glu Gln Gly Pro Trp Cys Tyr Thr
Thr Asp Pro Asp Lys Arg 65 70 75 80 Tyr Asp Tyr Cys Asn Ile Pro Glu
Cys Glu Glu Glu Cys Met Tyr Cys 85 90 95 Ser Gly Glu Lys Tyr Glu
Gly Lys Ile Ser Lys Thr Met Ser Gly Leu 100 105 110 Asp Cys Gln Ala
Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile 115 120 125 Pro Ala
Lys Phe Pro Ser Lys Asn Leu Lys Met Asn Tyr Cys His Asn 130 135 140
Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr Asp Pro Thr Lys 145
150 155 160 Arg Trp Glu Tyr Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro
Pro Pro 165 170 175 Pro Ser Pro Thr Tyr Gln Cys Leu Lys Gly Arg Gly
Glu Asn Tyr Arg 180 185 190 Gly Thr Val Ser Val Thr Val Ser Gly Lys
Thr Cys Gln Arg Trp Ser 195 200 205 Glu Gln Thr Pro His Arg His Asn
Arg Thr Pro Glu Asn Phe Pro Cys 210 215 220 Lys Asn Leu Glu Glu Asn
Tyr Cys Arg Asn Pro Asp Gly Glu Thr Ala 225 230 235 240 Pro Trp Cys
Tyr Thr Thr Asp Ser Gln Leu Arg Trp Glu Tyr Cys Glu 245 250 255 Ile
Pro Ser Cys Glu Ser Ser Ala Ser Pro Asp Gln Ser Asp Ser Ser 260 265
270 Val Pro Pro Glu Glu Gln Thr Pro Val Val Gln Glu Cys Tyr Gln Ser
275 280 285 Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr Ile Thr
Gly Lys 290 295 300 Lys Cys Gln Ser Trp Ala Ala Met Phe Pro His Arg
His Ser Lys Thr 305 310 315 320 Pro Glu Asn Phe Pro Asp Ala Gly Leu
Glu Met Asn Tyr Cys Arg Asn 325 330 335 Pro Asp Gly Asp Lys Gly Pro
Trp Cys Tyr Thr Thr Asp Pro Ser Val 340 345 350 Arg Trp Glu Tyr Cys
Asn Leu Lys Arg Cys Ser Glu Thr Gly Gly Ser 355 360 365 Val Val Glu
Leu Pro Thr Val Ser Gln Glu 370 375 42 368 PRT Homo sapiens
misc_feature Kringle 1-4 BKLS 42 Cys Lys Thr Gly Asn Gly Lys Asn
Tyr Arg Gly Thr Met Ser Lys Thr 1 5 10 15 Lys Asn Gly Ile Thr Cys
Gln Lys Trp Ser Ser Thr Ser Pro His Arg 20 25 30 Pro Arg Phe Ser
Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn 35 40 45 Tyr Cys
Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr 50 55 60
Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu 65
70 75 80 Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys
Ile Ser 85 90 95 Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp
Ser Gln Ser Pro 100 105 110 His Ala His Gly Tyr Ile Pro Ser Lys Phe
Pro Asn Lys Asn Leu Lys 115 120 125 Lys Asn Tyr Cys Arg Asn Pro Asp
Arg Glu Leu Arg Pro Trp Cys Phe 130 135 140 Thr Thr Asp Pro Asn Lys
Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys 145 150 155 160 Thr Thr Pro
Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly 165 170 175 Thr
Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His 180 185
190 Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr
195 200 205 Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys
Arg Asn 210 215 220 Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr
Asn Ser Gln Val 225 230 235 240 Arg Trp Glu Tyr Cys Lys Ile Pro Ser
Cys Asp Ser Ser Pro Val Ser 245 250 255 Thr Glu Gln Leu Ala Pro Thr
Ala Pro Pro Glu Leu Thr Pro Val Val 260 265 270 Gln Asp Cys Tyr His
Gly Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser 275 280 285 Thr Thr Thr
Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser Met Thr Pro 290 295 300 His
Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr 305 310
315 320 Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp Cys
Phe 325 330 335 Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu
Lys Lys Cys 340 345 350 Ser Glu Thr Glu Ala Ser Val Val Ala Pro Pro
Pro Val Val Leu Leu 355 360 365 43 30 DNA Artificial Sequence PCR
primer 43 atcgctcgag cgttatttga aaagaaagtg 30 44 28 DNA Artificial
Sequence PCR primer 44 atcggaattc aagcaggaca acaggcgg 28 45 28 DNA
Artificial Sequence PCR primer 45 atcgtacgta ttatttgaaa agaaagtg 28
46 459 PRT Murinae gen. sp. misc_feature Kringle 1-5 46 Glu Cys Lys
Thr Gly Ile Gly Asn Gly Tyr Arg Gly Thr Met Ser Arg 1 5 10 15 Thr
Lys Ser Gly Val Ala Cys Gln Lys Trp Gly Ala Thr Phe Pro His 20 25
30 Val Pro Asn Tyr Ser Pro Ser Thr His Pro Asn Glu Gly Leu Glu Glu
35 40 45 Asn Tyr Cys Arg Asn Pro Asp Asn Asp Glu Gln Gly Pro Trp
Cys Tyr 50 55 60 Thr Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys Asn
Ile Pro Glu Cys 65 70 75 80 Glu Glu Glu Cys Met Tyr Cys Ser Gly Glu
Lys Tyr Glu Gly Lys Ile 85 90 95 Ser Lys Thr Met Ser Gly Leu Asp
Cys Gln Ala Trp Asp Ser Gln Ser 100 105 110 Pro His Ala His Gly Tyr
Ile Pro Ala Lys Phe Pro Ser Lys Asn Leu 115 120 125 Lys Met Asn Tyr
Cys His Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys 130 135 140 Phe Thr
Thr Asp Pro Thr Lys Arg Trp Glu Tyr Cys Asp Ile Pro Arg 145 150 155
160 Cys Thr Thr Pro Pro Pro Pro Pro Ser Pro Thr Tyr Gln Cys Leu Lys
165 170 175 Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val Ser Val Thr Val
Ser Gly 180 185 190 Lys Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro His
Arg His Asn Arg 195 200 205 Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu
Glu Glu Asn Tyr Cys Arg 210 215 220 Asn Pro Asp Gly Glu Thr Ala Pro
Trp Cys Tyr Thr Thr Asp Ser Gln 225 230 235 240 Leu Arg Trp Glu Tyr
Cys Glu Ile Pro Ser Cys Glu Ser Ser Ala Ser 245 250 255 Pro Asp Gln
Ser Asp Ser Ser Val Pro Pro Glu Glu Gln Thr Pro Val 260 265 270 Val
Gln Glu Cys Tyr Gln Ser Asp Gly Gln Ser Tyr Arg Gly Thr Ser 275 280
285 Ser Thr Thr Ile Thr Gly Lys Lys Cys Gln Ser Trp Ala Ala Met Phe
290 295 300 Pro His Arg His Ser Lys Thr Pro Glu Asn Phe Pro Asp Ala
Gly Leu 305 310 315 320 Glu Met Asn Tyr Cys Arg Asn Pro Asp Gly Asp
Lys Gly Pro Trp Cys 325 330 335 Tyr Thr Thr Asp Pro Ser Val Arg Trp
Glu Tyr Cys Asn Leu Lys Arg 340 345 350 Cys Ser Glu Thr Gly Gly Ser
Val Val Glu Leu Pro Thr Val Ser Gln 355 360 365 Glu Pro Ser Gly Pro
Ser Asp Ser Glu Thr Asp Cys Met Tyr Gly Asn 370 375 380 Gly Lys Asp
Tyr Arg Gly Lys Thr Ala Val Thr Ala Ala Gly Thr Pro 385 390 395 400
Cys Gln Gly Trp Ala Ala Gln Glu Pro His Arg His Ser Ile Phe Thr 405
410 415 Pro Gln Thr Asn Pro Arg Ala Asp Leu Glu Lys Asn Tyr Cys Arg
Asn 420 425 430 Pro Asp Gly Asp Val Asn Gly Pro Trp Cys Tyr Thr Thr
Asn Pro Arg 435 440 445 Lys Leu Tyr Asp Tyr Cys Asp Ile Pro Leu Cys
450 455 47 80 PRT Murinae gen. sp. misc_feature Kringle 5 47 Cys
Met Tyr Gly Asn Gly Lys Asp Tyr Arg Gly Lys Thr Ala Val Thr 1 5 10
15 Ala Ala Gly Thr Pro Cys Gln Gly Trp Ala Ala Gln Glu Pro His Arg
20 25 30 His Ser Ile Phe Thr Pro Gln Thr Asn Pro Arg Ala Asp Leu
Glu Lys 35 40 45 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Asn Gly
Pro Trp Cys Tyr 50 55 60 Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr
Cys Asp Ile Pro Leu Cys 65 70 75 80
* * * * *